Antibody-STING agonist conjugates and their use in immunotherapy

ADCs comprising CDNs and antibodies provide targeted delivery to tumors, enhancing immune response and reducing systemic cytokine effects, addressing limitations of existing STING agonists in cancer therapy.

JP7576779B2Active Publication Date: 2024-11-01IMMUNESENSOR THERAPEUTICS INC +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2022502910
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-05-01
Filing Date
2020-07-20
Publication Date
2024-11-01
Estimated Expiration
2040-07-20

AI Technical Summary

Technical Problem

Existing STING agonists for cancer immunotherapy face limitations due to systemic cytokine responses and rapid leakage, necessitating targeted delivery to the tumor environment with extended duration.

Method used

Development of antibody-drug conjugates (ADCs) that combine cyclic dinucleotides (CDNs) with antibodies targeting specific antigens, allowing selective delivery and prolonged exposure to the tumor microenvironment.

Benefits of technology

Enhances immune stimulation within the tumor microenvironment while minimizing systemic side effects, promoting effective anti-tumor immunity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007576779000153
    Figure 0007576779000153
  • Figure 0007576779000154
    Figure 0007576779000154
  • Figure 0007576779000155
    Figure 0007576779000155
Patent Text Reader

Abstract

The present disclosure relates, inter alia, to antibody-drug conjugates comprising a STING agonist cyclic dinucleotide linked to an antibody, methods for their preparation, and uses thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] 1. Sequence Listing This application contains a Sequence Listing that has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. The ASCII copy created on July 17, 2020 is named 400160_005US_SL_ST25.txt and is 44,502 bytes in size.

[0002] The present disclosure relates, inter alia, to the use of STING agonists in antibody-drug conjugates (ADCs) for immunotherapy, compositions comprising the ADCs, methods of making the ADCs, and methods of using the ADCs to treat cancer. [Background technology]

[0003] In addition to its primary function in host defense against invading DNA-containing microorganisms, the cytoplasmic DNA-sensing pathway plays a central role in initiating and maintaining immune responses against malignant tumors. Cytoplasmic DNA from damaged tumor cells triggers the activation of an enzyme called cyclic AMP-GMP synthase (cGAS), which synthesizes 2'3'-cyclic AMP-GMP (cGAMP). As an endogenous ligand, cGAMP binds to and activates the ER adaptor protein stimulator of interferon genes (STING), leading to the induction of interferons and inflammatory cytokines, recruitment and maturation of antigen-presenting cells, and ultimately antitumor immunity carried out by T cells and natural killer (NK) cells. Several STING agonists similar to cGAMP but with improved therapeutic properties are in development for cancer immunotherapy. These drugs show promise for the treatment of various solid tumors but have obvious limitations. These compounds rely on intratumoral administration because they may induce systemic cytokine responses when injected in other ways. Even intratumoral injections may still induce undesirable cytokine responses because of rapid leakage into peripheral tissues. Short exposure of these compounds to immune cells in the tumor environment also reduces their efficacy, therefore, there is an urgent need for novel therapeutics that can specifically deliver STING agonists to the tumor environment with extended duration. Summary of the Invention

[0004] The present disclosure provides certain cyclic dinucleotides (CDNs) that can be bound to antibodies or antigen-binding fragments that target specific antigens in the microenvironment of diseased cells or tissues. For example, the antibodies or antigen-binding fragments can target cancer-associated antigens that present to cells in the tumor microenvironment, such as tumor cells or immune cells. The CDNs of the present disclosure can stimulate STING and thus stimulate the immune system. When the CDNs of the present disclosure are bound to antibodies that target antigens in diseased cells or tissues, they provide sufficient exposure of the CDNs in the microenvironment of diseased cells or tissues while reducing the associated side effects associated with extensive CDN leakage into peripheral tissues.

[0005] In one aspect, the present disclosure provides a compound having the structure of formula I: (Formula I) Ab-[-L-(D) m ] n and providing an antibody-drug conjugate (ADC) having the formula: During the ceremony, "D" represents a CDN (e.g., a CDN described herein, such as a CDN of formula II); "Ab" refers to an antibody or binding fragment thereof that binds to a target antigen; each "L" independently represents a linker linking one or more D's to Ab; "m" represents the number of occurrences of D linked to a given linker, and "n" represents the number of linkers attached to the Ab.

[0006] In an embodiment, the present disclosure provides a compound having the structure of formula Ia: (Formula Ia) Ab-[-LD] n and providing an ADC having the formula: During the ceremony, "D" represents a CDN (e.g., a CDN described herein, such as a CDN of formula II); "Ab" refers to an antibody or binding fragment thereof that binds to a target antigen; each "L" independently represents a linker linking D to Ab; and "n" represents the number of occurrences of D linked to Ab via a linker (L).

[0007] In another aspect, the disclosure provides certain CDNs (D) that can be administered alone or as part of an ADC of formula I. These CDNs have the structure of formula II: [ka] or a pharma- ceutically acceptable salt thereof, During the ceremony, R 1 are hydroxyl, thiol, amino, C 1-6 C substituted with alkylamino or -PEG-OH groups 1-6 Alkyl, e.g. C 2-6 Alkyl or C 2-3 is alkyl, R 3 and R 4 are independently hydrogen, halogen, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 alkynyl, wherein C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl is independently selected from halogen, thiol, hydroxyl, carboxyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C 1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 Alkyl)C(O)C 1-6 Alkyl, Amino, C 1-6 Alkylamino, di(C 1-6 optionally substituted with one or more groups selected from alkyl, amino, oxo and azido; R 2 , R 5 and R 6 are independently hydrogen, halogen, hydroxyl, azide, amino, C 1-6 Alkylamino, di(C 1-6 Alkyl)amino, C1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 3-6 Alkenyl-O-,C 2-6 Alkynyl or C 3-6 alkynyl-O-, wherein C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 3-6 Alkenyl-O-,C 2-6 Alkynyl and C 3-6 Alkynyl-O- is independently selected from halogen, thiol, hydroxyl, carboxyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C 1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 Alkyl)C(O)C 1-6 Alkyl, Amino, C 1-6 Alkylamino, di(C 1-6 Optionally substituted with one or more groups selected from amino, oxo, and azido, or R 6 and R 5 together form =CH2, or R 6 and R 4 together form a V selected from ethylene, -O-CH2- and -NH-CH2- 2 forming a bridge across the ring containing V 1 and V 2 are independently O, S or CH2; V 1 BG starting from the carbon of the ring containing 1 , and V 2 BG starting from the carbon of the ring containing 2 are independently -OP(O)R P -O-, -OP(S)R P -O-, -OP(O)R P -S-, -OP(S)R P -S-, -SP(O)R P -O-, -SP(S)R P -O-, -SP(O)RP -S-, -SP(S)R P -S-, or -NH-SO2-NH-, R P are each independently a hydroxyl, a thiol, or C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Alkenyl-O-,C 3-6 Alkynyl-O-, -PEG-OH, Borano (-BH3 - ), or -NR'R'', where C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Alkenyl-O-, and C 3-6 Alkynyl-O- is independently selected from halogen, thiol, hydroxyl, carboxyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C 1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 Alkyl)C(O)C 1-6 Alkyl, Amino, C 1-6 Alkylamino, di(C 1-6 (alkyl) optionally substituted with one or more groups selected from amino, oxo and azido; and R' and R'' are independently hydrogen or halogen, thiol, hydroxyl, carboxyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C 1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 Alkyl)C(O)C 1-6 Alkyl, Amino, C 1-6 Alkylamino, di(C 1-6 C optionally substituted with one or more groups selected from amino, oxo and azido 1-6 alkyl, or R' and R'' on the same nitrogen are taken together as C 3-5 Forming a heterocyclic ring, R a1 , R b1 , R a2and R b2 are independently hydrogen or C 1-3 is alkyl, and B 1 and B. 2 is, independently, [ka] is selected from the group consisting of V 3 is O or S, in particular O, Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , and Z 6 are each independently z or N, Z a is O(Z 5 is N) or NR', in which R z are each independently hydrogen, halogen, azide, amino, C 1-6 Alkylamino, di(C 1-6 Alkyl)amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 3-6 Alkenyl-O-,C 2-6 Alkynyl, C 3-6 Alkynyl-O-, -NO2, -CN, -C(O)C 1-6 Alkyl, -CO2H, -CO2C 1-6 Alkyl, -S(O)C 1-6 Alkyl, -S(O)C 1-6 Alkyl, -C(O)NR', ​​-C(O)NR'R'', -SO2NR'R'', -OC(O)C 1-6 Alkyl, -NR'C(O)C 1-6 Alkyl, -N(R')C(O)NR'R'', -N(R')SO2NR'R'', -N(R)SO2C 1-6 alkyl, or -OC(O)NR'R'', wherein C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6Alkenyl, C 3-6 Alkenyl-O-,C 2-6 Alkynyl and C 3-6 Alkynyl-O- is independently a halogen, a thiol, a hydroxyl, a carboxyl, or a C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C 1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 Alkyl)C(O)C 1-6 Alkyl, Amino, C 1-6 Alkylamino, di(C 1-6 (alkyl) optionally substituted with one or more groups selected from amino, oxo and azido; and R' and R'' are each independently hydrogen or a halogen, thiol, hydroxyl, carboxyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C 1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 Alkyl)C(O)C 1-6 Alkyl, Amino, C 1-6 Alkylamino, di(C 1-6 C optionally substituted with one or more groups selected from amino, oxo and azido 1-6 alkyl, or R' and R'' on the same nitrogen are taken together as C 3-5 It forms a heterocyclic ring.

[0008] The present disclosure provides a method for making an ADC of formula I by linking a CDN of formula II to an antibody via a linker. The CDN of formula II can be linked to an antibody via a cleavable or non-cleavable linker. In certain embodiments, the CDN is released into tumor cells, cancer-associated immune cells, or tumor microenvironment upon cleavage of the linker.

[0009] In the ADC of formula I, where the CDN (D) is of formula II, the CDN is R 1 Hydroxyl, thiol, amino, C1-6 It may be covalently attached to the linker (L) at the alkylamino or -PEG-OH group.

[0010] In one embodiment of the present disclosure, the CDN of formula II is represented by formula IIe: [ka] or a pharma- ceutically acceptable salt thereof; In the formula, R 1 , R 5 and R 6、 R P、 And B 1 and B. 2 is as defined above for formula II.

[0011] In one embodiment of the present disclosure, the CDN of formula II is represented by formula IIk: [ka] or a pharma- ceutically acceptable salt thereof; During the ceremony, W, X, Y and Z are independently CH or N; and R P are each independently as defined above for Formula II.

[0012] In some embodiments, the present disclosure provides a composition comprising a CDN and a base, wherein the CDN is a compound of formula II, such as formula IIe or IIk above, or formula IIn or IIo below. In some such embodiments, the composition consists of a CDN and a base. In some embodiments, the base is an amine base, such as pyridine. In some of these embodiments, the composition is anhydrous.

[0013] In some embodiments, the present disclosure provides a composition comprising a CDN and a linker or binder, or both a linker and binder, wherein the CDN is a compound of formula II, such as formula IIe or IIk above, or formula IIn or IIo below, and the binder facilitates the attachment of the CDN to the linker, for example, by generating an activated ester on the linker. In some embodiments, the composition further comprises an aprotic polar solvent. In some embodiments, the composition is anhydrous.

[0014] In some embodiments, the disclosure provides compounds that are cyclic dinucleotides (CDNs) linked to a linker (L) of formula L-CDN. In certain embodiments, the CDN is linked to the linker L through a thioether, amide, ester, carbamate, carbonate, urea, disulfide, or ether group, particularly through an amide, carbamate, or disulfide group. In certain embodiments, the CDN is of formula II, such as formula IIe or IIk above, or formula IIm, IIn, or IIo below, and the CDN is R of formula II. 1 Thiol, amino, or C 1-6 An alkylamino group is attached to L, which contains a site that can bind to a complementary site on an antibody.

[0015] In one embodiment, the ADC of formula I has the structure of formula III: [ka] having where the variables W, X, Y, Z, and R P and n is defined above for Formulas I and II.

[0016] In one embodiment, the ADC of formula I has the structure of formula IV: [ka] having where the variables W, X, Y, Z, and R Pand n are defined above in Formulas I and II.

[0017] In one embodiment, the ADC of formula I or III has the following structure (CDN-A): [ka] CDN(D) with or a pharma- ceutically acceptable salt thereof. The phrase "obtained from" refers to the R 1 It will be understood that an amino (-NH) functionality at a position indicates a covalent bond to the corresponding position of the linker. For example, in some embodiments, the amino group is covalently bonded to a carbonyl moiety of the linker, thus forming an amide or carbamate bond.

[0018] In another embodiment, the ADC of formula I or IV has the following structure (CDN-B): [ka] CDN(D) with or a pharma- ceutically acceptable salt thereof. The phrase "obtained from" refers to the R 1 It will be understood that a thiol (-SH) functional group at a position indicates a covalent bond to the corresponding position of the linker. For example, in some embodiments, a thiol group of a CDN is covalently bonded to a thiol group of a linker, thereby forming a disulfide bond.

[0019] In another embodiment, the ADC of formula I or III has the following structure: [ka] CDN(D) with or a pharma- ceutically acceptable salt thereof.

[0020] In another embodiment, the ADC of formula I or III has the following structure: [ka] CDN(D) with or a pharma- ceutically acceptable salt thereof.

[0021] In another embodiment, the ADC of formula I or III has the following structure: [ka] CDN(D) with or a pharma- ceutically acceptable salt thereof.

[0022] In some embodiments, the antibody or antigen-binding fragment of the ADC of Formula I, III, or IV targets a specific antigen expressed on tumor cells or immune cells in the tumor microenvironment. In certain embodiments, the antibody or antigen-binding fragment of the ADC of Formula I, III, or IV targets the receptor PD-L1. In other specific embodiments, the antibody or antigen-binding fragment thereof specifically binds to a cancer-associated tumor antigen that is a growth factor receptor (GFR). In some embodiments, the cancer-associated tumor antigen is an EGFR / ErbB / HER family GFR.

[0023] In one aspect, the disclosure provides a method of inducing an immune response in a subject (e.g., a human patient) by administering a therapeutically effective amount of an ADC of Formula I, III, or IV. For example, an ADC of Formula I, III, or IV can be used to induce interferon-β (IFNβ) in a human subject.

[0024] The ADC of formula I, III or IV can be used in combination with one or more additional therapeutic agents. The additional therapeutic agent can be administered before, simultaneously with, or after the administration of the additional therapeutic agent. In certain embodiments, the ADC of formula I, III or IV can be used in combination with an immune checkpoint inhibitor. For example, the ADC of formula I, III or IV can be administered with an inhibitor of PD-1, PD-L1 or CTLA-4, or a combination thereof.

[0025] In another embodiment, an ADC of Formula I, III or IV can be administered with a free CDN that is not conjugated to the antibody or antigen-binding fragment of Formula I. In such cases, the free CDN can be the same as or different from the CDN that is conjugated to the antibody of the ADC of Formula I, III or IV. [Brief description of the drawings]

[0026]

FIG. 1A - 1D

[0027]

FIG. 2A - 2C

[0028]

FIG. 3A - 3B

[0029]

FIG. 4A - 4F

[0030]

FIG. 5A - 5B

[0031]

FIG. 6A - 6F

[0032]

FIG. 7A - 7F

[0033]

FIG. 8A - 8D

[0034]

FIG. 9A - 9D

[0035]

FIG. 10A - 10E

[0036] The present disclosure provides antibody-drug conjugates (ADCs) each comprising an antibody, one or more cyclic dinucleotides (CDNs), and one or more linkers connecting the one or more CDNs to the antibody. The ADCs of the present disclosure have the ability to stimulate and / or bind STING and promote an immune response.

[0037] 6.1. Antibody-Drug Conjugates (ADCs) In certain embodiments, the ADCs of the disclosure generally have the structure of Formula I: (Formula I) Ab-[-L-(D) m ] n having During the ceremony, "D" represents a CDN (e.g., a CDN described herein, such as a CDN of formula II); "Ab" refers to an antibody or binding fragment thereof that binds to a target antigen; each "L" independently represents a linker linking one or more D's to Ab; "m" represents the number of occurrences of D linked to a given linker, and "n" represents the number of linkers attached to the Ab.

[0038] In certain embodiments of Formula I, m represents a selected integer from 1 to 10, including 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some cases, m ranges from 1 to 2, 1 to 3, 1 to 4, 1 to 5, 1 to 6, 1 to 7, 1 to 8, 1 to 9, or 1 to 10, such as 1 to 2, 1 to 3, 1 to 4, 1 to 5, or 1 to 6. In other embodiments, Formula I describes ADCs in a mixture of ADCs exhibiting a range of values ​​of m such that m ranges from 1 to 2, 1 to 3, 1 to 4, 1 to 5, 1 to 6, 1 to 7, 1 to 8, 1 to 9, or 1 to 10, such as 1 to 2, 1 to 3, 1 to 4, 1 to 5, or 1 to 6. In certain embodiments, Formula I describes ADCs in a mixture of ADCs such that greater than 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the ADCs in the mixture have m values ​​of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, Formula I describes ADCs in a mixture of ADCs such that greater than 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the ADCs in the mixture have m values ​​in the range of 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, or 1-10, e.g., 1-2, 1-3, 1-4, 1-5, or 1-6.

[0039] In other embodiments, formula I describes an ADC in a mixture of ADCs, where m is "m ave ", which represents the average m value of the mixture, i.e., the average number of CDNs linked to a given linker (L) in the mixture, and can be calculated by dividing the total number of CDNs linked to the antibody by the total number of CDN-containing linkers (L) in the mixture. In such embodiments, m ave represents an integer or non-integer value in the range 1-10, e.g., 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, or 1-9.

[0040] In some embodiments of Formula I, n represents an integer selected from 1 to 20, including 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In some cases, n is in the range of 1 to 2, 1 to 3, 1 to 4, 1 to 5, 1 to 6, 1 to 7, 1 to 8, 1 to 9, 1 to 10, 1 to 11, 1 to 12, 1 to 13, 1 to 14, 1 to 15, 1 to 16, 1 to 17, 1 to 18, 1 to 19, or 1 to 20, such as 1 to 2, 1 to 3, 1 to 4, 1 to 5, 1 to 6, 1 to 7, or 1 to 8. In other embodiments, formula I describes an ADC in a mixture of ADCs exhibiting a range of n values, such that n is in the range of 1 to 2, 1 to 3, 1 to 4, 1 to 5, 1 to 6, 1 to 7, 1 to 8, 1 to 9, 1 to 10, 1 to 11, 1 to 12, 1 to 13, 1 to 14, 1 to 15, 1 to 16, 1 to 17, 1 to 18, 1 to 19 or 1 to 20, such as 1 to 2, 1 to 3, 1 to 4, 1 to 5, 1 to 6, 1 to 7, 1 to 8, 1 to 9 or 1 to 10. In certain embodiments, Formula I describes ADCs in a mixture of ADCs such that greater than 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the ADCs in the mixture have an n value of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In some embodiments, Formula I describes ADCs in a mixture of ADCs such that more than 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the ADCs in the mixture of ADCs have n values ​​in the range of 1 to 2, 1 to 3, 1 to 4, 1 to 5, 1 to 6, 1 to 7, 1 to 8, 1 to 9, 1 to 10, 1 to 11, 1 to 12, 1 to 13, 1 to 14, 1 to 15, 1 to 16, 1 to 17, 1 to 18, 1 to 19, or 1 to 20, e.g., 1 to 2, 1 to 3, 1 to 4, 1 to 5, 1 to 6, 1 to 7, 1 to 8, 1 to 9, or 1 to 10.

[0041] In other embodiments, formula I describes an ADC in a mixture of ADCs, where n is "n ave", which represents the average n value of the mixture, i.e., the average number of linkers (L) attached to a given antibody (Ab) in the mixture, and can be calculated by dividing the total number of linkers (L) attached to an antibody by the total number of linker-containing antibodies (Ab) in the mixture. In such an embodiment, n ave represents an integer or non-integer value in the range 1 to 20, e.g., 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 1-11, 1-12, 1-13, 1-14, 1-15, 1-16, 1-17, 1-18, 1-19, or 1-20.

[0042] In one embodiment, m is 1, in which case the ADC has a 1:1 ratio of linker to CDN and has formula Ia: (Formula Ia) Ab-[-LD] n It can be expressed by During the ceremony, "D" represents a CDN (e.g., a CDN described herein, such as a CDN of formula II); "Ab" refers to an antibody or binding fragment thereof that binds to a target antigen; each "L" independently represents a linker linking one or more D's to an Ab; and "n" represents the number of occurrences of D linked to Ab via a linker (L).

[0043] In some embodiments of formula Ia, n represents an integer selected from 1 to 20, including 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In some cases, n is in the range of 1 to 2, 1 to 3, 1 to 4, 1 to 5, 1 to 6, 1 to 7, 1 to 8, 1 to 9, 1 to 10, 1 to 11, 1 to 12, 1 to 13, 1 to 14, 1 to 15, 1 to 16, 1 to 17, 1 to 18, 1 to 19, or 1 to 20, such as 1 to 2, 1 to 3, 1 to 4, 1 to 5, 1 to 6, 1 to 7, or 1 to 8. In other embodiments, formula Ia describes an ADC in a mixture of ADCs exhibiting a range of n values, such that n ranges from 1 to 2, 1 to 3, 1 to 4, 1 to 5, 1 to 6, 1 to 7, 1 to 8, 1 to 9, 1 to 10, 1 to 11, 1 to 12, 1 to 13, 1 to 14, 1 to 15, 1 to 16, 1 to 17, 1 to 18, 1 to 19 or 1 to 20, such as 1 to 2, 1 to 3, 1 to 4, 1 to 5, 1 to 6, 1 to 7, or 1 to 8. In certain embodiments, Formula Ia describes ADCs in a mixture of ADCs such that greater than 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the ADCs in the mixture have an n value of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In some embodiments, Formula Ia describes ADCs in a mixture of ADCs such that more than 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the ADCs in the mixture have n values ​​in the range of 1 to 2, 1 to 3, 1 to 4, 1 to 5, 1 to 6, 1 to 7, 1 to 8, 1 to 9, 1 to 10, 1 to 11, 1 to 12, 1 to 13, 1 to 14, 1 to 15, 1 to 16, 1 to 17, 1 to 18, 1 to 19, or 1 to 20, such as 1 to 2, 1 to 3, 1 to 4, 1 to 5, 1 to 6, 1 to 7, or 1 to 8.

[0044] In other embodiments, formula Ia describes an ADC in a mixture of ADCs, where n is "n ave ", which represents the average n value of the mixture, i.e., the average number of linkers (L) attached to a given antibody (Ab) in the mixture, and can be calculated by dividing the total number of linkers (L) attached to an antibody by the total number of linker-containing antibodies (Ab) in the mixture. In such an embodiment, nave represents an integer or non-integer value in the range 1 to 20, e.g., 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 1-11, 1-12, 1-13, 1-14, 1-15, 1-16, 1-17, 1-18, 1-19, or 1-20.

[0045] The ADCs disclosed herein are "modular" in nature, in that each has the above-mentioned modular components Ab, L, and D. Throughout this disclosure, various specific, non-limiting embodiments and examples of these modular components are described. It is intended that all modules of the described specific embodiments can be combined with each other as if each specific combination was explicitly described individually.

[0046] Those of skill in the art will also understand that the various ADCs described herein may be in the form of a salt, and in some specific embodiments, a pharma- ceutically acceptable salt.

[0047] 6.2. Cyclic dinucleotides (CDNs) As used herein, a CDN comprises two nucleosides linked by two bridging groups. In one embodiment, the CDN is a 2'3'-CDN, meaning that each nucleoside comprises a cyclic 5-carbon sugar (pentose), with the first nucleoside linked at the 2' position of its sugar to the 5' position of the sugar of the second nucleoside, e.g., by an intervening bridging group, to form a 2'-5' bond, and the second nucleoside linked at the 3' position of its sugar to the 5' position of the sugar of the first nucleoside, e.g., by an intervening bridging group, to form a 3'-5' bond. Examples of suitable 2'3'-CDNs include 2'3'-cGAMP and its analogs or derivatives, including pharma- ceutically acceptable salts. The CDN of formula II below is a 2'3'-CDN.

[0048] In other embodiments, the CDN is a 3'3'-CDN, where the first nucleotide is linked to the second nucleotide, for example, by a 3'-5' linkage in a manner similar to that described above, with an intervening bridging group, and the second nucleotide is linked to the first nucleotide, for example, by a 3'-5' linkage in a manner similar to that described above, with an intervening bridging group. Examples of suitable 3'3'-CDNs include 3'3'-cGAMP and its analogs or derivatives, including pharma- ceutically acceptable salts.

[0049] In other embodiments, the CDN is a 2'2'-CDN, where the first nucleotide is linked to the second nucleotide, for example, by a 2'-5' linkage in a manner similar to that described above, with an intervening bridging group, and the second nucleotide is linked to the first nucleotide, for example, by a 2'-5' linkage in a manner similar to that described above, with an intervening bridging group. Examples of suitable 2'2'-CDNs include 2'2'-cGAMP and its analogs or derivatives, including pharma- ceutically acceptable salts.

[0050] In other embodiments, the CDN is a 3'2'-CDN, and the first nucleotide is linked to the second nucleotide by a 3'-5' linkage, for example, with an intervening bridging group, in a manner similar to that described above, and the second nucleotide is linked to the first nucleotide by a 2'-5' linkage, for example, with an intervening bridging group, in a manner similar to that described above. Examples of suitable 3'2'-CDNs include 3'2'-cGAMP and its analogs or derivatives, including pharma- ceutically acceptable salts.

[0051] Nucleosides In some examples, each nucleoside of the CDN comprises a nucleobase that can be a pyrimidine base or a purine base, independently of each other. For example, each nucleobase can be a canonical nucleobase (e.g., adenine, guanine, thymine, uracil, or cytosine) or a non-canonical modified non-natural nucleobase (e.g., xanthine, hypoxanthine, 7-methylguanine, 5,6-dihydrouracil, 5-methylcytosine, 5-hydroxymethylcytosine, 1-methylcytosine, 2,6-diaminopurine, 6,8-diaminopurine, 2-aminoimidazo[1,2a][1,3,5]triazin-4(1H)-one, 6-amino-5-nitropyridin-2-one, iso-guanine, iso-cytosine, 5-(2,4-diaminopyrimidine), 4-thiouracil, pseudouracil, etc.). Suitable nucleobases include those having the variable B 1 and B. 2 Regarding these, the following are included:

[0052] In some cases, the CDN comprises two nucleosides that comprise two pyrimidine bases or two purine bases, or one pyrimidine base and one purine base. In some embodiments, the two nucleosides comprise two purine bases, for example, adenine and guanine, two adenines, or two guanines, particularly adenine and guanine or two adenines. It is understood that the description of the indefinite article "a" or "an" before a particular nucleobase or other defined chemical structure (e.g., "adenine") indicates that both the canonical nucleobase and its modified variants are contemplated.

[0053] In some embodiments, a CDN comprises two nucleosides, each of which comprises a cyclic five-carbon sugar (pentose), such as D- or L-ribose or deoxyribose, D- or L-arabinose, D- or L-lyxose, D- or L-xylose, or modified forms thereof. In some cases, one of the pentoses of the CDN (e.g., ribose) is at the 3' position of the sugar, e.g., at the 3' position of C 1-6 Alkyl groups (e.g., C2-6 C is bonded to a linker (L) via an alkyl group. 1-6 The alkyl groups are hydroxyl, thiol, amino, C 1-6 Alkylamino or -PEG-OH groups, hydroxyl, thiol, amino, or C 1-6 Alkylamino group, thiol group, amino group, or C 1-6 In other embodiments, one of the pentoses (e.g., ribose) of the CDN is optionally substituted at the 2' position of the sugar, e.g., at the 2' position of C 1-6 Alkyl groups (e.g., C 2-6 C is bonded to a linker (L) via an alkyl group. 1-6 The alkyl groups are hydroxyl, thiol, amino, C 1-6 Alkylamino or -PEG-OH groups, hydroxyl, thiol, amino, or C 1-6 Alkylamino group, thiol group, amino group, or C 1-6 Optionally substituted with an alkylamino group, or with a thiol or amino group. In some embodiments, the linker (L) is a hydroxyl, thiol, amino, C 1-6 It is attached to the CDN by replacing the proton of the alkylamino or -PEG-OH group.

[0054] The following description of the 3'-position of the pentose can also be applied to the 2'-position of the pentose.

[0055] In some cases, the 3' group of the pentose (e.g., ribose) is replaced with a hydroxyl C 2-6 C such as alkyl group 1-6 It is an alkyl group, for example, -ethylene-OH, -propylene-OH, -butylene-OH, or -pentylene-OH. In some embodiments, the linker (L) is linked by replacing the hydroxyl proton with one of the above groups.

[0056] In some cases, the 3' group of the pentose (e.g., ribose) is replaced with a thiol C2-6 C such as alkyl group 1-6 It is an alkyl group, for example, -ethylene-SH, -propylene-SH, -butylene-SH, or -pentylene-SH. In some embodiments, the linker (L) is linked by replacing the proton of a thiol with one of the above groups.

[0057] In some cases, the 3' group of the pentose (e.g., ribose) is replaced with an amino C 2-6 C such as alkyl group 1-6 It is an alkyl group, for example, -ethylene-NH2, -propylene-NH2, -butylene-NH2, or -pentylene-NH2. In some embodiments, the linker (L) is linked by replacing the amino proton with one of the above groups.

[0058] In some embodiments, the group at the 3' position of the pentose (e.g., ribose) is C 1-6 Alkylamino-substituted C 2-6 C such as alkyl group 1-6 is an alkyl group, for example, -ethylene-N(C 1-6 Alkyl)H, -Propylene-N(C 1-6 Alkyl)H, -Butylene-N(C 1-6 Alkyl)H, or -Pentylene-N(C 1-6 In some embodiments, the linker (L) is one of the above groups. 1-6 The linkage is achieved by replacing the proton of the alkylamino.

[0059] In one embodiment, the 3' group of the pentose (e.g., ribose) is a C substituted with a -PEG-OH group. 2-6 C such as alkyl group 1-6It is an alkyl group, such as ethylene-PEG-OH, -propylene-PEG-OH, -butylene-PEG-OH, or -pentylene-PEG-OH. In some embodiments, the linker (L) is linked by replacing the proton of the terminal hydroxyl of the -PEG-OH group. "PEG" is a group consisting of the repeating structure -(O-CH-CH) x - and is understood to refer to polymer polyethylene glycols, polyethylene oxides or polyoxyethylenes having an average molecular weight of 200 to 10000 g / mol, for example 200, 400, 800, 1000, 2000 or 4000 to 5000, 6000 8000 or 10000 g / mol, for example 400 to 8,000 g / mol, 400 to 2000 g / mol, 5000 to 10000 g / mol, 1000 to 4000 g / mol, 1000 to 6000 g / mol or 2000 to 6000 g / mol, for example less than 4000, 5000 or 6000 g / mol.

[0060] In some cases, the group at the 3' position of the pentose (e.g., ribose) is a hydroxyl, thiol, amino, C 1-6 C substituted with alkylamino or -PEG-OH groups 2-3 Alkyl groups, such as -ethylene-OH, -propylene-OH, -ethylene-SH, -propylene-SH, -ethylene-NH2, -propylene-NH2, -ethylene-N(C 1-6 Alkyl)H, -Propylene-N(C 1-6 In some embodiments, the linker (L) is a hydroxyl, thiol, amino or C alkyl group at one of the above groups. 1-6 The linkage is effected by replacing the proton of the alkylamino or -PEG-OH group.

[0061] In some cases, the group at the 3' position of the pentose (e.g., ribose) is a hydroxyl, thiol, amino, C 1-6C2 alkyl groups (ethyl groups) substituted with alkylamino or -PEG-OH groups, e.g., -ethylene-OH, -ethylene-SH, -ethylene-NH2, -ethylene-N(C 1-6 In some embodiments, the linker (L) is a hydroxyl, thiol, amino or C at one of the above groups. 1-6 The linkage is effected by replacing the proton of the alkylamino or -PEG-OH group.

[0062] In some cases, the group at the 3' position of the pentose (e.g., ribose) is a hydroxyl, thiol, amino, C 1-6 alkylamino, or a C3 alkyl group (propyl group) substituted with a -PEG-OH group, such as -propylene-OH, -propylene-SH, -propylene-NH2, -propylene-N(C 1-6 In some embodiments, the linker (L) is a hydroxyl, thiol, amino or C alkyl group. 1-6 The linkage is effected by replacing the proton of the alkylamino or -PEG-OH group.

[0063] In one embodiment, one of the pentoses of the CDN (e.g., ribose) is attached to a linker (L) at the 3' position of the sugar via a substituted methyl group at the 3' position, and the methyl group can be, for example, a hydroxyl, thiol, amino, C 1-6 Alkylamino or -PEG-OH groups, hydroxyl, thiol, amino or C 1-6 Alkylamino group, thiol group, amino group, or C 1-6 In some embodiments, the linker (L) is substituted with an alkylamino group, a thiol group, an amino group, or a thiol group. In some embodiments, the linker (L) is substituted with a hydroxyl, thiol, amino, C 1-6 It is attached to the CDN by replacing the proton of the alkylamino or -PEG-OH group.

[0064] In one embodiment, the CDN comprises two nucleosides, each containing a ribose, one of the riboses being C at the 3′ position of the ribose ring. 2-6 Alkyl groups (e.g., C2 alkyl, C3 alkyl or C 2-3 C is bonded to a linker (L) via an alkyl group. 2-6 The alkyl groups are hydroxyl, thiol, amino, C 1-6 Alkylamino or -PEG-OH groups, hydroxyl, thiol, amino or C 1-6 Alkylamino group, thiol group, amino group, or C 1-6 Optionally substituted with alkylamino groups, or with thiol or amino groups, the linker (L) being hydroxyl, thiol, amino, C 1-6 They are attached to the CDN by replacing the protons of the alkylamino or -PEG-OH groups.

[0065] In one embodiment, the CDN comprises two nucleosides, each containing a ribose, one of which is attached to a linker (L) via a substituted ethyl group at the 3′ position of the ribose ring, the ethyl group being, for example, a hydroxyl, thiol, amino, C 1-6 Alkylamino or -PEG-OH groups, hydroxyl, thiol, amino or C 1-6 Alkylamino group, thiol group, amino group, or C 1-6 substituted with an alkylamino group or with a thiol or amino group, and the linker (L) is hydroxyl, thiol, amino, C 1-6 They are attached to the CDN by replacing the protons of the alkylamino or -PEG-OH groups.

[0066] In one embodiment, the CDN comprises two nucleosides, each containing a ribose, one of the riboses being linked to a linker (L) via a substituted ethyl group at the 3' position of the ribose ring selected from -CH2CH2-OH, -CH2CH2-SH, and -CH2CH2-NH2, particularly -CH2CH2-SH and -CH2CH2-NH2, and the linker (L) is linked to the CDN by replacing a proton of a hydroxyl, thiol, or amino group.

[0067] 6.2.2.Bridging group Due to the cyclic structure, the CDN includes two bridging groups that link the nucleosides to form the CDN macrocycle. In certain embodiments, the bridging groups independently include 2-5 atoms, e.g., 3 atoms, in the bridge between the two sugars of the nucleoside. For example, -OP(=O)(OH)-O- can be a bridging group, where it is understood that the sugars are linked at the terminal oxygen atom and there are 3 atoms in the bridge. The bridging groups can independently include only heteroatoms in the bridge, both heteroatoms and carbon atoms in the bridge, or only carbon atoms in the bridge.

[0068] In some cases, the bridging group is a divalent phosphate or thiophosphate group or modified variants thereof, such as -OP(=O)(OH)-O- or -OP(=O)(SH)-O-. For example, two bridging groups are independently -OP(O)R P -O-, -OP(S)R P -O-, -OP(O)R P -S-, -OP(S)R P -S-, -SP(O)R P -O-, -SP(S)R P -O-, -SP(O)R P -S- or -SP(S)R P -You can choose from S, R P is further defined below. In some embodiments, R of the bridging group P are each independently selected from hydroxyl or thiol.

[0069] It is understood that when both bridging groups are phosphate groups or modified variants thereof, each bridging group in combination with a nucleoside as described above represents a nucleotide, and both sets of bridging groups and nucleosides provide a cyclic dinucleotide. Nevertheless, the CDNs disclosed herein are not necessarily limited to bridging groups that are phosphate groups.

[0070] 6.2.3.Specific CDN The present disclosure provides a CDN (D) that can be administered alone or as part of an ADC of formula I. In some cases, the CDN has the structure of formula II below. It is understood that a reference to formula I also includes a reference to subformula Ia. Similarly, a reference to formula II also includes a reference to subformulas of formula II, such as formula IIa, IIb, etc. Formula II has the structure: [ka] or a pharma- ceutically acceptable salt thereof; During the ceremony, R 1 are hydroxyl, thiol, amino, C 1-6 C substituted with alkylamino or -PEG-OH groups 1-6 Alkyl, e.g. C 2-6 Alkyl or C 2-3 is alkyl, R 3 and R 4 are independently hydrogen, halogen, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 alkynyl, wherein C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl is independently selected from halogen, thiol, hydroxyl, carboxyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C 1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 Alkyl)C(O)C 1-6 Alkyl, Amino, C1-6 Alkylamino, di(C 1-6 optionally substituted with one or more groups selected from alkyl, amino, oxo and azido; R 2 , R 5 and R 6 are independently hydrogen, halogen, hydroxyl, azide, amino, C 1-6 Alkylamino, di(C 1-6 Alkyl)amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 3-6 Alkenyl-O-,C 2-6 Alkynyl or C 3-6 alkynyl-O-, wherein C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 3-6 Alkenyl-O-,C 2-6 Alkynyl and C 3-6 Alkynyl-O- is independently selected from halogen, thiol, hydroxyl, carboxyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C 1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 Alkyl)C(O)C 1-6 Alkyl, Amino, C 1-6 Alkylamino, di(C 1-6 Optionally substituted with one or more groups selected from amino, oxo, and azido, or R 6 and R 5 together form =CH2, or R 6 and R 4 together form a V selected from ethylene, -O-CH2- and -NH-CH2- 2 forming a bridge across the ring containing V 1 and V 2 are independently O, S or CH2; V 1 BG starting from a carbon in the ring containing 1and V 2 BG starting from a carbon in the ring containing 2 are independently -OP(O)R P -O-, -OP(S)R P -O-, -OP(O)R P -S-, -OP(S)R P -S-, -SP(O)R P -O-, -SP(S)R P -O-, -SP(O)R P -S-, -SP(S)R P -S-, -NH-P(O)R P -O-, -OP(O)R P -NH-, -NH-P(S)R P -O-, -OP(S)R P -NH- or -NH-SO2-NH-, R P are each independently a hydroxyl, a thiol, or C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Alkenyl-O-,C 3-6 Alkynyl-O-, -PEG-OH, Borano (-BH3 - ), or -NR'R'', where C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Alkenyl-O-, and C 3-6 Alkynyl-O- is independently selected from halogen, thiol, hydroxyl, carboxyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C 1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 Alkyl)C(O)C 1-6 Alkyl, Amino, C 1-6 Alkylamino, di(C 1-6 alkyl) optionally substituted with one or more groups selected from amino, oxo, and azido; and R' and R'' are independently hydrogen or halogen, thiol, hydroxyl, carboxyl, C 1-6 Alkoxy, C 1-6Hydroxyalkoxy, -OC(O)C 1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 Alkyl)C(O)C 1-6 Alkyl, Amino, C 1-6 Alkylamino, di(C 1-6 C optionally substituted with one or more groups selected from amino, oxo and azido 1-6 alkyl, or R' and R'' on the same nitrogen are taken together as C 3-5 Forming a heterocyclic ring, R a1 , R b1 , R a2 and R b2 are independently hydrogen or C 1-3 is alkyl, B 1 and B. 2 is, independently, [ka] is selected from V 3 is O or S, in particular O, Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , and Z 6 are each independently z or N, Z a is O(Z 5 is N) or NR', in which R z are each independently hydrogen, halogen, azide, amino, C 1-6 Alkylamino, di(C 1-6 Alkyl)amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 3-6 Alkenyl-O-,C 2-6 Alkynyl, C 3-6 Alkynyl-O-, -NO2, -CN, -C(O)C1-6 Alkyl, -CO2H, -CO2C 1-6 Alkyl, -S(O)C 1-6 Alkyl, -S(O)C 1-6 Alkyl, -C(O)NR', ​​-C(O)NR'R'', -SO2NR'R'', -OC(O)C 1-6 Alkyl, -NR'C(O)C 1-6 Alkyl, -N(R')C(O)NR'R'', -N(R')SO2NR'R'', -N(R)SO2C 1-6 alkyl, or -OC(O)NR'R'', wherein C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 3-6 Alkenyl-O-,C 2-6 Alkynyl, and C 3-6 Alkynyl-O- is independently a halogen, a thiol, a hydroxyl, a carboxyl, or a C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C 1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 Alkyl)C(O)C 1-6 Alkyl, Amino, C 1-6 Alkylamino, di(C 1-6 optionally substituted with one or more groups selected from alkyl, amino, oxo and azido; R' and R'' are each independently hydrogen or a halogen, thiol, hydroxyl, carboxyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C 1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 Alkyl)C(O)C 1-6 Alkyl, Amino, C 1-6 Alkylamino, di(C 1-6 C optionally substituted with one or more groups selected from amino, oxo and azido 1-6 alkyl, or R' and R'' on the same nitrogen are taken together as C3-5 It forms a heterocyclic ring.

[0071] In some examples, when a CDN (D) of formula II is covalently attached to a linker (L) of an ADC of formula I or Ia, the CDN can be represented by R 1 Hydroxyl, thiol, amino, C 1-6 Covalent attachment to the linker is via the alkylamino or -PEG-OH group.

[0072] In one embodiment, R 1 are hydroxyl, thiol, amino, C 1-6 C substituted with alkylamino or -PEG-OH groups 2-6 In some embodiments, R 1 is hydroxyl, thiol, amino, or C 1-6 Alkylamino-substituted C 2-6 In one embodiment, R 1 is a thiol, amino, or C 1-6 Alkylamino-substituted C 2-6 In some embodiments, R 1 is a thiol or amino substituted C 2-6 In one embodiment, R 1 is a thiol-substituted C 2-6 In some embodiments, R 1 is an amino-substituted C 2-6 For any of these embodiments, R 1 is C 2-4 Alkyl, e.g., hydroxyl, thiol, amino, or C 1-6 Alkylamino-substituted C 2-3 Alkyl, e.g., hydroxyl, thiol, amino, or C 1-6 It may be ethyl substituted with alkylamino.

[0073] In some embodiments, R 1 is a C substituted with a hydroxyl group. 2-4 In some such embodiments, R1 is a C alkyl substituted with hydroxyl. In other such embodiments, R 1 is a C alkyl substituted with hydroxyl. In yet other such embodiments, R 1 is a C4 alkyl substituted with hydroxyl.

[0074] In some embodiments, R 1 is C substituted with an amino (-NH2) group. 2-4 In some such embodiments, R 1 is a C alkyl substituted with an amino group. In other such embodiments, R 1 is a C alkyl substituted with an amino group. In yet other such embodiments, R 1 is a C4 alkyl substituted with an amino group.

[0075] In some embodiments, R 1 is a C substituted with a thiol (-SH) group. 2-4 In some such embodiments, R 1 is a C alkyl substituted with a thiol group. In other such embodiments, R 1 is a C alkyl substituted with a thiol group. In yet other such embodiments, R 1 is a C4 alkyl substituted with a thiol group.

[0076] In some embodiments, R 1 is C 1-6 C substituted with alkylamino groups 2-4 In some such embodiments, R 1 is a C alkyl substituted with a methylamino group. In other such embodiments, R 1 is a C alkyl substituted with a methylamino group. In yet other such embodiments, R 1 is a C3 alkyl substituted with a methylamino group.

[0077] In some embodiments, R3 and R 4 are independently hydrogen, halogen, C 1-6 Alkyl, C 2-6 Alkenyl, or C 2-6 alkynyl, wherein C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl is unsubstituted. In certain embodiments, R 3 and R 4 are independently hydrogen, C 1-6 Alkyl or C 2-6 alkynyl, wherein C 1-6 Alkyl and C 2-6 The alkynyl is unsubstituted.

[0078] In some embodiments, R 3 and R 4 One of them is hydrogen and the other is a halogen, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl is independently selected from halogen, thiol, hydroxyl, carboxyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C 1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 Alkyl)C(O)C 1-6 Alkyl, Amino, C 1-6 Alkylamino, di(C 1-6 In some embodiments, R is optionally substituted with one or more groups selected from alkyl, amino, oxo, and azido. 3 and R 4 One of them is hydrogen and the other is a halogen, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 alkynyl, wherein C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6Alkynyl is unsubstituted. In certain embodiments, R 3 and R 4 One of them is hydrogen and the other is C 1-6 Alkyl or C 2-6 alkynyl, wherein C 1-6 Alkyl and C 2-6 Alkynyl is unsubstituted. In some embodiments, R 3 and R 4 are both hydrogen.

[0079] In one embodiment, R 2 is hydrogen, halogen, hydroxyl, azide, amino, C 1-6 Alkyl, or C 1-6 Alkoxy, C 1-6 Alkyl and C 1-6 Alkoxy is independently halogen, thiol, hydroxyl, carboxyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C 1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 Alkyl)C(O)C 1-6 Alkyl, Amino, C 1-6 Alkylamino, di(C 1-6 In some embodiments, R is optionally substituted with one or more groups selected from alkyl, amino, oxo, and azido. 2 is hydrogen, halogen, hydroxyl, azide, amino, C 1-6 Alkyl, or C 1-6 Alkoxy, C 1-6 Alkyl and C 1-6 Alkoxy is unsubstituted. In one embodiment, R 2 is hydrogen or halogen, e.g., fluorine. In the examples, R 2 is hydrogen.

[0080] In some embodiments, R 5 and R 6 are independently hydrogen, halogen, hydroxyl, azide, amino, C 1-6 Alkyl, or C1-6 Alkoxy, C 1-6 Alkyl and C 1-6 Alkoxy is independently halogen, thiol, hydroxyl, carboxyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C 1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 Alkyl)C(O)C 1-6 Alkyl, Amino, C 1-6 Alkylamino, di(C 1-6 In one embodiment, R is optionally substituted with one or more groups selected from alkyl, amino, oxo, and azido. 5 and R 6 are independently hydrogen, halogen, hydroxyl, azide, amino, C 1-6 Alkyl, or C 1-6 Alkoxy, C 1-6 Alkyl and C 1-6 The alkoxy is unsubstituted. In some embodiments, R 5 and R 6 is independently hydrogen, halogen, or hydroxyl. 5 and R 6 together equals =CH2.

[0081] In one embodiment, R 5 is hydrogen and R 6 is hydrogen, halogen, hydroxyl, azide, amino, C 1-6 Alkylamino, di(C 1-6 Alkyl)amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 3-6 Alkenyl-O-,C 2-6 Alkynyl or C 3-6 alkynyl-O-, wherein C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 3-6 Alkenyl-O-,C 2-6 Alkynyl and C3-6 Alkynyl-O- is independently selected from halogen, thiol, hydroxyl, carboxyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C 1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 Alkyl)C(O)C 1-6 Alkyl, Amino, C 1-6 Alkylamino, di(C 1-6 In some embodiments, R is optionally substituted with one or more groups selected from alkyl, amino, oxo, and azido. 5 is hydrogen and R 6 is hydrogen, halogen, hydroxyl, azide, amino, C 1-6 Alkyl, or C 1-6 Alkoxy, C 1-6 Alkyl and C 1-6 Alkoxy is independently halogen, thiol, hydroxyl, carboxyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C 1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 Alkyl)C(O)C 1-6 Alkyl, Amino, C 1-6 Alkylamino, di(C 1-6 In one embodiment, R is optionally substituted with one or more groups selected from alkyl, amino, oxo, and azido. 5 is hydrogen and R 6 is hydrogen, halogen, hydroxyl, azide, amino, C 1-6 Alkyl, or C 1-6 Alkoxy, C 1-6 Alkyl and C 1-6 The alkoxy is unsubstituted. In some embodiments, R 5 is hydrogen and R 6 is hydrogen, halogen (e.g., fluorine or chlorine), hydroxyl or unsubstituted C 1-6 In some embodiments, R 5is hydrogen, and R 6 is a halogen, such as fluorine or chlorine. 5 is hydrogen and R 6 is hydroxyl. In other embodiments, R 5 is hydrogen, and R 6 is unsubstituted C 1-6 Alkoxy, for example methoxy.

[0082] In one embodiment, R 6 is hydrogen and R 5 is hydrogen, halogen, hydroxyl, azide, amino, C 1-6 Alkylamino, di(C 1-6 Alkyl)amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 3-6 Alkenyl-O-,C 2-6 Alkynyl or C 3-6 alkynyl-O-, wherein C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 3-6 Alkenyl-O-,C 2-6 Alkynyl and C 3-6 Alkynyl-O- is independently selected from halogen, thiol, hydroxyl, carboxyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C 1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 Alkyl)C(O)C 1-6 Alkyl, Amino, C 1-6 Alkylamino, di(C 1-6 In some embodiments, R is optionally substituted with one or more groups selected from alkyl, amino, oxo, and azido. 6 is hydrogen and R 5 is hydrogen, halogen, hydroxyl, azide, amino, C 1-6 Alkyl, or C 1-6 Alkoxy, C 1-6 Alkyl and C 1-6Alkoxy is independently halogen, thiol, hydroxyl, carboxyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C 1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 Alkyl)C(O)C 1-6 Alkyl, Amino, C 1-6 Alkylamino, di(C 1-6 In one embodiment, R is optionally substituted with one or more groups selected from alkyl, amino, oxo, and azido. 6 is hydrogen and R 5 is hydrogen, halogen, hydroxyl, azide, amino, C 1-6 Alkyl, or C 1-6 Alkoxy, C 1-6 Alkyl and C 1-6 The alkoxy is unsubstituted. In some embodiments, R 6 is hydrogen and R 5 is hydrogen, halogen (e.g., fluorine or chlorine), hydroxyl or unsubstituted C 1-6 In some embodiments, R 6 is hydrogen, and R 5 is a halogen, such as fluorine or chlorine. 6 is hydrogen and R 5 is hydroxyl. In other embodiments, R 5 is hydrogen, and R 6 is unsubstituted C 1-6 Alkoxy, for example methoxy.

[0083] In some embodiments, R 5 and R 6 One of R is hydrogen and the other is a halogen, e.g., fluorine. 5 is hydrogen and R 6 is halogen, e.g., fluorine. In certain embodiments, R 6 is hydrogen and R 5 is a halogen, for example fluorine.

[0084] In some cases, R 5 and R 6 are both hydrogen or halogen, e.g., R 5 and R 6 are hydrogen, or R 5 and R 6 are both halogens, for example fluorine.

[0085] In some embodiments, R 5 is hydrogen. In other embodiments, R 5 is hydroxyl. In other embodiments, R 5 is a halogen. For example, R 5 can be fluorine, bromine or chlorine.

[0086] In some embodiments, R 6 is hydrogen. In other embodiments, R 6 is hydroxyl. In other embodiments, R 6 is methoxy. In another embodiment, R 6 is a halogen. For example, R 6 can be fluorine, bromine or chlorine.

[0087] In one embodiment, V 1 and V 2 is independently O or S. In some embodiments, V 1 and V 2 is independently O or CH. In some embodiments, V 1 and V 2 are both O. In one embodiment, V 1 and V 2 are both S. In one embodiment, V 1 and V 2 At least one of V is O. 1 and V 2 At least one of V is S. 1 and V 2 At least one of them is CH2.

[0088] In some embodiments, the BG 1 and B.G. 2 are independently -OP(O)R P -O- or -OP(S)R P In one embodiment, BG 1 and B.G. 2 At least one of the is -OP(O)R P In some embodiments, BG 1 and B.G. 2 At least one of the following is -OP(S)R P In one embodiment, BG 1 -OP(O)R P -O- and BG 2 -OP(S)R P In some embodiments, BG 1 -OP(O)R P -O- and BG 2 -OP(S)R P In one embodiment, BG 1 and B.G. 2 Both are -OP(O)R P -O-.

[0089] In one embodiment, R P are each independently a hydroxyl, a thiol, or C 1-6 Alkyl, borano (-BH3 - ), or -NR'R''. In some embodiments, R P are each independently hydroxyl or thiol. P is hydroxyl. In some embodiments, R P is a thiol. In some embodiments, one R P is a hydroxyl and the other is a thiol.

[0090] In some embodiments, the BG 1 and B.G. 2 Both are -OP(O)R P-O- and R P each independently represents a hydroxyl, a thiol, or a C 1-6 Alkyl, borano (-BH3 - ), or -NR'R''. In one embodiment, BG 1 and B.G. 2 Both are -OP(O)R P -O- and R P are each independently hydroxyl or thiol. In some embodiments, BG 1 and B.G. 2 Both are -OP(O)R P -O- and R P is hydroxyl. 1 and B.G. 2 Both are -OP(O)R P -O- and R P is a thiol. In some embodiments, BG 1 -OP(O)R P -O- and R P is hydroxyl, BG 2 -OP(O)R P -O- and R P is a thiol. In another embodiment, BG 1 -OP(O)R P -O- and R P is a thiol and BG 2 -OP(O)R P -O- and R P is hydroxyl.

[0091] In some cases, BG 1 and B.G. 2 At least one of the following is -NH-P(O)R P -O-, -OP(O)R P -NH-, -NH-P(S)R P -O- or -OP(S)R P -NH-. In some cases, BG 1 and B.G. 2 At least one of the following is -NH-P(O)R P -O- or -OP(O)RP In one embodiment, BG 1 and B.G. 2 Both are -NH-P(O)R P -O- or -OP(O)R P -NH-. In some cases, BG 1 and B.G. 2 At least one of the following is -NH-P(O)R P -O-, -OP(O)R P -NH-, -NH-P(S)R P -O- or -OP(S)R P -NH-, R P are each independently hydroxyl or thiol. 1 and B.G. 2 At least one of the following is -NH-P(O)R P -O- or -OP(O)R P -NH-, R P are each independently hydroxyl or thiol. 1 and B.G. 2 Both are -NH-P(O)R P -O- or -OP(O)R P -NH-, R P are each independently hydroxyl or thiol. In some embodiments, BG 1 and B.G. 2 Both are -NH-P(O)R P -O- or -OP(O)R P -NH-, R P is hydroxyl. In another embodiment, BG 1 and B.G. 2 Both are -NH-P(O)R P -O- or -OP(O)R P -NH-, R P is a thiol.

[0092] In one embodiment, R P When is -NR'R'', R' and R'' are independently hydrogen or unsubstituted C 1-6alkyl, or R' and R'' taken together on the same nitrogen are C aryl groups such as morpholine, pyrrolidine, or piperazine. 3-5 It forms a heterocyclic ring.

[0093] In one embodiment, B 1 and B. 2 are the same nucleobase. 1 and B. 2 are different nucleobases. In some embodiments, B 1 and B. 2 are both purine nucleobases. In one embodiment, B 1 and B. 2 are both pyrimidine nucleobases. In some embodiments, B 1 is a purine nucleobase, and B 2 is a pyrimidine nucleobase. In one embodiment, B 1 is a pyrimidine nucleobase, B 2 is a purine nucleobase.

[0094] In some instances, B 1 and B. 2 is independently selected from adenine, guanine, thymine, uracil and cytosine, and modified variants thereof. 1 and B. 2 In some embodiments, both of B are adenine or modified variants thereof. 1 and B. 2 In one embodiment, both of B are guanine or modified variants thereof. 1 is guanine or a modified variant thereof, and B 2 is adenine or a modified variant thereof. In some embodiments, B 1 is adenine or a modified variant thereof, and B 2 is guanine or a modified variant thereof.

[0095] In some embodiments, B 1 and B. 2 is, independently, [ka] is selected from the group consisting of Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , and Z 6 are each independently z or N, Z a is O(Z 5 is N) or NR', in which R z are each independently hydrogen, halogen, azide, amino, C 1-6 Alkylamino, di(C 1-6 Alkyl)amino, C 1-6 Alkyl, C 1-6 Alkoxy, -C(O)C 1-6 Alkyl, -CO2H, -CO2C 1-6 Alkyl, -C(O)NR', ​​-C(O)NR'R'', -OC(O)C 1-6 Alkyl, -NR'C(O)C 1-6 alkyl, -N(R')C(O)NR'R'', or -OC(O)NR'R'', C 1-6 Alkyl and C 1-6 Each alkoxy is independently a halogen, a thiol, a hydroxyl, a carboxyl, a C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C 1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 Alkyl)C(O)C 1-6 Alkyl, Amino, C 1-6 Alkylamino, di(C 1-6 optionally substituted with one or more groups selected from alkyl, amino, oxo and azido; R' and R'' are each independently hydrogen or a halogen, thiol, hydroxyl, carboxyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 Alkyl)C(O)C 1-6 Alkyl, Amino, C 1-6 Alkylamino, di(C 1-6 C optionally substituted with one or more groups selected from amino, oxo and azido 1-6 alkyl, or R' and R'' on the same nitrogen are taken together as C 3-5 It forms a heterocyclic ring.

[0096] In some embodiments, B 1 and B. 2 For one or both Z 1 CR z (e.g., CH or CNH2). In some embodiments, one or both of Z 5 CR z (e.g., CH or CNH2). In some embodiments, one or both of Z 1 CR z (e.g., CH or CNH2) and Z 5 Either or both of the z (e.g., CH or CNH2). In one embodiment, both Z 1 CR z (e.g., CH or CNH2) and both Z 5 CR z (CH or CNH2, etc.).

[0097] In some cases, B. 1 and B. 2 About Z 3 CR z (e.g., CH or CNH2). In one embodiment, Z 3 CR z (e.g., CH or CNH2) and one or both Z 1 CR z (e.g., CH or CNH2). In one embodiment, Z 3 CR z (e.g., CH or CNH2) and one or both Z5 CR z (e.g., CH or CNH2). In one embodiment, Z 3 CR z (e.g., CH or CNH2) and both Z 1 CR z (e.g., CH or CNH2) and both Z 5 CR z (CH or CNH2, etc.).

[0098] In some cases, B. 1 and B. 2 About Z a NH or NC 1-6 In another embodiment, Z is NR′, such as alkyl. a is O.

[0099] In an example embodiment, one or both Z 2 is N. In one embodiment, Z 4 is N. In some embodiments, one or both of Z 2 is N and Z 4 is N. In one embodiment, both Z 2 is N and Z 4 is N.

[0100] In an example embodiment, one or both Z 6 is N. In one embodiment, Z 4 is N. In some embodiments, one or both of Z 6 is N and Z 4 is N. In one embodiment, both Z 6 is N and Z 4 is N. In some embodiments, one or both of Z 6 is N and one or both Z 2 is N. In some embodiments, both Z 6 is N and both Z 2 is N.

[0101] In some embodiments, B 1 and B.2 is, independently, [ka] is selected from the group consisting of Z 1 , Z 3 , and Z 5 are each independently z or N, Z a is O(Z 5 is N) or NR', in which R z are each independently hydrogen, halogen, azide, amino, C 1-6 Alkylamino, di(C 1-6 Alkyl)amino, C 1-6 Alkyl, C 1-6 Alkoxy, -C(O)C 1-6 Alkyl, -CO2H, -CO2C 1-6 Alkyl, -C(O)NR', ​​-C(O)NR'R'', -OC(O)C 1-6 Alkyl, -NR'C(O)C 1-6 alkyl, -N(R')C(O)NR'R'', or -OC(O)NR'R'', C 1-6 Alkyl and C 1-6 Each alkoxy is independently a halogen, a thiol, a hydroxyl, a carboxyl, a C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C 1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 Alkyl)C(O)C 1-6 Alkyl, Amino, C 1-6 Alkylamino, di(C 1-6 optionally substituted with one or more groups selected from alkyl, amino, oxo and azido; R' and R'' are each independently hydrogen or a halogen, thiol, hydroxyl, carboxyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 Alkyl)C(O)C 1-6 Alkyl, Amino, C 1-6 Alkylamino, di(C 1-6 C optionally substituted with one or more groups selected from amino, oxo and azido 1-6 alkyl, or R' and R'' on the same nitrogen are taken together as C 3-5 It forms a heterocyclic ring.

[0102] In some embodiments, B 1 and B. 2 is, independently, [ka] is selected from the group consisting of Z a is NR', wherein R z are each independently hydrogen, halogen, azide, amino, C 1-6 Alkylamino, di(C 1-6 Alkyl)amino, C 1-6 Alkyl, C 1-6 Alkoxy, -C(O)C 1-6 Alkyl, -CO2H, -CO2C 1-6 Alkyl, -C(O)NR', ​​-C(O)NR'R'', -OC(O)C 1-6 Alkyl, -NR'C(O)C 1-6 alkyl, -N(R')C(O)NR'R'', or -OC(O)NR'R'', C 1-6 Alkyl and C 1-6 Each alkoxy is independently a halogen, a thiol, a hydroxyl, a carboxyl, a C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C 1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 Alkyl)C(O)C 1-6 Alkyl, Amino, C1-6 Alkylamino, di(C 1-6 optionally substituted with one or more groups selected from alkyl, amino, oxo and azido; R' and R'' are each independently hydrogen or a halogen, thiol, hydroxyl, carboxyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C 1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 Alkyl)C(O)C 1-6 Alkyl, Amino, C 1-6 Alkylamino, di(C 1-6 C optionally substituted with one or more groups selected from amino, oxo and azido 1-6 alkyl, or R' and R'' on the same nitrogen are taken together as C 3-5 It forms a heterocyclic ring.

[0103] In one embodiment, B 1 and B. 2 is independently [ka] is selected from.

[0104] In one embodiment, R a1 , R b1 , R a2 , and R b2 are all hydrogen. In some embodiments, R a1 , R b1 , R a2 and R b2 At least one of the C groups, such as methyl 1-3 In some cases, R a1 and R a2 is C 1-3 alkyl, e.g., methyl. In some embodiments, R a1 , R b1 , R a2 and R b2One of them is C, such as methyl. 1-3 It is an alkyl.

[0105] In some cases, the CDN has the structure of formula IIa: [ka] or a pharma- ceutically acceptable salt thereof; In the formula, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 , V 1 and V 2 , B.G. 1 and B.G. 2 , B 1 and B. 2 is as defined above for formula II.

[0106] In some embodiments of Formula IIa, R 1 is a C substituted with hydroxyl, thiol or amino. 2-4 In certain embodiments of Formula IIa, R 1 is a thiol or amino substituted C 2-4 Alkyl, for example ethyl.

[0107] In some cases, the CDN has the structure of formula IIb: [ka] or a pharma- ceutically acceptable salt thereof; In the formula, R 1 , R 5 and R 6 , V 1 and V 2 , B.G. 1 and B.G. 2 , B 1 and B. 2 is as defined above for formula II.

[0108] In some embodiments of Formula IIb, R 1 is a C substituted with hydroxyl, thiol or amino. 2-4 In certain embodiments of Formula IIb, R 1 is a thiol or amino substituted C 2-4 Alkyl, for example ethyl.

[0109] In some cases, the CDN has the structure of formula IIc: [ka] or a pharma- ceutically acceptable salt thereof. In the formula, R 1 , R 5 and R 6 , B.G. 1 and B.G. 2 , and B 1 and B. 2 is as defined above for formula II.

[0110] In some embodiments of Formula IIc, R 1 is a C substituted with hydroxyl, thiol or amino. 2-4 In certain embodiments of Formula IIc, R 1 is a thiol or amino substituted C 2-4 Alkyl, for example ethyl.

[0111] In some cases, the CDN has the structure of formula IId: [ka] or a pharma- ceutically acceptable salt thereof. In the formula, R 1 , R 5 , R 6 and R P , V 1 and V 2 , and B 1 and B. 2 is as defined above for formula II.

[0112] In some embodiments of Formula IId, R 1 is a C substituted with hydroxyl, thiol or amino. 2-4 In certain embodiments of formula IId, R 1 is a thiol or amino substituted C 2-4 Alkyl, for example ethyl.

[0113] In some cases, the CDN has the structure of formula IIe: [ka] or a pharma- ceutically acceptable salt thereof. In the formula, R 1 , R 5 , R 6 and R P , and B 1 and B. 2 is as defined above for formula II.

[0114] In some embodiments of Formula IIe, R 1 is a C substituted with hydroxyl, thiol or amino. 2-4 In certain embodiments of formula IIe, R 1 is a thiol or amino substituted C 2-4 Alkyl, for example ethyl.

[0115] In some cases, the CDN has the structure of formula IIf: [ka] or a pharma- ceutically acceptable salt thereof; During the ceremony, Y and Z are independently CH or N; R 1 , R 5 , R 6 , R P and B. 1is as defined above for formula II.

[0116] In some embodiments of formula IIf, R 1 is a C substituted with hydroxyl, thiol or amino. 2-4 In some embodiments of formula IIf, R 1 is a thiol or amino substituted C 2-4 Alkyl, for example ethyl.

[0117] In some cases, the CDN has the structure of formula IIg: [ka] or a pharma- ceutically acceptable salt thereof; During the ceremony, W and X are independently CH or N; R 1 , R 5 , R 6 , R P and B. 2 is as defined above for formula II.

[0118] In some embodiments of Formula IIg, R 1 is a C substituted with hydroxyl, thiol or amino. 2-4 In certain embodiments of Formula IIg, R 1 is a thiol or amino substituted C 2-4 Alkyl, for example ethyl.

[0119] In some cases, the CDN has the structure of formula IIh: [ka] or a pharma- ceutically acceptable salt thereof; During the ceremony, W, X, Y and Z are independently CH or N; and R 1 , R 5, R 6 and R P is as defined above for formula II.

[0120] In some embodiments of Formula IIh, R 1 is a C substituted with hydroxyl, thiol or amino. 2-4 In certain embodiments of formula IIh, R 1 is a thiol or amino substituted C 2-4 Alkyl, for example ethyl.

[0121] In some cases, the CDN has the structure of formula IIi: [ka] or a pharma- ceutically acceptable salt thereof; During the ceremony, W, X, Y and Z are independently CH or N; and R 1 , R 5 , R 6 and R P is as defined above for formula II.

[0122] In some embodiments of Formula IIi, R 1 is a C substituted with hydroxyl, thiol or amino. 2-4 In certain embodiments of formula IIi, R 1 is a thiol or amino substituted C 2-4 Alkyl, for example ethyl.

[0123] In some cases, the CDN has the structure of formula IIj: [ka] or a pharma- ceutically acceptable salt thereof; During the ceremony, W, X, Y and Z are independently CH or N; and R1 , R 5 , R 6 and R P is as defined above for formula II.

[0124] In some embodiments of Formula IIj, R 1 is a C substituted with hydroxyl, thiol or amino. 2-4 In certain embodiments of formula IIj, R 1 is a thiol or amino substituted C 2-4 Alkyl, for example ethyl.

[0125] In some cases, the CDN has the structure of formula IIk: [ka] or a pharma- ceutically acceptable salt thereof; During the ceremony, W, X, Y and Z are independently CH or N; and R 1 and R P is as defined above for formula II.

[0126] In some embodiments of Formula IIk, R 1 is a C substituted with hydroxyl, thiol or amino. 2-4 In certain embodiments of formula IIk, R 1 is a thiol or amino substituted C 2-4 Alkyl, for example ethyl.

[0127] In some cases, the CDN has the structure of formula IIm: [ka] or a pharma- ceutically acceptable salt thereof; During the ceremony, R 1 is a C substituted with a thiol or amino group. 2-4alkyl, for example ethyl; X and Z are independently CH or N; R P is each independently hydroxyl or thiol.

[0128] In some embodiments, the CDN has the structure of formula IIn: [ka] or a pharma- ceutically acceptable salt thereof; During the ceremony, X and Z are independently CH or N; R P is each independently hydroxyl or thiol.

[0129] In some embodiments, the CDN has the structure of formula IIo: [ka] or a pharma- ceutically acceptable salt thereof; During the ceremony, X and Z are independently CH or N; R P is each independently hydroxyl or thiol.

[0130] In some embodiments, in formulas IId-k and IIm-o, both R P In certain embodiments, in Formula IId-k and IIm-o, both R P is a thiol. In some embodiments, in formulas IId-k and IIm-o, BG 1 (Top left R P ) corresponding to R P is hydroxyl, BG 2 (Bottom right R P ) corresponding to R P is a thiol. In some embodiments, in Formula IId-k and IIm-o, BG 1 R corresponds toP is a thiol and BG 2 R corresponds to P is hydroxyl.

[0131] In one embodiment, the CDN has the following structure (CDN-A): [ka] or a pharma- ceutically acceptable salt thereof.

[0132] In one embodiment, the CDN has the following structure: [ka] or a pharma- ceutically acceptable salt thereof.

[0133] In one embodiment, the CDN has the following structure: [ka] or a pharma- ceutically acceptable salt thereof.

[0134] In one embodiment, the CDN has the following structure: [ka] or a pharma- ceutically acceptable salt thereof.

[0135] In one embodiment, the CDN has the following structure (CDN-B): [ka] or a pharma- ceutically acceptable salt thereof.

[0136] In one embodiment, the CDN has the following structure: [ka] or a pharma- ceutically acceptable salt thereof.

[0137] In one embodiment, the CDN has the following structure: [ka] or a pharma- ceutically acceptable salt thereof.

[0138] In one embodiment, the CDN has the following structure: [ka] or a pharma- ceutically acceptable salt thereof.

[0139] The present disclosure provides a method of making an ADC of formula I by attaching a CDN of formula II (e.g., CDN-A or CDN-B) to an antibody via a linker. The CDN of formula II can be attached to the antibody via a cleavable or non-cleavable linker. In certain embodiments, the CDN is released into tumor cells, cancer-associated immune cells, or the tumor microenvironment upon cleavage of the linker.

[0140] In the ADC of formula I, where the CDN (D) is of formula II (e.g., CDN-A or CDN-B), the CDN is R 1 Hydroxyl, thiol, amino, C 1-6 The CDN of formula II may be covalently attached to the linker (L) at an alkylamino or -PEG-OH group. It is understood that the CDN of formula II may also be unattached to a linker (L) or an ADC and may be administered in the manner described herein alone, in combination with an ADC described herein, in combination with other active agents (e.g., immuno-oncology agents, such as immune checkpoint inhibitors, including anti-PD1 antibodies, anti-PD-L1 antibodies, and anti-CTLA-4 antibodies), or in combination with an ADC described herein and in combination with other active agents (such as immuno-oncology agents).

[0141] A CDN of formula II (e.g., CDN-A or CDN-B) can stimulate STING when used alone or as a component of an ADC of formula I. In certain embodiments, the CDN can be attached to an antibody or antigen-binding fragment via a linker. As disclosed herein, the CDN can be attached to an antibody or antigen-binding fragment via a linker. 1 Hydroxyl, amino, thiol, C 1-6 The CDN can be covalently attached to the linker via a chemical reaction between the alkylamino or -PEG-OH group and the corresponding group on the linker. In other words, in some embodiments, the CDN can be 1 is connected to a linker (L) by one of the following bonds present in R 1 is R 1 Hydroxyl, amino, thiol, C 1-6 R excluding alkylamino or -PEG-OH groups 1 Represents the remainder of the part: R 1 -OL, R 1 -NH-L,R 1 -SL, R 1 -N(C 1-6 Alkyl)-L or R 1 -PEG-OL. Particular antibodies, antigen-binding fragments and linkers are described below.

[0142] 6.3. Antibodies and Antigen-Binding Fragments As used herein, the term "antibody" refers to an immunoglobulin molecule that specifically binds to a particular target antigen. Antibodies can be of human or non-human origin. Antibodies can be linked to CDNs, as described in Section 6.2, via linkers. Antibodies can be polyclonal, monoclonal, genetically engineered, and / or otherwise modified in nature. The antibodies that make up the ADCs of the present disclosure are suitable for administration to humans, for example, as humanized or fully human antibodies.

[0143] Antibodies contain heavy and light chains with hypervariable regions known as complementarity determining regions (CDRs) that mediate the binding of the antibody to a target antigen. Antibodies generally contain three CDRs, i.e., V H CDR#1, VH CDR#2 and V H Variable region (V H ) and three CDRs, namely, V L CDR#1, V L CDR#2 and V L Variable region (V L Specific embodiments of the ADCs of the disclosure include those exemplary CDRs and / or V H and / or V L These include, but are not limited to, antibodies and / or antigen-binding fragments comprising the sequence.

[0144] The antibody constituting the ADC of the present disclosure may be any antibody isotype, including, for example, IgA, IgD, IgE, IgG, IgM or IgY, or may be in the form of a full-length antibody that may be derived from any antibody isotype. In some embodiments, the antibody constituting the ADC is an IgG (e.g., IgG1, IgG2, IgG3 or IgG4). In some embodiments, the antibody comprises all or a portion of the constant region of an antibody.

[0145] The antibodies that make up the ADCs of the disclosure can be bispecific antibodies, dual variable domain antibodies, multi- or single-chain antibodies, single domain antibodies, camelized antibodies, scFv-Fc antibodies, Surrobodies (including surrogate light chain constructs), and the like.

[0146] The ADCs of the present disclosure may include full-length (intact) antibody molecules and antigen-binding fragments. As used herein, the term "fragment" refers to a portion of an intact antibody that contains fewer amino acid residues than the intact antibody. As used herein, the term "antigen-binding fragment" refers to a polypeptide fragment of an antibody that mediates binding to an antigen or competes with the intact antibody for antigen binding. Suitable exemplary antigen-binding fragments include Fab, Fab', F(ab')2, Fv, scFv, dAb, Fd, or isolated complementarity determining regions (CDRs) with sufficient framework for binding. As will be appreciated by one of skill in the art, fragments can be obtained by molecular engineering, or by chemical or enzymatic treatment of intact antibodies or antibody chains, or by recombinant means.

[0147] The antibody or antigen-binding fragment thereof is not limited to a particular method of generation or production and can be prepared using well-known techniques such as hybridoma technology, recombinant technology, phage display technology, transgenic animals, or some combination thereof.

[0148] 6.4. Target antigens and antibodies The antibodies or antigen-binding fragments that make up the ADCs contemplated by this disclosure specifically bind to one or more cancer-associated tumor- or immune cell-associated antigens.

[0149] In some embodiments, the cancer-associated tumor or immune cell-associated antigen is a T cell co-inhibitory molecule. In some embodiments, the antibody or antigen-binding fragment thereof specifically binds to a tumor-associated antigen selected from PD-L1, PD-L2, CD47, CD80, CD86, HVEM, UL144, CD155, CD112, CD113, Galectin-1, Galectin-3, Galectin-9, CD48, LIGHT, BTLA, and CD160. In some embodiments, the tumor-associated antigen is a molecule that binds to a T cell molecule selected from BTLA, Tim-3, PD-1, CTLA-4, TIGIT, CD244, and CD223.

[0150] In some embodiments, the antibody is an anti-PD-L1 antibody, such as atezolizumab, durvalumab, avelumab, or an antigen-binding fragment thereof, or an antibody with an equivalent amino sequence thereof, or an antigen-binding fragment thereof.

[0151] In some embodiments, the antibody is an anti-CD47 antibody such as Hu5F9-G4, IBI188, CC-90002, ZL1201, TTI-621, AO-176, an antibody of SGN-CD47M, an antigen-binding domain of ALX148 or an antigen-binding fragment thereof, or an antibody or antigen-binding fragment thereof having an equivalent amino acid sequence.

[0152] In other embodiments, the antibody or antigen-binding fragment thereof specifically binds to a cancer-associated tumor antigen that is a growth factor receptor (GFR). In certain embodiments, the cancer-associated tumor antigen is an EGFR / ErbB / HER family GFR. In some embodiments, the cancer-associated tumor antigen is selected from EGFR / HER1 (ErbB1), HER2 / c-Neu (ErbB2), Her3 (ErbB3) and Her4 (ErbB4) receptors. In certain embodiments, the cancer-associated tumor antigen is an IGFR family GFR. In some embodiments, the cancer-associated tumor antigen is a receptor for IGF1R or IGF2R. In some embodiments, the cancer-associated tumor antigen is a TGF-βR (TβR) family GFR. In some embodiments, the cancer-associated tumor antigen is a receptor for TβR I or TβR II. In certain embodiments, the cancer-associated tumor antigen is a VEGFR family GFR. In some embodiments, the cancer-associated tumor antigen is a receptor for VEGFR1, VEGFR2 or VEGFR3. In some embodiments, the cancer-associated tumor antigen is a PDGFR family GFR. In some embodiments, the cancer-associated tumor antigen is a receptor of PDGFR-α or PDGFR-β. In some embodiments, the cancer-associated tumor antigen is a FGFR family GFR. In some embodiments, the cancer-associated tumor antigen is a receptor of FGFR1, FGFR2, FGFR3 or FGFR4.

[0153] In some embodiments, the antibody is an anti-EGFR / HER1 (ErbB1) antibody, such as cetuximab, panitumumab, necitumumab, or an antigen-binding fragment thereof, or an antibody or antigen-binding fragment thereof with an equivalent amino sequence. In some embodiments, the antibody is an anti-HER2 (ErbB2) antibody, such as trastuzumab, pertuzumab, or an antigen-binding fragment thereof, or an antibody or antigen-binding fragment thereof with an equivalent amino sequence. In some embodiments, the antibody is an anti-VEGFR2 antibody, such as ramucirumab, or an antigen-binding fragment thereof, or an antibody or antigen-binding fragment thereof with an equivalent amino sequence. In some embodiments, the antibody is an anti-PDGFR-α antibody, such as olaratumab, or an antigen-binding fragment thereof, or an antibody or antigen-binding fragment thereof with an equivalent amino sequence.

[0154] In other embodiments, the antibody or antigen-binding fragment thereof specifically binds to a lymphoma-associated antigen, hi certain embodiments, the lymphoma-associated antigen is CD20, CD30, CD19 / CD3, CD22, or CD33.

[0155] In some embodiments, the antibody is an anti-CD20 antibody, such as rituximab, ibritumomab, ofatumumab, obinutuzumab, or an antigen-binding fragment thereof, or an antibody or antigen-binding fragment thereof with an equivalent amino sequence. In some embodiments, the antibody is an anti-CD30 antibody, such as brentuximab, or an antigen-binding fragment thereof, or an antibody or antigen-binding fragment thereof with an equivalent amino sequence. In some embodiments, the antibody is an anti-CD19 / CD3 antibody, such as blinatumomab, or an antigen-binding fragment thereof, or an antibody or antigen-binding fragment thereof with an equivalent amino sequence. In some embodiments, the antibody is an anti-CD22 antibody, such as inotuzumab, or an antigen-binding fragment thereof, or an antibody or antigen-binding fragment thereof with an equivalent amino sequence. In some embodiments, the antibody is an anti-CD33 antibody, such as gemtuzumab, or an antigen-binding fragment thereof, or an antibody or antigen-binding fragment thereof with an equivalent amino sequence.

[0156] In other embodiments, the antibody or antigen-binding fragment thereof specifically binds to a myeloma-associated antigen. In certain embodiments, the lymphoma-associated antigen is SLAMF7 or CD38.

[0157] In some embodiments, the antibody is an anti-SLAMF7 antibody, such as elotuzumab, or an antigen-binding fragment thereof, or an antibody with an equivalent amino sequence, or an antigen-binding fragment thereof. In some embodiments, the antibody is an anti-CD38 antibody, such as daratumumab, or an antigen-binding fragment thereof, or an antibody with an equivalent amino sequence, or an antigen-binding fragment thereof.

[0158] In other embodiments, the antibody or antigen-binding fragment thereof specifically binds to a blastoma-associated antigen. In certain embodiments, the blastoma-associated antigen is GD2.

[0159] In some embodiments, the antibody is an anti-GD2 antibody, such as dinutuximab, or an antigen-binding fragment thereof, or an antibody having an equivalent amino sequence thereto, or an antigen-binding fragment thereof.

[0160] In other embodiments, the antibody or antigen-binding fragment thereof specifically binds to a RANK ligand.

[0161] In some embodiments, the antibody is an anti-RANK ligand antibody, such as denosumab, or an antigen-binding fragment thereof, or an antibody having an equivalent amino sequence thereto, or an antigen-binding fragment thereof.

[0162] In one embodiment, the antibody is an antibody that binds to an antigen that is selectively expressed or overexpressed on cancer cells, such as PD-L1 and EGFR.

[0163] In some embodiments, the antibody is an antibody that binds to an antigen derived from a microorganism that infects human cells.

[0164] As used herein, "alpha" and "anti-" are used interchangeably, for example, when describing an "anti-PD-L1" antibody or an "alpha-PD-L1" antibody.

[0165] As used herein, hyphenated protein names are used synonymously with their unhyphenated forms (i.e., "PD-L1" and "PDL1" are used interchangeably).

[0166] As used herein, numbering of immunoglobulin amino acid residues is done according to the Eu numbering system unless otherwise indicated.

[0167] Linker In the ADCs described herein, the CDN is linked to the antibody or antigen-binding fragment by a multi-atom linker. The linker links the CDN to the antibody or antigen-binding fragment by forming a covalent bond with the CDN at one position on the linker and a covalent bond with the antibody or antigen-binding fragment at another position on the linker. The linker can be monovalent with respect to the CDN (e.g., Formula Ia) to covalently attach a single CDN to a single site on the antibody or fragment thereof. The linker can also be multivalent with respect to the CDN (e.g., Formula I where m>1) to covalently attach two or more CDNs to a single site on the antibody or fragment thereof. As used herein, the term "linker" is intended to include unlinked, partially linked (i.e., only to the CDN or Ab), and fully linked linkers (i.e., to both the CDN and Ab). In a specific embodiment, the moieties containing functional groups on the antibody and linker that form a covalent bond between the antibody and linker are each designated R X and R Y It is specifically shown as:

[0168] The linker that connects CDN to antibody or its fragment may be long, short, flexible, fixed, hydrophilic or hydrophobic in nature, or may comprise segments with different properties.A wide variety of linkers are known in the art that are useful for linking drugs to antibodies or their fragments in the context of ADC.These and other linkers can be used to connect CDN to the antibody or antigen-binding fragment of the ADC described herein.

[0169] In certain embodiments, the linker comprises 2-100, 2-75, 2-50, 2-25, 2-10, 5-100, 5-75, 5-50, 5-25, 5-10, 10-100, 10-75, 10-50, or 10-25 atoms in the chain connecting the CDN to the antibody or antigen-binding fragment (including any atom at the end of the linker that may be derived from the CDN or the antibody or antigen-binding fragment). Similarly, linkers (as discussed below) used in linkers that bind to CDNs can also contain 2-100, 2-75, 2-50, 2-25, 2-10, 5-100, 5-75, 5-50, 5-25, 5-10, 10-100, 10-75, 10-50, or 10-25 atoms in the chain that connects the CDN to a site on the linker that can bind to a complementary site on an antibody or antigen-binding fragment.

[0170] The linker can be chemically stable to the extracellular environment and serum, or can be intentionally unstable and contain a bond capable of releasing the CDN into the extracellular environment or tumor microenvironment.

[0171] In some embodiments, the linker comprises a bond designed to release the CDN upon internalization of the ADC within a cell, hi some specific embodiments, the linker comprises a bond designed to cleave and / or immolate or otherwise degrade specifically or non-specifically within the cell.

[0172] The number of CDNs linked to an antibody or antigen-binding fragment thereof of an ADC can vary (referred to as the "drug-antibody ratio" or "DAR") and is limited by the number of available attachment sites on the antibody or antigen-binding fragment thereof and the number of CDNs linked to a single linker. In an ADC that includes multiple CDNs, each CDN can be the same or different. ADCs with a DAR of 10 or greater are contemplated, so long as the CDNs do not exhibit unacceptable levels of aggregation under conditions of use and / or storage. In some embodiments, the ADCs described herein can have a DAR ranging from 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, or 1-4. In some embodiments, the ADCs described herein can have a DAR ranging from 2-10, 2-9, 2-8, 2-7, 2-6, 2-5, or 2-4. In certain specific embodiments, the ADCs can have a DAR of 1, 2, 3, or 4. In other specific embodiments, the ADCs can have a DAR of 5, 6, 7, or 8. In some specific embodiments, the ADC may have a DAR of 1.

[0173] By way of example, and not limitation, listed below are some cleavable and non-cleavable linkers that can be included in the ADCs described herein.

[0174] 6.5.1. Cleavable Linkers In some embodiments, the linker is cleavable in vivo by a chemical or enzymatic process that releases the CDN. In some cases, the CDN is cleaved from the linker to regenerate the same CDN before binding to the linker. In other embodiments, the free CDN is a modified CDN from the CDN originally bound to the linker, the modified CDN has residual functional groups from the linker, but retains efficacy or even exhibits enhanced efficacy over the original CDN. In general, the cleavable linker incorporates one or more chemical bonds that are chemically or enzymatically cleavable, while the remainder of the linker is non-cleavable.

[0175] In some embodiments, the cleavable linker comprises a chemically labile group. The chemically labile group takes advantage of the different properties of plasma and some cytoplasmic compartments, such as the acidic environment of endosomes and lysosomes, or the high thiol concentration (e.g., glutathione) in the cytosol. In some embodiments, the plasma stability of a linker that comprises a chemically labile group can be increased or decreased by using a substituent to change the steric hindrance near the chemically labile group.

[0176] In some embodiments, the chemically labile group of the cleavable linker is an acid labile group. The acid labile group remains intact during circulation at the neutral pH of blood and can undergo hydrolysis to release the CDN under acidic conditions, for example, in the acidic tumor microenvironment, or upon internalization into endosomal (pH 5.0-6.5) and lysosomal (pH 4.5-5.0) cellular compartments. This pH-dependent release mechanism of the cleavable linker can be optimized by chemical modification, for example, substitution, to tailor the release of the CDN to a specific pH. In some embodiments, the cleavable linker comprises an acid labile group, such as a hydrazone, hydrazine, cis-aconityl, acetal, orthoester, or imine group. In some embodiments, the acid labile group undergoes cleavage in the tumor microenvironment, endosomes of tumor or immune cells, lysosomes of tumor or immune cells, acidic intracellular compartments of tumor or immune cells, or any combination thereof. In some embodiments, the acid labile group does not undergo cleavage in the tumor microenvironment, the endosomes of tumor or immune cells, the lysosomes of tumor or immune cells, and / or the acidic intracellular compartments of tumor or immune cells. As contemplated herein, the cleavability of the acid labile group may be determined by the pH sensitivity of the fully attached linker of the ADC. The acid labile linker may include additional cleavage sites, such as additional acid labile cleavage sites and / or enzyme labile cleavage sites.

[0177] In some embodiments, the cleavable linker comprises a disulfide group. The disulfide is designed to release the drug upon internalization into cells where the cytosol provides a more reducing environment compared to the extracellular environment. Disulfide bond cleavage generally requires the presence of cytoplasmic thiol cofactors such as (reduced) glutathione (GSH) so that disulfide-containing linkers are reasonably stable in the circulating blood and selectively release the drug in the cytosol. The intracellular enzyme protein disulfide isomerase, or similar enzymes that can cleave disulfide bonds, may also contribute to disulfide cleavage. Tumor cells may induce hypoxia due to irregular blood flow, leading to enhanced activity of reductive enzymes and even higher glutathione concentrations.

[0178] Exemplary ADCs that include disulfide-containing linkers have the following formula: [ka] Including, During the ceremony, D represents a CDN (e.g., CDN-A or CDN-B); S of SD is derived from CDN, NH of Ab-NH is derived from Ab, S of Ab-S is derived from Ab, Ab stands for antibody or binding fragment thereof "n" represents the number of D's bound to Ab via a linker; R is independently hydrogen or C 1-3 It is an alkyl.

[0179] In certain embodiments, the linker has the structure [ka] Including, * The NH of -NH can be derived from Ab, [ka] is the direct or indirect point of attachment of the linker to the CDN (e.g., R of a CDN, e.g., CDN-A or CDN-B). 1 In one embodiment, [ka] is CDN R 1 represents the point of direct attachment of the linker to the thiol of the group, [ka] S adjacent to R 1 It is the thiol part of the group.

[0180] Another type of cleavable linker contemplated for the disclosed ADC is an enzyme-cleavable linker. Such linkers are typically peptide-based or contain peptide regions, and can be more stable in plasma and extracellular environments than chemically unstable linkers. Peptide bonds are generally stable in serum due to the higher pH value compared to lysosomes and the presence of endogenous inhibitors of lysosomal proteases. The release of CDN from ADC can occur through the action of lysosomal proteases, such as cathepsin and plasmin, which can be present at high levels in certain tumor cells. In some embodiments, the cleavable peptide is cleaved by lysosomal enzymes. In some embodiments, the cleavable peptide is cleaved by cathepsin (e.g., cathepsin B) or plasmin.

[0181] As those skilled in the art will recognize, proteolytic cleavage of a peptide linker directly attached to a CDN can generate an amino acid adduct of the CDN upon amide bond hydrolysis.Therefore, for the ADCs of the present disclosure, an enzyme-cleavable linker is also contemplated that includes a self-immolative spacer to spatially separate the CDN from the cleavage site.The use of a self-immolative spacer allows for the removal of the fully active, chemically unmodified CDN of formula II upon amide bond hydrolysis.

[0182] One contemplated self-immolative spacer is a bifunctional para-aminobenzyl alcohol group, which is linked at one end to the amine group of a carbamate-functionalized CDN with a benzyl hydroxyl group and at the other end to an amino group to form an amide bond with the peptide (i.e., a PABC group). Upon protease-mediated cleavage of the peptide, the resulting CDN is activated, resulting in a 1,6-elimination reaction that releases the unmodified CDN, carbon dioxide, and the remainder of the linker. In some embodiments, the cleavable linker comprises a PABC group. Further contemplated self-immolative spacers are heterocyclic variants of PABC that have been described (see, for example, U.S. Pat. No. 7,989,434, incorporated herein by reference).

[0183] In some embodiments, the enzyme-cleavable linker is a non-peptide linker. In some embodiments, the non-peptide linker is peptidomimetic. In some embodiments, the non-peptide linker is cleaved by a tumor-specific protease. In some embodiments, the non-peptide linker is cleaved by a tumor-specific protease that is increased in abundance in tumors and / or tumor microenvironments. In some embodiments, the non-peptide linker is cleaved by cathepsin B. In some embodiments, the non-peptide linker is cyclobutane-1,1-dicarboxamide.

[0184] In some embodiments, the enzyme-cleavable linker is a β-glucuronic acid-based linker. Cleavage of the β-glucuronide glycosidic bond can occur via the lysosomal enzyme β-glucuronidase, which is abundant in lysosomes and overexpressed in some tumor types, but has low activity outside the cell.

[0185] Cleavable linkers may contain non-cleavable moieties or segments, and / or cleavable segments or moieties may be included in other non-cleavable linkers to make them cleavable.By way of example only, polyethylene glycol (PEG) and related polymers may contain cleavable groups in the polymer backbone.For example, polyethylene glycol or polymer linkers may contain one or more cleavable groups, such as disulfides, hydrazines, hydrazones, dipeptides, or cyclobutane-1,1-dicarboxamides.

[0186] In certain embodiments, the linker comprises an enzyme-cleavable peptide moiety, e.g., a peptide represented by formula VIIIa, VIIIb, VIIIc, VIIId, VIIIe, VIIIf, or VIIIg: [ka] [ka] and a linker comprising During the ceremony, "Peptide" refers to a peptide or peptidomimetic chain (designated N→C, without indicating the carboxyl and amino "terminus") cleavable by a lysosomal enzyme; T represents a chain (e.g., a polymeric chain) comprising one or more ethylene glycol units or alkylene chains, or a combination thereof; R a is hydrogen, C 1-6 selected from alkyl, sulfonate and methylsulfonate; R b is hydrogen, [ka] is selected from n is an integer ranging from 2 to 10, for example 3 to 6, in particular 5; p is an integer ranging from 0 to 5; q is an integer ranging from 0 to 5, particularly 3; w is 0 or 1; * -S- in -S- can be from Ab, x is 0 or 1, * The NH of -NH can be from Ab, y is 0 or 1; * The NH of -NH can be from Ab, z is 0 or 1; [ka] represents the point of attachment of a direct or indirect linker to a CDN (e.g., R of a CDN, e.g., CDN-A or CDN-B). 1 hydroxyl, amino, thiol, etc.), * represents the point of attachment to the remainder of the linker or to the antibody, directly or indirectly; or a salt thereof.

[0187] In some embodiments, the cleavable peptide moiety or "peptide" of Formulas VIIIa-d has the following structure: [ka] Including, When x, y and w are 0, the terminal -NH- can be derived from Ab.

[0188] In some embodiments, the cleavable peptide moiety or "peptide" of Formula VIIIe has the following structure: [ka] where w is 1.

[0189] In certain embodiments, the cleavable peptide moiety or "peptide" of Formulas VIIIa-g contains 2-20 amino acid residues, e.g., 2-15, 2-10, 2-7, or 2-5 residues, including a tetrapeptide, tripeptide, or dipeptide. In certain embodiments, the cleavable peptide moiety or "peptide" is a dipeptide, e.g., Ala-Ala, Ala-(D)Asp, Ala-Cit, Ala-Lys, Ala-Val, Asn-Cit, Asp-Cit, Asn-Lys, Asn-(D)Lys, Asp-Val, Cit-Ala, Cit-Asn, Cit-Asp, Cit-Cit, Cit-Lys, Cit-Ser, Cit-Val, Glu-Val, PhenylGly-(D)Lys, H The cleavable peptide moiety or "peptide" comprises a dipeptide selected from is-Val, Ile-Cit, Ile-Pro, Ile-Val, Leu-Cit, Lys-Cit, Me3Lys-Pro, Met-Lys, Met-(D)Lys, Phe-Arg, Phe-Cit, Phe-Lys, Pro-(D)Lys, Ser-Cit, Trp-Cit, Val-Ala, Val-(D)Asp, NorVal-(D)Asp, Val-Cit, Val-Glu, Val-Lys, and salts thereof. In certain embodiments, the dipeptide is Val-Cit. In certain embodiments, the cleavable peptide moiety or "peptide" comprises a tripeptide such as Glu-Val-Cit. In certain embodiments, the cleavable peptide moiety or "peptide" comprises a tetrapeptide such as Gly-Phe-Leu-Gly or Ala-Leu-Ala-Leu.

[0190] In one embodiment, the linker is of Formula VIIIa and has the following structure: [ka] and "peptide" is Glu-Val-Cit.

[0191] In one embodiment, the linker is of Formula VIIIc and has the following structure: [ka] and "peptide" is Val-Cit.

[0192] In certain embodiments, the cleavable peptide moiety or "peptide" of Formula VIIId is a dipeptide, e.g., Ala-Ala, Ala-(D)Asp, Ala-Cit, Ala-Lys, Ala-Val, Asn-Cit, Asp-Cit, Asn-Lys, Asn-(D)Lys, Asp-Val, Cit-Ala, Cit-Asn, Cit-Asp, Cit-Cit, Cit-Lys, Cit-Ser, Cit-Val, Glu-Val, PhenylGly-(D)Lys In some embodiments, the cleavable peptide moiety or "peptide" of formula VIIId comprises a dipeptide selected from the group consisting of His-Val, Ile-Cit, Ile-Pro, Ile-Val, Leu-Cit, Lys-Cit, Me3Lys-Pro, Met-Lys, Met-(D)Lys, Phe-Arg, Phe-Cit, Phe-Lys, Pro-(D)Lys, Ser-Cit, Trp-Cit, Val-Ala, Val-(D)Asp, NorVal-(D)Asp, Val-Cit, Val-Glu, Val-Lys, and salts thereof. In some embodiments, the dipeptide of formula VIIId is Val-Cit. In some embodiments, the cleavable peptide moiety or "peptide" of formula VIIId comprises a tripeptide such as Glu-Val-Cit. In certain embodiments, the cleavable peptide moiety or "peptide" of Formula VIIId comprises a tetrapeptide such as Gly-Phe-Leu-Gly or Ala-Leu-Ala-Leu.

[0193] In one embodiment, the linker is of formula VIIId and has the following structure: [ka] and "peptide" is Val-Cit.

[0194] In one embodiment, the linker is of Formula VIIIe and has the following structure: [ka] The "peptide" includes [ka] It is.

[0195] 6.5.2. Groups Used to Attach the Linker to the Antibody A variety of linking groups can be used to attach the linker-CDN synthon to the antibody to produce the ADC. The linking group of the linker-CDN synthon is generally electrophilic in nature. In some embodiments, the linking group is selected from a maleimide group; an activated disulfide such as DSDM, SPDB, or sulfo-SPDB; an active ester such as NHS ester or HOBt ester; an alkyl or benzyl halide such as a haloformate, an acid halide, or a haloacetamide. In some embodiments, the resulting link between the linker (L) and the antibody (Ab) is a thioether, an amide, an ester, a carbamate, a carbonate, a urea, a disulfide, or an ether.

[0196] For the disclosed ADCs, "self-stabilizing" maleimides and "bridged disulfides" are also contemplated. Examples of "self-stabilizing" maleimide groups are provided in US 2013 / 0309256, which is incorporated herein by reference. Examples of "bridged disulfides" are provided in Badescu et al., 2014, Bioconjugate Chem. 25:1124-1136, and WO 2013 / 085925, each of which is incorporated herein by reference. 6.5.3. ADCs with Cathepsin-Cleavable Linkers

[0197] As noted above, in some embodiments of the disclosure, the CDN (e.g., CDN-A or CDN-B) and antibody comprising the ADC of the disclosure are linked via a cathepsin-cleavable linker. In one such embodiment, the ADC has the structure of Formula III: [ka] having where the variables W, X, Y, Z, and R P and n is defined above for Formulas I and II. In the above schematic: [ka] represents the covalent attachment of a cathepsin-cleavable linker to an antibody or antigen-binding fragment (Ab).

[0198] In one embodiment, the pyrrolidine-2,5-dione group of the linker of formula III is linked to an antibody (Ab) through a thiol group at its 3-position. For example, pyrrolidine-2,5-dione can be covalently attached to an antibody at its 3-position via a cysteine ​​residue of the antibody. The resulting ADC has the structure of formula IIIa: [ka] having where the variables W, X, Y, Z, and R P and n is defined above for Formulas I and II.

[0199] In one embodiment, the ADC has the following structure: [ka] has.

[0200] 6.5.4. ADCs with Glutathione-Cleavable Linkers As noted above, in some embodiments of the disclosure, the CDN (e.g., CDN-A or CDN-B) and antibody comprising the ADC of the disclosure are linked via a glutathione-cleavable linker. In one such embodiment, the ADC has the structure of formula IV: [ka] having where the variables W, X, Y, Z, and R P and n is defined above in Formulas I and II. In the above schematic diagram: [ka] represents the covalent bond between the glutathione cleavable linker and the antibody (Ab).

[0201] In one embodiment, the carbonyl group of the linker in formula IV is attached to a lysine or other amino acid residue of the antibody having an amino group-containing side chain, e.g., to a carbonyl group. [ka] The resulting ADC can be covalently linked to the antibody by forming an amide bond with the amino group in the bond. The resulting ADC has the structure of Formula IVa: [ka] having where the variables W, X, Y, Z, and R P and n is defined above in Formulas I and II.

[0202] In one embodiment, the ADC has the following structure: [ka] has.

[0203] 6.6. Methods for preparing antibody-drug conjugates Generally, the ADC of formula I can be prepared according to the following scheme: Ab-R X +R Y -L-(D) m → (Formula I) Ab-[-L-(D) m ] n It can be prepared according to where Ab, L, D, m and n are as defined above for formula I, and R X and R Y represent complementary groups that are capable of forming a covalent bond with each other.

[0204] Relatedly, the ADC of formula Ia may be prepared according to the following scheme: Ab-R X +R Y -LD → (Formula Ia) Ab-[-LD] n It can be prepared according to where Ab, L, D and n are as defined above for formula I, and R X and R Y represents complementary groups capable of forming a covalent bond with one another, as defined above.

[0205] R X and R Y The identity of the group is determined by the R Y -L-(D) m or R Y The R -LD synthon depends on the chemistry used to link the R -LD to the antibody. The synthon is typically linked to the side chain of an amino acid residue of the antibody, including, for example, the free thiol group of an accessible cysteine ​​residue or the primary amino group of an accessible lysine residue. In some embodiments, R X is a group on the side chain of an amino acid of the antibody, e.g., an amino group or a thiol group. In one embodiment, R X is the amino group of an amino acid side chain, such as lysine, 5-hydroxylysine, ornithine, or a statine, particularly lysine. X is a thiol group of an amino acid side chain such as cysteine ​​or homocysteine, especially cysteine. In such conjugation, a free thiol group can be obtained by first fully or partially reducing the antibody to break the interchain disulfide bridges between the cysteine ​​residues. Some functional groups R Y And chemistries may be used to form bonds with thiol groups, examples of which include, but are not limited to, maleimides and haloacetyls.

[0206] For the disclosed ADCs, engineered antibodies with mutations to one or more codons to disrupt one or more disulfide bridges are also contemplated, including, by way of example and not limitation, mutating a single cysteine ​​residue in an interchain disulfide bridge to a serine residue to generate a free thiol from the unpaired cysteine. For the disclosed ADCs, engineered antibodies with mutations to one or more codons to introduce a thiol-bearing residue for linker attachment are also contemplated, by way of example and not limitation, mutating one or more residues to a cysteine ​​residue or incorporating additional cysteine ​​residues into the amino acid sequence of the antibody or antigen-binding fragment thereof.

[0207] In one embodiment, R X is a thiol, such as from a cysteine ​​residue on an antibody, and R Y is a group selected from haloacetyl, maleimide, aziridine, acryloyl, vinylsulfone, pyridyl disulfide, TNB-thiol, and alkylating or arylating agents. X is a thiol group, such as from a cysteine ​​residue on an antibody, and R Y is a maleimide group. In some embodiments, R X is the primary amino group of a lysine residue. X And chemistries can be used for lysine attachment, examples include, but are not limited to, NHS-esters and isothiocyanates.

[0208] In one embodiment, R X is an amine, such as from a lysine residue on an antibody, and R Y is a group capable of alkylating or acylating an amine. In some embodiments, R X is an amine, such as from a lysine residue on an antibody, and R Yis a group selected from isothiocyanates, isocyanates, acyl azides, NHS esters, sulfonyl chlorides, aldehydes, glyoxals, epoxides, oxiranes, carbonates, aryl halides, imidoesters, carbodiimides, anhydrides, and fluorophenyl esters. X is an amine, such as from a lysine residue on an antibody, and R Y is an NHS ester.

[0209] As contemplated for the ADCs of the present disclosure, conjugation chemistry is not limited to available side chain groups. Antibodies can also be engineered to include amino acid residues for conjugation, including, by way of example and not limitation, converting side chains such as amines to other useful groups such as thiols by linking an appropriate small molecule to the amine. For example, a side chain containing a primary amine of an amino acid can be converted to a -NH-CH, including -NH-CH-CH-SH. 1-6 It may be converted to a thiol-containing side chain such as alkyl-SH, where -NH- is derived from a primary amine.

[0210] As will be appreciated by those skilled in the art, the number of CDNs linked to an antibody molecule can vary, resulting in heterogeneous ADC preparations in which some antibodies contain 1, about 2, about 3, etc. linked CDNs (and some do not). The degree of heterogeneity depends, among other things, on the chemistry used to link the CDNs. For example, when an IgG1 antibody is reduced to provide thiol groups for conjugation, a heterogeneous mixture of antibodies with 0, 1, 2, 3, 4, 5, 6, 7, or 8 linked CDNs per molecule is often produced. Furthermore, R Y R XBy adjusting the molar ratio of , ADCs with 0, 1, 2, 3, 4, 5, 6, 7 or 8 linked CDNs per molecule can be produced. Thus, depending on the context, it will be understood that the drug-antibody ratio (DAR) described can be the average of a population of ADCs. For example, "DAR3" refers to a heterogeneous ADC preparation with an average drug-antibody ratio of 3, e.g., a mixture of ADCs with equal numbers of DAR2 and DAR4.

[0211] Purity can be assessed by a variety of methods, as known in the art. By way of specific example, ADC preparations can be analyzed by HPLC, hydrophobic exchange, ion exchange, size exclusion, or other chromatography, and purity can be assessed by analyzing the area under the curve of the resulting peaks.

[0212] In some embodiments, the disclosure relates to a method of making an ADC comprising: (a) attaching one or more CDNs of the disclosure (i.e., a CDN of Formula II) to a linker (e.g., an L described herein) to generate a linker attached to the one or more CDNs; and (b) attaching one or more of the CDN-attached linkers to an antibody or antigen-binding fragment thereof (e.g., an Ab described herein) to generate an ADC.

[0213] In certain embodiments, the disclosure relates to a method of making an ADC, comprising (b) attaching one or more CDN-conjugated linkers (i.e., a CDN of formula II and, e.g., an L as described herein) to an antibody or antigen-binding fragment thereof (e.g., an Ab as described herein) to generate the ADC.

[0214] In certain embodiments, the present disclosure relates to a method of making a linker attached to one or more CDNs, comprising: (a) attaching one or more CDNs of the present disclosure (i.e., a CDN of formula II) to a linker (e.g., L as described herein) to produce a linker attached to the one or more CDNs.

[0215] In other embodiments, the disclosure relates to a method of making an ADC that includes (a) conjugating one or more linkers (e.g., an L described herein) to an antibody or antigen-binding fragment thereof (e.g., an Ab described herein) to generate a linker-conjugated antibody, and (b) conjugating one or more CDNs of the disclosure (i.e., a CDN of formula II) to the linker-conjugated antibody to generate an ADC.

[0216] In certain embodiments, the disclosure relates to a method of making an ADC, comprising (b) conjugating one or more CDNs of the disclosure (i.e., a CDN of formula II) to a linker-linked antibody or antigen-binding fragment thereof (e.g., one or more Ls described herein, e.g., an Ab described herein) to produce the ADC.

[0217] In certain embodiments, the present disclosure relates to a method of making a linker-linked antibody, comprising: (a) attaching one or more linkers (e.g., L, as described herein) to an antibody or antigen-binding fragment thereof (e.g., Ab, as described herein) to generate the linker-linked antibody.

[0218] In some embodiments, the disclosure relates to a method of making an ADC that includes (a) attaching a CDN of the disclosure (i.e., a CDN of formula II) to a linker (e.g., an L described herein) to generate a linker attached to the CDN, and (b) attaching a plurality of CDN-attached linkers to an antibody or antigen-binding fragment thereof (e.g., an Ab described herein) to generate an ADC.

[0219] In other embodiments, the disclosure relates to a method of making an ADC comprising: (a) attaching a plurality of linkers (e.g., L described herein) to an antibody or antigen-binding fragment thereof (e.g., Ab described herein) to generate a linker-conjugated antibody; and (b) attaching a plurality of CDNs of the disclosure (i.e., a CDN of formula II) to the linker-conjugated antibody to generate an ADC.

[0220] 6.6.1. CDN Compositions for Handling CDNs Prior to Conjugation As noted above, the CDNs of the disclosure (i.e., a CDN of formula II, such as CDN-A or CDN-B) may be conjugated to a linker (e.g., an L described herein) to generate one or more CDN-conjugated linkers, or may be conjugated to a linker-conjugated antibody (e.g., one or more L described herein, e.g., an Ab described herein) to generate an ADC. Thus, the disclosure provides CDN compositions that facilitate purification, drying, or handling of the CDNs used in these conjugation steps.

[0221] In this regard, the present disclosure provides a CDN composition comprising a CDN of formula II (including subformulas of formula II, such as formula IIa, IIb, etc.) and a base, such as an amine base. In some embodiments, the amine base is liquid at room temperature and pressure, such as pyridine, piperidine, pyrrolidine, morpholine, lutidine (e.g., 2,6-lutidine), triethylamine (TEA) or diisopropylethylamine (DIPEA), especially pyridine. In certain embodiments, the CDN composition comprising the CDN and the base is an anhydrous composition having less than 100, 50, 25, or 10 ppm water. The CDN composition comprising the CDN and the base can be dried by concentrating under high vacuum before use in the conjugation process.

[0222] In some embodiments, the CDN composition comprises a CDN of formula II, such as formula IIk, IIm, IIn, or IIo, and an amine base, such as pyridine. 1 In one embodiment, the CDN composition comprises a CDN of formula II having an amino group at position 1, and an amine base such as pyridine. 1 In some embodiments, the CDN composition comprises a CDN-A, or a pharma- ceutically acceptable salt thereof, as described herein, and an amine base, such as pyridine, and is optionally anhydrous. In some embodiments, the CDN composition comprises a CDN-B, or a pharma- ceutically acceptable salt thereof, as described herein, and an amine base, such as pyridine, and is optionally anhydrous.

[0223] The disclosure also provides CDN compositions that are aqueous solutions comprising a CDN of formula II (including subformulas of formula II, such as formula IIa, IIb, etc.) and a buffer suitable for obtaining a pH in the range of 5 to 10, including 5 to 8, e.g., a pH of 5, 5.5, 5.8, 6, 6.2, 6.5, 7, 7.5, or 8, or any pH range generated by using these pH values, such as 5 to 7, as endpoints. In certain embodiments, the buffer is suitable for obtaining a pH of 6+ / -0.2. In some embodiments, the buffer is a phosphate buffer. In some embodiments, the CDN composition is an aqueous solution comprising a CDN of formula II, including subformulas of formula II, such as formula IIa, IIb, etc. 1 The CDN composition is an aqueous solution comprising a CDN of formula II having a thiol group at position 1, for example formula IIo, and a buffer suitable for obtaining a pH of 6+ / -0.2, for example a phosphate buffer. In certain embodiments, the CDN composition is an aqueous solution comprising a CDN of formula IIo and a buffer suitable for obtaining a pH of 6+ / -0.2, for example a phosphate buffer. In one embodiment, the CDN composition is an aqueous solution comprising CDN-B or a pharma- ceutically acceptable salt thereof and a buffer suitable for obtaining a pH of 6+ / -0.2, in particular a phosphate buffer.

[0224] 6.6.2. CDN Compositions for Attaching a CDN to a Linker Preparation of the above CDN-linked linkers (i.e., comprising a linker described herein, e.g., a CDN of Formula II, e.g., CDN-A or CDN-B, linked to L) can include preparation of one or more CDN compositions for linking the CDN to the linker.

[0225] In this regard, the present disclosure provides CDN compositions comprising a CDN of formula II (including subformulas of formula II, such as formula IIa, IIb, etc.) and either a linker (e.g., L, as described herein) or a coupling agent, or both a linker and a coupling agent, where the coupling agent facilitates coupling of the CDN to the linker. In some embodiments, the coupling agent can activate the linker for coupling to the CDN, for example, by generating an activated ester on the linker, such that the CDN can react with the activated ester of the linker to couple the CDN to the linker. Examples of suitable coupling agents include hydroxybenzotriazole (HOBt), N-hydroxysuccinimide (NHS), dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), and hexafluorophosphate azabenzotriazole tetramethyluranium (HATU). In certain embodiments, the CDN composition further comprises an aprotic polar solvent such as dimethylformamide (DMF), dimethylacetamide (DMA), acetonitrile or tetrahydrofuran (THF), particularly DMF. In certain embodiments, the CDN composition comprising a CDN and either or both of a linker and a binder is an anhydrous composition having less than 100, 50, 25, or 10 ppm water.

[0226] In certain embodiments, the CDN composition has formula IIk, IIm, IIn, or IIo (R 1 In some embodiments, the CDN composition comprises a CDN of formula II, such as a CDN having an amino or thiol group at the R position, and either a linker (e.g., L as described herein) or a coupling agent, or both a linker and a coupling agent. 1 In some embodiments, the CDN composition comprises a CDN of formula II having an amino or thiol group at the R position, and either a linker or a coupling agent, or both a linker and a coupling agent. 1In one embodiment, the CDN composition comprises a CDN having an amino or thiol group at the carboxyl position, and either a linker or a binder, or both a linker and a binder. In one embodiment, the CDN composition comprises CDN-A or CDN-B, or a pharma- ceutically acceptable salt of either, as described herein, either a linker or a binder, or both a linker and a binder, and optionally an aprotic polar solvent as described above. In one embodiment, the CDN composition comprises CDN-A or CDN-B, or a pharma- ceutically acceptable salt of either, a linker, and an aprotic polar solvent. In one embodiment, the CDN composition comprises CDN-A or CDN-B, or a pharma- ceutically acceptable salt of either, a binder, and an aprotic polar solvent.

[0227] 6.6.3. CDN-bound linkers As described above, CDN-linked linkers can be useful intermediates in the preparation of the ADCs described herein. In some embodiments, the CDN-linked linker comprises a CDN of formula II (e.g., CDN-A or CDN-B) linked to a linker, e.g., L, described herein. For example, the CDN-linked linker can have the formula L-CDN, where L comprises a moiety capable of binding to a complementary site on an antibody or antigen-binding fragment, and the CDN is of formula II (including subformulas such as formulas IIk, IIm, IIn, and IIo), and the CDN is R of formula II. 1 Hydroxyl, thiol, amino, C 1-6 Covalent attachment to the linker is via the alkylamino or -PEG-OH group.

[0228] In some embodiments, the CDN and linker of the CDN-linked linker are linked via a thioether, amide, ester, carbamate, carbonate, urea, disulfide or ether group, particularly an amide, carbamate or disulfide group. For example, in some embodiments, the CDN and linker of the CDN-linked linker are linked via an amide group. In such embodiments, the CDN-linked linker has the formula LC(O)NH-CDN or LC(O)N(C 1-6alkyl)-CDN, where CDN is of formula II (including subformulas such as formulas IIk, IIm, and IIn), and R 1 is amino or C 1-6 C substituted with alkylamino groups 1-6 Alkyl, e.g., C 2-6 Alkyl or C 2-3 and alkyl, either of which forms the amine portion of the amide group of said formula. In one such embodiment, the CDN-attached linker has the formula LC(O)NH-CDN, where CDN is of formula II (including subformulas such as IIk, IIm, and IIn), and R of formula II is 1 is an amino-substituted C 2-3 and alkyl, for example ethyl, which forms the amine portion of the amide group of the formula.

[0229] In some embodiments, the CDN-attached linker has the structure of formula IXa: [ka] having In the formula, R L represents the remainder of the linker L, and the variables W, X, Y, Z and R P is defined above for Formulas I and II.

[0230] In other embodiments, the CDN and linker of the CDN-linked linker are linked via a carbamate group. In such embodiments, the CDN-linked linker has the formula L-OC(O)NH-CDN or L-OC(O)N(C 1-6 alkyl)-CDN, where CDN is of formula II (including subformulas such as formulas IIk, IIm, and IIn), and R 1 is amino or C 1-6 C substituted with alkylamino groups 1-6 Alkyl, e.g., C 2-6 Alkyl or C 2-3and alkyl, either of which forms the amine portion of the carbamate group of the formula. In one such embodiment, the CDN-attached linker has the formula L-OC(O)NH-CDN, where CDN is of formula II (including subformulas such as IIk, IIm, and IIn), and R of formula II is 1 is an amino-substituted C 2-3 and alkyl, for example ethyl, which forms the amine portion of the carbamate group of the formula.

[0231] In some embodiments, the CDN-attached linker has the structure of formula IXb: [ka] having In the formula, R L represents the remainder of the linker L, and the variables W, X, Y, Z and R P is defined above for Formulas I and II.

[0232] In some embodiments, the CDN-attached linker has the following structure: [ka] having where the variables W, X, Y, Z and R P is defined above for Formulas I and II.

[0233] In other embodiments, the CDN and linker of the CDN-linked linker are linked via a urea group. In such embodiments, the CDN-linked linker has the formula L-NHC(O)NH-CDN or L-NHC(O)N(C 1-6 alkyl)-CDN, where CDN is of formula II (including subformulas such as formulas IIk, IIm, and IIn), and R 1 is amino or C 1-6 C substituted with alkylamino groups 1-6 Alkyl, e.g., C 2-6 Alkyl or C 2-3and alkyl, either of which forms the rightmost amine portion of the urea group of said formula. In one such embodiment, the CDN-attached linker has the formula L-NHC(O)NH-CDN, where CDN is of formula II (including subformulas such as formulas IIk, IIm, and IIn), and R of formula II is 1 is an amino-substituted C 2-3 It is an alkyl, for example ethyl, which forms the rightmost amine portion of the urea group of the formula.

[0234] In some embodiments, the CDN-attached linker has the structure of formula IXc: [ka] having In the formula, R L represents the remainder of the linker L, and the variables W, X, Y, Z and R P is defined above for Formulas I and II.

[0235] In other embodiments, the CDN and linker of the CDN-linked linker are linked via an ester group. In such embodiments, the CDN-linked linker may have the formula LC(O)O-CDN, where CDN is of formula II (including subformulas such as IIk, IIm, and IIn), and R of formula II is 1 is a C substituted with a hydroxyl or -PEG-OH group. 1-6 Alkyl, e.g., C 2-6 Alkyl or C 2-3 and alkyl, either of which forms the alcohol portion of the ester group of said formula. In one such embodiment, the CDN-attached linker has the formula LC(O)O-CDN, where CDN is of formula II (including subformulas such as formulas IIk, IIm, and IIn), and R of formula II is 1 is a C substituted with a hydroxyl group. 2-3 Alkyl, for example ethyl, forms the alcohol portion of the ester group of the formula.

[0236] In some embodiments, the CDN-attached linker has the structure of formula IXd: [ka] having In the formula, R L represents the remainder of the linker L, and the variables W, X, Y, Z and R P is defined above for Formulas I and II.

[0237] In other embodiments, the CDN and linker of the CDN-linked linker are attached via a carbonate group. In such embodiments, the CDN-linked linker may have the formula L-OC(O)O-CDN, where CDN is of formula II (including subformulas such as IIk, IIm, and IIn), and R of formula II is 1 is a C substituted with a hydroxyl or -PEG-OH group. 1-6 Alkyl, e.g., C 2-6 Alkyl or C 2-3 and alkyl, either of which forms the rightmost alcohol portion of the carbonate group of the formula. In one such embodiment, the CDN-attached linker has the formula L-OC(O)O-CDN, where CDN is of formula II (including subformulas such as IIk, IIm, and IIn), and R of formula II is 1 is a C substituted with a hydroxyl group. 2-3 An alkyl, for example ethyl, forms the rightmost alcohol portion of the carbonate group in the formula.

[0238] In some embodiments, the CDN-attached linker has the structure of formula IXe: [ka] having In the formula, R L represents the remainder of the linker L, and the variables W, X, Y, Z and R P is defined above for Formulas I and II.

[0239] In other embodiments, the CDN and linker of the CDN-linked linker are linked via a disulfide group. In such embodiments, the CDN-linked linker may have the formula LSS-CDN, where the CDN is of formula II (including subformulas such as IIk, IIm, and IIo), and R of formula II is 1 is a C substituted with a thiol group. 1-6 Alkyl, e.g., C 2-6 Alkyl or C 2-3 In one such embodiment, the CDN-linked linker has the formula LSS-CDN, where the CDN is of formula II (including subformulas such as IIk, IIm, and IIo), and R of formula II is 1 is a C substituted with a thiol group. 2-3 Alkyl, for example ethyl, forms the rightmost portion of the disulfide group in the formula.

[0240] In some embodiments, the CDN-attached linker has the structure of formula IXf: [ka] having In the formula, R L represents the remainder of the linker L, and the variables W, X, Y, Z and R P is defined above for Formulas I and II.

[0241] In some embodiments, the CDN-attached linker has the following structure: [ka] having where the variables W, X, Y, Z and R P is defined above for Formulas I and II.

[0242] 6.7. Pharmaceutical Compositions and Medicaments The ADC and / or CDN described herein may be in the form of a pharmaceutical composition comprising the ADC or CDN and one or more carriers, excipients and / or diluents.The composition may be formulated for pharmaceutical use in humans and may comprise a pharma- ceutically acceptable carrier, such as an aqueous, optionally buffered, solution, suspension or dispersion.The composition may also be a lyophilized solid composition that can be reconstituted before use.

[0243] The pharmaceutical composition may be in any suitable form and may be administered to a patient by various routes, such as intravenous, intratumoral, subcutaneous, intramuscular, oral, intranasal, intrathecal, transdermal, topical, or local. The route of administration in each case may depend on the specific antibody and / or ADC, the subject, and the nature and severity of the disease and the physical condition of the subject. In some embodiments, the pharmaceutical composition is administered intravenously, intratumoral, subcutaneously, or intramuscularly in the form of a liquid formulation.

[0244] In some embodiments, the ADCs and / or CDNs described herein, including their pharmaceutical compositions, are administered systemically, such as subcutaneously, intraperitoneally, intramuscularly, or intravenously, particularly intravenously. In other embodiments, the ADCs and / or CDNs described herein, including their pharmaceutical compositions, are administered locally to the tumor site, e.g., intratumorally, or to the tumor microenvironment.

[0245] The present disclosure also provides CDNs of Formula II (including subformulas of Formula II, such as Formula IIa, IIb, etc.) for use in the manufacture of a medicament for treatment, including one or more of the various cancers described below, in combination with one or more additional therapeutic agents described below, e.g., for promoting an immune response in a subject and / or for treating cancer.

[0246] 6.8. Treatment method In certain embodiments, an ADC of this disclosure (i.e., an ADC of formula I) or a CDN of this disclosure (i.e., a CDN of formula II, such as CDN-A or CDN-B) can be used therapeutically. In some embodiments, the disclosure relates to a pharmaceutical composition described herein comprising an ADC of this disclosure (i.e., an ADC of formula I) or a CDN of this disclosure (i.e., a CDN of formula II) for use in therapy.

[0247] The ADCs and / or CDNs disclosed herein can be used alone or in combination with each other and / or with other therapeutic agents. As shown in the examples discussed below, the ADCs and CDNs can promote immune responses when delivered to a subject. For example, the ADCs and CDNs of the present disclosure can induce interferon-β (IFNβ) in a human subject, alone or in combination. The ability of the ADCs and CDNs of the present disclosure to promote immune responses is due in part to their ability to stimulate STING. The ADCs can deliver the CDNs of the present disclosure (e.g., compounds of formula II) to target tumor or cancer-associated immune cells or tumor microenvironment, causing activation of STING and a resulting immune response. Binding of the CDN to an antibody or antigen-binding fragment thereof that binds to a cancer-associated tumor or immune cell antigen targets the delivery of the CDN and prolongs and enhances the immune response.

[0248] The ADC of the present disclosure can promote a greater immune response than either unconjugated CDN or antibody comprising ADC.Unexpectedly, it has been found that the ADC of the present disclosure can promote a greater immune response than the additional immune response of unconjugated CDN and antibody comprising ADC.In other words, by conjugating the CDN of the present disclosure with specific immunotherapy antibody, synergistic effects can be obtained.In other embodiments, as discussed herein, the CDN of the present disclosure can be administered without being part of ADC.

[0249] Thus, in one aspect, the disclosure provides a method of inducing or promoting an immune response in a subject, comprising administering an effective amount of an ADC of the disclosure (i.e., an ADC of formula I). ​​In another aspect, the disclosure provides a method of inducing or promoting an immune response in a subject, comprising administering an effective amount of a CDN of the disclosure (i.e., a CDN of formula II). Also, in another aspect, the disclosure provides a method of inducing or promoting an immune response in a subject, comprising administering an effective amount of an ADC of the disclosure in combination with a CDN of the disclosure. In some embodiments, the ADC and / or CDN are administered to a mammal in need thereof. In certain embodiments, the ADC and / or CDN are administered to a human in need thereof.

[0250] In certain embodiments, the ADCs or CDNs of the disclosure are used to treat cancer. For example, the ADCs or CDNs of the disclosure can be used to treat cancer of the lung, bone, pancreas, skin, head, neck, uterus, ovary, stomach, colon, breast, esophagus, small intestine, intestine, endocrine system, thyroid, parathyroid, adrenal gland, urethra, prostate, penis, testes, ureter, bladder, kidney, or liver. Additional cancers treatable by the ADCs or CDNs of the disclosure include rectal cancer, cancer of the anal region; carcinoma of the fallopian tube, endometrium, cervix, vagina, vulva, renal pelvis, and renal cell; sarcoma of soft tissue; myxoma; rhabdomyoma; fibroma; lipoma; teratoma; cholangiocarcinoma; hepatoblastoma; angiosarcoma; hemangioma; liver cancer; fibrosarcoma; chondrosarcoma; myeloma; chronic or acute leukemia; lymphocytic lymphoma; primary CNS lymphoma; CNS neoplasms; spinal axis tumors; squamous cell carcinoma; synovial sarcoma; malignant pleural mesothelioma; brain stem glioma; pituitary adenoma; bronchial adenoma; chondromatous hanlartoma; endothelioma; Hodgkin's disease; or a combination of one or more of the foregoing cancers.

[0251] Thus, in one aspect, the disclosure provides a method of treating cancer in a subject comprising administering a pharmaceutical composition comprising a pharma- ceutically acceptable amount of an ADC of the disclosure (i.e., an ADC of formula I). ​​In another aspect, the disclosure provides a method of treating cancer in a subject comprising administering a pharmaceutical composition comprising a pharma- ceutically acceptable amount of a CDN of the disclosure (i.e., a CDN of formula II). In some embodiments, the pharmaceutical composition is administered to a mammal in need thereof. In certain embodiments, the pharmaceutical composition is administered to a human in need thereof.

[0252] In another aspect, the disclosure provides a method of treating cancer in a subject by administering to the subject (e.g., a human) a pharmaceutical composition comprising at least one additional anti-cancer agent and a pharma- ceutically acceptable amount of an ADC of the disclosure (i.e., an ADC of formula I). ​​The ADC and one or more additional anti-cancer agents may be administered together or separately, and if administered separately, administration may be by any convenient route, in separate or combined pharmaceutical compositions, simultaneously or sequentially, in any order. In some embodiments, the additional anti-cancer agent enhances expression of the target antigen of the antibody or antigen-binding fragment of the ADC of formula I. The amounts of the ADC and other pharma- ceutically active anti-cancer agents and the relative timing of administration are selected to obtain the desired combined therapeutic effect.

[0253] In some examples, the present disclosure provides a method of treating cancer in a subject by administering to the subject (e.g., a human) a pharmaceutical composition comprising at least one additional anti-cancer agent and a pharma- ceutically acceptable amount of a CDN of the present disclosure (i.e., a CDN of formula II). The CDN and one or more additional anti-cancer agents may be administered together or separately, and if administered separately, administration may be by any convenient route, either in separate or combined pharmaceutical compositions, simultaneously or sequentially, and in any order. The amounts of the CDN and other anti-cancer agents and the relative timing of administration are selected to obtain the desired combined therapeutic effect.

[0254] The combination of the ADC or CDN of the present disclosure and one or more anticancer drugs may be administered together in a single pharmaceutical composition. Alternatively, the ADC or CDN and one or more anticancer drugs may be formulated separately. When formulated separately, they can be provided in any convenient composition, conveniently in the manner known for the compounds in the art.

[0255] Thus, the ADCs or CDNs of the disclosure may be used in combination with other therapeutic methods for cancer treatment, e.g., anti-neoplastic therapies, immune checkpoint inhibitors, other chemotherapeutic agents, hormonal agents, antibody agents, and surgical and / or radiation therapies, particularly radiation.

[0256] In one embodiment, the ADC of the present disclosure (i.e., ADC of formula I) or the CDN of the present disclosure (i.e., CDN of formula II), or both the ADC and CDN of the present disclosure, are used in combination with an immune checkpoint inhibitor to treat cancer. Immune checkpoint inhibitors, such as humanized antibodies against PD-1, PD-L1, and CTLA4, have recently been shown to be very successful in treating several types of metastatic cancer, including melanoma, non-small cell lung cancer, renal cell carcinoma, and bladder cancer (Sharma and Allison, 2015, Science 348, 56). However, only a small proportion of cancer patients still benefit from checkpoint inhibitor therapy, in part because anti-tumor immune cells, such as CD8 T cells, are generated in insufficient numbers and / or do not infiltrate tumors. As shown in the examples described herein, the combination of the ADC and / or CDN of the present disclosure with an immune checkpoint inhibitor can function synergistically to treat cancers that are refractory to immune checkpoint inhibitor monotherapy.

[0257] In one embodiment, the present disclosure provides a method of treating cancer in a subject by administering a pharmaceutical composition comprising a pharma- ceutically acceptable amount of an ADC of the present disclosure (i.e., an ADC of Formula I) or a CDN of the present disclosure (i.e., a CDN of Formula II), or both an ADC and a CDN of the present disclosure, in combination with a PD-L1 inhibitor. Examples of PD-L1 inhibitors that can be used in combination with an ADC of the present disclosure include, but are not limited to, atezolizumab (Tecentriq®), avelumab (Bavencio®), durvalumab (Imfinzi®), BMS-936559, and CK-301. In an embodiment, an ADC and / or CDN of the present disclosure is not administered in combination with a PD-L1 inhibitor, including those described above.

[0258] In one embodiment, the present disclosure provides a method of treating cancer in a subject by administering a pharmaceutical composition comprising a pharma- ceutically acceptable amount of an ADC of the present disclosure (i.e., an ADC of formula I) or a CDN of the present disclosure (i.e., a CDN of formula II), or both an ADC and a CDN of the present disclosure, in combination with a PD-1 inhibitor. Examples of PD-1 inhibitors that can be used in combination with an ADC of the present disclosure include, but are not limited to, pembrolizumab (Keytruda®), nivolumab (Opdivo®), cemiplimab (Libtayo®), AMP-224, AMP-514, and PDR001. In an embodiment, the ADC and / or CDN of the present disclosure are not administered in combination with a PD-1 inhibitor, including those described above.

[0259] In one embodiment, the present disclosure provides a method of treating cancer in a subject by administering a pharmaceutical composition comprising a pharma- ceutically acceptable amount of an ADC of the present disclosure (i.e., an ADC of formula I) or a CDN of the present disclosure (i.e., a CDN of formula II), or both an ADC and a CDN of the present disclosure, in combination with a CTLA-4 inhibitor. Examples of CTLA-4 inhibitors that can be used in combination with an ADC of the present disclosure include, but are not limited to, ipilimumab (Yervoy®) and tremelimumab. In an embodiment, the ADC and / or CDN of the present disclosure are not administered in combination with a CTLA-4 inhibitor, including those described above.

[0260] In another embodiment, the disclosure provides a method of treating cancer in a subject by administering a pharma- ceutically acceptable amount of an ADC of the disclosure (i.e., an ADC of Formula I) or a CDN of the disclosure (i.e., a CDN of Formula II), or a pharmaceutical composition comprising both an ADC and a CDN of the disclosure, together with one or more anti-microtubule agents, such as diterpenoids and vinca alkaloids; platinum coordination complexes; alkylating agents, such as nitrogen mustards, oxazaphosphorines, alkylsulfonates, nitrosoureas, and triazenes; antibiotics, such as anthracyclines, actinomycins, and bleomycins; topoisomerase II inhibitors, such as epipodophyllotoxins; antimetabolites, such as purine and pyrimidine analogs and antifolate compounds; topoisomerase I inhibitors, such as camptothecins; hormones and hormone analogs; signal transduction pathway inhibitors; non-receptor tyrosine angiogenesis inhibitors; immunotherapeutic agents; pro-apoptotic agents; and / or cell cycle signaling inhibitors.

[0261] The ADC of formula I can be used, for example, in combination with a STING agonist that is not bound to an antibody or antigen-binding fragment, to treat cancer or induce or promote immune response.In some embodiments, the STING agonist that is not bound to an antibody or antigen-binding fragment is a CDN, such as one of those described herein, i.e., 2'3'-CDN.In other embodiments, the STING agonist is a 3'3'-CDN, a 2'2'-CDN, or a 3'2'-CDN.In some embodiments, the STING agonist is a benzophenone analog.In further embodiments, the STING agonist is a dimeric amide benzimidazole. Examples of STING agonists that are not linked to an antibody or antigen-binding fragment that can be used in combination with the ADCs of the disclosure include IMSA101, ADU-S100 (MIW815), BMS-986301, CRD5500, CMA (10-carboxymethyl-9-acridanone), diABZI STING agonist-1 (e.g., CAS number: 2138299-34-8), DMXAA (ASA404 / vadimezan), E7766, GSK-532, GSK-3745417, MK-1454, MK-2118, SB-11285, SRCB-0074, TAK-676, and TTI-10001. The STING agonist can be administered prior to, concurrently with, or following administration of the ADC of Formula I.

[0262] The ADC of formula I can be used in combination with a "free" CDN that is not bound to an antibody or antigen-binding fragment of formula I, for example, to treat cancer or to induce or promote an immune response. The free CDN can be administered before, simultaneously with, or after administration of the ADC of formula I. In such cases, the free CDN can be the same as or different from the CDN bound to the antibody of the ADC of formula I. The free CDN can be cGAMP, e.g., 2'3'-cGAMP or an analog or derivative thereof, or a pharma- ceutically acceptable salt thereof. In other embodiments, the free CDN is 3'3'-cGAMP, 2'2'-cGAMP, 3'2'-cGAMP, or an analog or derivative of any of these, or a pharma-ceutically acceptable salt thereof.

[0263] Thus, the present disclosure provides methods of treating cancer in a subject by administering a pharmaceutical composition comprising at least one CDN that is not bound to an antibody (a "free CDN") and a pharma- ceutically acceptable amount of an ADC of the disclosure (i.e., an ADC of Formula I). ​​The ADC of Formula I and the free CDN may be administered together or separately, and, if administered separately, administration may be by any convenient route, separately or in combination, simultaneously or sequentially, and in any order.

[0264] In one embodiment, the free CDN administered in combination with an ADC of formula I is the following compound, or a pharma- ceutically acceptable salt thereof: [ka]

[0265] In another embodiment, the free CDN administered in combination with an ADC of formula I is the following compound, or a pharma- ceutically acceptable salt thereof: [ka]

[0266] In another embodiment, the free CDN administered in combination with an ADC of formula I is the following compound, or a pharma- ceutically acceptable salt thereof: [ka]

[0267] In another embodiment, the free CDN administered in combination with an ADC of formula I is the following compound, or a pharma- ceutically acceptable salt thereof: [ka]

[0268] In another embodiment, the free CDN administered in combination with an ADC of formula I is the following compound, or a pharma- ceutically acceptable salt thereof: [ka]

[0269] In another embodiment, the free CDN administered in combination with an ADC of formula I is the following compound, or a pharma- ceutically acceptable salt thereof: [ka]

[0270] In another embodiment, the free CDN administered in combination with an ADC of formula I is the following compound, or a pharma- ceutically acceptable salt thereof: [ka]

[0271] In another embodiment, the free CDN administered in combination with an ADC of formula I is the following compound, or a pharma- ceutically acceptable salt thereof: [ka]

[0272] In another embodiment, the free CDN administered in combination with an ADC of formula I is the following compound, or a pharma- ceutically acceptable salt thereof: [ka]

[0273] In another embodiment, the free CDN administered in combination with an ADC of formula I is the following compound, or a pharma- ceutically acceptable salt thereof: [ka]

[0274] In another embodiment, the free CDN administered in combination with an ADC of formula I is the following compound, or a pharma- ceutically acceptable salt thereof: [ka]

[0275] In another embodiment, the free CDN administered in combination with an ADC of formula I is the following compound, or a pharma- ceutically acceptable salt thereof: [ka]

[0276] In another embodiment, the free CDN administered in combination with an ADC of formula I is the following compound, or a pharma- ceutically acceptable salt thereof: [ka]

[0277] In another embodiment, the free CDN administered in combination with an ADC of formula I is the following compound, or a pharma- ceutically acceptable salt thereof: [ka]

[0278] In another embodiment, the free CDN administered in combination with an ADC of formula I is the following compound, or a pharma- ceutically acceptable salt thereof: [ka]

[0279] In another embodiment, the free CDN administered in combination with an ADC of formula I is the following compound, or a pharma- ceutically acceptable salt thereof: [ka]

[0280] In another embodiment, the free CDN administered in combination with an ADC of formula I is the following compound, or a pharma- ceutically acceptable salt thereof: [ka]

[0281] In another embodiment, the free CDN administered in combination with an ADC of formula I is the following compound, or a pharma- ceutically acceptable salt thereof: [ka]

[0282] In another embodiment, the free CDN administered in combination with an ADC of formula I is the following compound, or a pharma- ceutically acceptable salt thereof: [ka]

[0283] 7. Example The following examples highlighting certain features and characteristics of exemplary embodiments of CDNs, ADCs, and methods of treating patients using these ADCs are provided for purposes of illustration and not limitation. Abbreviation 1 H-NMR Proton Nuclear Magnetic Resonance Spectroscopy 19 F-NMR 19 F nuclear magnetic resonance spectroscopy 31 P-NMR 31 P nuclear magnetic resonance spectroscopy G Guanine A Adenine A Bz 6N-Benzoyladenine Gib 2N-isobutyryl Bz Benzoyl DCA Dichloroacetic acid DCM Dichloromethane DMOCP 2-chloro-5,5-dimethyl-1,3,2-dioxaphosphineane 2-oxide DMT 4,4'-Dimethoxytrityl DMTCl 4,4'-Dimethoxytrityl Chloride PBS Phosphate Buffered Saline Py. Pyridine TBS t-Butyldimethylsilyl TrCl Tris(hydroxymethyl)aminomethane hydrochloride IBX 2-Iodoxybenzoic acid LAH Lithium Aluminum Hydride DMF Dimethylformamide NMM N-Methylmorpholine Et3N Triethylamine

[0284] Example 1. Preparation of CDN-A Schemes A1 and A2 below show the synthesis of a CDN disclosed herein ("CDN-A"). The synthesis and characterization of CDNs and synthetic intermediates are described below. Synthesis of intermediate 19 from 1 [ka] [ka]

[0285] Step 1: Synthesis of (3aR,5R,6S,6aR)-5-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-6-ol [ka] A solution of (2R,4S,5R)-5-(hydroxymethyl)tetrahydrofuran-2,3,4 triol (100 g, 0.67 mol) in acetone (2.6 L) containing H2SO4 (concentrated sulfuric acid, 184.00 g, 1.88 mol, 100 mL, 2.8 equiv.) is stirred at 20 °C for 1 h. A solution of Na2CO3 (130 g, 1.23 mol, 1.8 equiv.) in H2O (600 mL) is carefully added at 0 °C. The mixture is stirred for another 2.5 h before a second batch of Na2CO3 (70 g, 0.66 mol) is added. After 0.5 h, the precipitate is collected by filtration and washed with acetone (0.5 L x 3). The filtrate is concentrated and purified by column chromatography (SiO2, DCM:MeOH=10:1-5:1) to give (3aR,5R,6R)-5-(hydroxymethyl)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-6-ol (53.5 g, 0.28 mol, 85% yield) as a yellow oil. (MS: [M+Na] + 213.0)

[0286] Step 2: Synthesis of 3aR,5R,6S,6aR)-2,2-dimethyl-5-((trityloxy)methyl)tetrahydrofuro[2,3-d][1,3]dioxol-6-ol [ka] To a solution of (3aR,5R,6R)-5-(hydroxymethyl)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-6-ol (125 g, 0.66 mol) in pyridine (600 mL) is added TrCl (219.9 g, 0.79 mol, 1.2 equiv). After 16 h at 60 °C, the mixture is cooled and concentrated. The residue is partitioned between CHCl (400 mL) and aqueous NaHCO (sat., 800 mL). The aqueous phase is extracted with CHCl (2 × 600 mL). The combined organic layers are dried over Na2SO4, filtered, concentrated and purified by column chromatography (SiO2, petroleum ether / ethyl acetate=10:1-5:1) to give (3aR,5R,6R)-2,2-dimethyl-5-(trityloxymethyl)-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-6-ol (250 g, 0.58 mol, 88% yield) as a white solid. (MS: [M+Na] + 455.0)

[0287] Step 3: Synthesis of (3aR,5R,6aS)-2,2-dimethyl-5-((trityloxy)methyl)dihydrofuro[2,3-d][1,3]dioxol-6(3aH)-one [ka] To a solution of (3aR,5R,6R)-2,2-dimethyl-5-(trityloxymethyl)-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-6-ol (250 g, 0.58 mol) in CH3CN (1.5 L) is added IBX (323 g, 1.2 mol, 2.00 equiv). The mixture is stirred at 90°C for 6 h. After cooling, the mixture is filtered. The filtrate is concentrated to give (3aR,5R,6aS)-2,2-dimethyl-5-(trityloxymethyl)-3a,6a-dihydrofuro[2,3-d][1,3]dioxol-6-one (240 g, 0.56 mol, 96.5% yield) as a pale yellow oil. (MS: [M+Na] + 453.0)

[0288] Step 4: Synthesis of (E)-methyl-2-((3aR,5S,6aR)-2,2-dimethyl-5-((trityloxy)methyl)furo[2,3-d][1,3]dioxol-6(3aH,5H,6aH)-ylidene)acetate [ka] To a mixture of NaH (14.5 g, 0.36 mol, 60% in oil, 1.3 equiv.) and THF (1.00 L), methyl 2-dimethoxyphosphoryl acetate (66 g, 0.36 mol, 52.4 mL, 1.3 equiv.) is added dropwise over 15 min at 0 °C. The mixture is stirred at the same temperature for 45 min, and then a solution of (3aR,5R,6aS)-2,2-dimethyl-5-(trityloxymethyl)-3a,6a-dihydrofuro[2,3-d][1,3]dioxol-6-one (120 g, 0.28 mol, 1 equiv.) in THF (500 mL) is added dropwise. After 15 h at 25 °C, the reaction is quenched with NH4Cl (sat., 50 mL) at 0 °C. The mixture is concentrated and partitioned between brine (500 mL) and CHCl2 (500 mL x 3). The combined organic layers are dried over Na2SO4, filtered, concentrated and purified by column chromatography (SiO2, petroleum ether / ethyl acetate=15:1-5:1) to give methyl (2E)-2-[(3aR,5S,6aR)-2,2-dimethyl-5-(trityloxymethyl)-3a,6a-dihydrofuro[2,3-d][1,3]dioxol-6-ylidene]acetate (65 g, 0.53 mol, 96% yield) as a pale yellow oil. (MS: [M+Na] + 509.0)

[0289] Step 5: Synthesis of methyl 2-((3aR,5S,6R,6aR)-2,2-dimethyl-5-((trityloxy)methyl)tetrahydrofuro[2,3-d][1,3]dioxol-6-yl)acetate [ka] To a solution of methyl (2E)-2-[(3aR,5S,6aR)-2,2-dimethyl-5-(trityloxymethyl)-3a,6a-dihydrofuro[2,3-d][1,3]dioxol-6-ylidene]acetate (260 g, 0.53 mol) in EtOAc (700 mL) is added Pd / C (10% on carbon, 10 g) under N2 atmosphere. The suspension is degassed and purged with H2 three times. The mixture is stirred under H2 (20 psi) at 25 °C for 16 h. The catalyst is removed by filtration. The filtrate is concentrated and purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 15:1 to 10:1) to give methyl 2-[(3aR,5S,6S)-2,2-dimethyl-5-(trityloxymethyl)-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-6-yl]acetate (210 g, 0.43 mol, 80.4% yield) as a white solid. (MS: [M+Na] + 511.1)

[0290] Step 6: Synthesis of 2-((3aR,5S,6R,6aR)-2,2-dimethyl-5-((trityloxy)methyl)tetrahydrofuro[2,3-d][1,3]dioxol-6-yl)ethanol [ka] To a mixture of LiAlH4 (15.5 g, 0.41 mol, 2 equiv.) and THF (500 mL) is slowly added a solution of methyl 2-[(3aR,5S,6S)-2,2-dimethyl-5-(trityloxymethyl)-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-6-yl]acetate (100 g, 0.20 mol) in THF (20 mL) at 0° C. After stirring at 25° C. for 2.5 h, the reaction is quenched with water (15 mL) and NaOH (aq., 15%, 15 mL) at 0° C. The crude product is dried over Na2SO4, filtered, concentrated and purified by column chromatography (SiO2, petroleum ether / ethyl acetate=5:1 to 2:1) to give 2-[(3aR,5S,6S)-2,2-dimethyl-5-(trityloxymethyl)-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-6-yl]ethanol (80 g, 0.35 mol, 85% yield) as a pale yellow oil. 1 HNMR (400MHz, CDCl3)δ=7.43-7.35(m, 6H), 7.25-7.18(m, 6H), 7.18-7.11(m,3H), 5.82(d,J=3.8Hz,1H), 4.62(t,J=4.2Hz,1H), 3.86(td,J=3.5,10.2Hz,1H), 3.61-3 .47(m,2H), 3.37(dd,J=2.8,10.7Hz,1H), 3.02(dd,J=4.1,10.7Hz,1H), 2.13(tt,J =4.8,9.9Hz,1H), 1.73-1.62(m,2H), 1.42(s,3H), 1.40-1.31(m,1H), 1.26(s,3H). MS:[M+Na] + 483.2

[0291] Step 7: Synthesis of (3aR,5S,6R,6aR)-6-(2-(benzyloxy)ethyl)-2,2-dimethyl-5-((trityloxy)methyl)tetrahydrofuro[2,3-d][1,3]dioxole [ka] To a mixture of NaH (27.1 g, 0.68 mol, 60% in oil, 4.00 equiv.) and THF (500 mL), a solution of 2-[(3aR,5S,6S)-2,2-dimethyl-5-(trityloxymethyl)-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-6-yl]ethanol (78 g, 0.17 mol) in THF (200 mL) is added dropwise over 5 min at -20 °C. After addition, the mixture is stirred at 25 °C for 2 h. BnBr (60.3 mL, 0.51 mol, 3.00 equiv.) is added dropwise. The mixture is stirred at 80 °C for 14 h. After cooling to 0 °C, the reaction is quenched with aqueous NH4Cl (sat., 20 mL), diluted with H2O (400 mL), and extracted with CHF (400 mL x 3). The combined organic layers are dried over Na2SO4, filtered, concentrated and purified by column chromatography (SiO2, petroleum ether / ethyl acetate=15:1 to 5:1) to give (3aR,5S,6S)-6-(2-benzyloxyethyl)-2,2-dimethyl-5-(trityloxymethyl)-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxole (90 g, 0.16 mol, 97% yield) as a white solid. (MS: [M+Na] + =573.1)

[0292] Step 8: Synthesis of (3aR,5S,6R,6aR)-6-(2-(benzyloxy)ethyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methanol [ka] To a solution of (3aR,5S,6S)-6-(2-benzyloxyethyl)-2,2-dimethyl-5-(trityloxymethyl)-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxole (90 g, 0.16 mol) in CHCl2 (300 mL) is added CHCl2COOH (30 mL, 0.16 mol, 1.00 equiv). After 3 h at 25 °C, the reaction mixture is neutralized to pH 7.0 with aqueous NaHCO3 (saturated, 500 mL) at 0 °C. The crude product is extracted with CHCl2 (100 mL × 3). The combined organic layers are dried over MgSO4, filtered, concentrated and purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 5:1 to 2:1) to give [(3aR,5S,6S)-6-(2-benzyloxyethyl)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-5-yl]methanol (44 g, 0.14 mol, 87% yield) as a yellow oil.

[0293] Step 9: Synthesis of (3aR,5S,6R,6aR)-6-(2-(benzyloxy)ethyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methylbenzoate [ka] To a solution of [(3aR,5S,6S)-6-(2-benzyloxyethyl)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-5-yl]methanol (62 g, 0.2 mol) in CHCl (200 mL) is added BzCl (35 mL, 0.3 mol, 1.50 equiv.) and EtN (55.7 mL, 0.4 mol, 2 equiv.). After 1 h at 25 °C, the reaction mixture is concentrated and purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 15:1 to 10:1) to give [(3aR,5S,6S)-6-(2-benzyloxyethyl)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-5-yl]methylbenzoate (80 g, 0.19 mol, 97% yield) as a pale yellow oil. (MS: [M+Na] + 435.1)

[0294] Step 10: Synthesis of ((2S,3S,4R)-3-(2-(benzyloxy)ethyl)-4,5-dihydroxytetrahydrofuran-2-yl)methylbenzoate [ka] To a mixture of [(3aR,5S,6S)-6-(2-benzyloxyethyl)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-5-yl]methylbenzoate (20 g, 49 mmol) and HO (6 mL) is added HOAc (28 mL, 10 equiv.). The mixture is stirred at 100 °C for 5 h. After cooling, the reaction mixture is neutralized with aqueous NaHCO3 (saturated 2 L) and extracted with CHCl2 (400 mL x 3). The combined organic layers are concentrated to give [(2S,3R,5R)-3-(2-benzyloxyethyl)-4,5-dihydroxy-tetrahydrofuran-2-yl]methylbenzoate (17.5 g, 47 mmol, 96% yield) as a pale yellow oil, which is used in the next step without purification. (MS: [M+Na] + 395.1)

[0295] Step 11: Synthesis of (3R,4R,5S)-5-((benzoyloxy)methyl)-4-(2-(benzyloxy)ethyl)tetrahydrofuran-2,3-diyl acetate [ka] To a solution of [(2S,3R,5R)-3-(2-benzyloxyethyl)-4,5-dihydroxy-tetrahydrofuran-2-yl]methylbenzoate (70 g, 0.19 mol) in pyridine (300 mL) is added Ac2O (0.75 mol, 70.4 mL, 4.0 equiv). The mixture is stirred at 60 °C for 4 h. After cooling to 25 °C, the reaction mixture is neutralized to about pH 7 with aqueous NaHCO3 (saturated) and extracted with CHCl2 (300 mL × 3). The organic layer is concentrated and purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10:1 to 5:1) to give [(2S,3S,5S)-4,5-diacetoxy-3-(2-benzyloxyethyl)tetrahydrofuran-2-yl]methylbenzoate (80 g, 93% yield) as a white solid. (MS: [M+Na] + 479.1)

[0296] Step 12: Synthesis of ((2S,3R,4R,5R)-4-acetoxy-3-(2-(benzyloxy)ethyl)-5-(2-isobutyramido-6-oxo-1H-purin-9(6H)-yl)tetrahydrofuran-2-yl)methylbenzoate [ka] To a solution of 2-methyl-N-(6-oxo-1,9-dihydropurin-2-yl)propanamide (18.9 g, 85.4 mmol, 1.30 equiv.) in CH3CN (300 mL) is added BSA (84.5 mL, 341.7 mmol, 5.2 equiv.) at 20 °C. After stirring at 65 °C for 0.5 h, the mixture is cooled and concentrated. The residue is dissolved in MeCN (600 mL), followed by the addition of a solution of [(2S,3S,5S)-4,5-diacetoxy-3-(2-benzyloxyethyl)tetrahydrofuran-2-yl]methylbenzoate (30 g, 65.7 mmol) in MeCN (150 mL) and TMSOTf (17.8 mL, 98.6 mmol, 1.5 equiv.) at -15 °C. The mixture is stirred at 65 °C for 15 h. After cooling, the mixture is concentrated and purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 5:1 to 1:1) to give ((2S,3R,4R,5R)-4-acetoxy-3-(2-(benzyloxy)ethyl)-5-(2-isobutyramido-6-oxo-1H-purin-9(6H)-yl)tetrahydrofuran-2-yl)methylbenzoate (30 g, 48.6 mmol, 74% yield) as a white solid. (MS: [M+1] + 618.1) 1 HNMR (400MHz, CHLOROFORM-d) δ=12.00(s,1H), 9.11(s,1H), 7.92-7.84(m,2H), 7.82-7.76(m, 1H), 7.58(t,J=7.1Hz,1H), 7.46-7.37(m,2H), 7.27-7.16(m, 5H), 5.90-5.85(m,1H), 5.74(d,J =5.3Hz,1H), 4.78-4.61(m,2H), 4.55-4.38(m,3H), 3.55(t,J=5.8Hz,2H), 3.23-3.14(m,1H), 2 .47(spt,J=6.9Hz,1H), 2.22-2.10(m,3H), 1.83(q,J=6.1Hz,2H), 1.17(dd,J=6.9,8.9Hz,6H).

[0297] Step 13: Synthesis of ((2S,3R,4R,5R)-4-acetoxy-3-(2-hydroxyethyl)-5-(2-isobutyramido-6-oxo-1H-purin-9(6H)-yl)tetrahydrofuran-2-yl)methylbenzoate [ka] To a solution of [(2S,3S,5R)-4-acetoxy-3-(2-benzyloxyethyl)-5-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-2-yl]methylbenzoate (25 g, 40.5 mmol) in EtOH (500 mL) is added Pd / C (38 g, 10% on carbon) and HOAc (25.00 mL, 437.1 mmol, 11 equiv.) under N2. The suspension is purged with H2 three times and stirred under H2 (40 Psi) at 50 °C for 48 h. After cooling, the reaction mixture is filtered. The filtrate is concentrated and purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 5:1 to 2:1) to give [(2S,3S,5R)-4-acetoxy-3-(2-hydroxyethyl)-5-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-2-yl]methylbenzoate (20 g, 37.9 mmol, 94% yield) as a white solid. (MS: [M+1] + 528.3)

[0298] Step 14: Synthesis of [(2S,3R,5R)-4-acetoxy-3-(2-iodoethyl)-5-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-2-yl]methylbenzoate [ka] To a solution of [(2S,3R,5R)-4-acetoxy-3-(2-hydroxyethyl)-5-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-2-yl]methylbenzoate (3 g, 5.69 mmol, 1 equiv.) in THF (90 mL) is added imidazole (1.16 g, 17.06 mmol, 3 equiv.) and triphenylphosphine (4.47 g, 17.06 mmol, 3 equiv.) in one portion, followed by slow addition of a solution of I2 (2.60 g, 10.24 mmol, 1.8 equiv.) in THF (10 mL). The reaction mixture is stirred at 25° C. for 16 h, quenched with saturated aqueous Na2SO3 (8 mL), and evaporated to give a residue. The residue is dissolved in ethyl acetate (80 mL) and washed with water (80 mL). The aqueous layer is extracted with EtOAc (150 mL x 3). The combined organic layers are dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue is purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1:1 to 1:3) to give [(2S,3R,5R)-4-acetoxy-3-(2-iodoethyl)-5-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-2-yl]methylbenzoate (2.3 g, 64% yield) as a yellow solid. (MS: [M+1] + 638.2)

[0299] Step 15: Synthesis of [(2S,3R,4R,5R)-4-acetoxy-3-(2-azidoethyl)-5-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-2-yl]methylbenzoate [ka] To a solution of [(2S,3R,4R,5R)-4-acetoxy-3-(2-iodoethyl)-5-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-2-yl]methylbenzoate (3.8 g, 5.96 mmol, 1 equiv.) in THF (40 mL) is added NaN3 (2.52 g, 38.75 mmol, 6.5 equiv.) and H2O (10 mL). The mixture is stirred at 50 °C for 2 h. The mixture is quenched with saturated aqueous Na2CO3 solution (50 mL) and extracted with EtOAc (100 mL x 3). The combined organic layers are dried over anhydrous Na2SO4 and concentrated under reduced pressure to give [(2S,3R,4R,5R)-4-acetoxy-3-(2-azidoethyl)-5-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-2-yl]methylbenzoate (2 g, 61% yield) as a yellow solid. (MS: [M+1] + 553.1)

[0300] Step 16: Synthesis of N-[9-[(2R,3R,4S,5S)-4-(2-azidoethyl)-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-6-oxo-1H-purin-2-yl]-2-methyl-propanamide [ka] To a solution of [(2S,3R,5R)-4-acetoxy-3-(2-azidoethyl)-5-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-2-yl]methylbenzoate (2.55 g, 4.62 mmol, 1 equiv.) in EtOH (220 mL) is added aqueous NaOH (2 M, 23 mL, 10 equiv.) at 0 °C. The resulting mixture is stirred at ambient temperature for 0.5 h. The reaction mixture is adjusted to pH = 7-8 at 0 °C by adding HCOOH, and the mixture is concentrated under reduced pressure to give a residue. The residue is purified by preparative HPLC (MeCN and water with 0.1% FA, 0%-70%) to give N-[9-[(2R,3R,4S,5S)-4-(2-azidoethyl)-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-6-oxo-1H-purin-2-yl]-2-methyl-propanamide (1.6 g, 3.94 mmol, 85% yield) as a white solid. (MS: [M+1] + 407.1).

[0301] Step 17: Synthesis of N-[9-[(2R,3R,4S,5S)-4-(2-azidoethyl)-5-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-hydroxy-tetrahydrofuran-2-yl]-6-oxo-1H-purin-2-yl]-2-methyl-propanamide [ka] To a solution of N-[9-[(2R,3R,4S,5S)-4-(2-azidoethyl)-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-6-oxo-1H-purin-2-yl]-2-methyl-propanamide (1.6 g, 3.94 mmol) in pyridine (15 mL) is added DMTCl (1.60 g, 4.72 mmol, 1.2 equiv). The mixture is stirred at 25° C. for 3 h. The reaction mixture is quenched by the addition of MeOH (10 mL) at 25° C. The mixture is concentrated under reduced pressure to give a residue as a yellow oil. The residue is purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 1 to EtOH / ethyl acetate = 1:250) to give N-[9-[(2R,3R,4S,5S)-4-(2-azidoethyl)-5-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-hydroxy-tetrahydrofuran-2-yl]-6-oxo-1H-purin-2-yl]-2-methyl-propanamide (950 mg, 1.34 mmol, 34% yield) as a yellow solid. (MS: [M+1] + 709.4).

[0302] Step 18: Synthesis of [(2R,3R,4R,5S)-4-(2-azidoethyl)-5-(hydroxymethyl)-2-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-3-yl]oxyphosphinic acid [ka] To a solution of N-[9-[(2R,3R,4S,5S)-4-(2-azidoethyl)-5-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-hydroxytetrahydrofuran-2-yl]-6-oxo-1H-purin-2-yl]-2-methyl-propanamide (700 mg, 988 μmol) in pyridine (6 mL) is added diphenyl phosphite (809.5 mg, 3.46 mmol, 664 μL, 3.5 equiv). After 1 h at 25 °C, DCM (5 mL) and Et3N (3 mL) are added and the mixture is stirred at 25 °C for another 1.5 h. The mixture is concentrated and the residue is partitioned between DCM (20 mL) and aqueous NaHCO3 (5%, 20 mL). The organic phase is evaporated to give the crude intermediate, which is redissolved in a mixture of HO (3 mL) and 2,2-dichloroacetic acid (382 mg, 2.96 mmol, 243 μL, 3 equiv.) in DCM (10 mL). The mixture is stirred at 25 °C for 0.5 h. The reaction is quenched with EtN (3.0 mL), and then the mixture is evaporated to give a residue. The residue is purified by reverse phase column (MeCN and water with 0.1% TEA, 0% to 70%) to give [(2R,3R,4R,5S)-4-(2-azidoethyl)-5-(hydroxymethyl)-2-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-3-yl]oxyphosphinic acid (400 mg, 82% yield, 95% purity) as a white solid. (MS: [M+1] + 471.0) Synthesis of CDN-A from intermediate 19 [ka]

[0303] Step 1: Synthesis of [(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5S)-4-(2-azidoethyl)-5-(hydroxymethyl)-2-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-3-yl]oxy-(2-cyanoethoxy)phosphoryl]oxymethyl]-5-(6-benzamidopurin-9-yl)-4-[tertbutyl(dimethyl)silyl]oxy-tetrahydrofuran-3-yl]oxyphosphinic acid [ka] To a solution of [(2R,3R,4R,5R)-5-(6-benzamidopurin-9-yl)-4-[tert-butyl(dimethyl)silyl]oxy-2-(hydroxymethyl)tetrahydrofuran-3-yl]oxyphosphinic acid (400 mg, 727.8 μmol) in CH3CN (3 mL) is added a solution of tetrazole (0.45 M in MeCN, 6.47 mL, 4 equiv.). The mixture is stirred at 25° C. for 5 min. N-[9-[(2R,3R,4R,5S)-4-(2-azidoethyl)-5-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-[2-cyanoethoxy-(diisopropylamino)phosphanyl]oxytetrahydrofuran-2-yl]-6-oxo-1H-purin-2-yl]-2-methyl-propanamide (595 mg, 655 μmol, 0.9 eq.) is added. After 0.5 h at 25° C., 2-hydroperoxy-2-methyl-propane (197 mg, 2.18 mmol, 209 μL, 3 eq.) is added and the mixture is stirred for 0.5 h at 25° C. Then, 2,2-dichloroacetic acid (938 mg, 7.28 mmol, 598 μL, 10 eq.) in DCM (10 mL) is added. The mixture is stirred at 25° C. for 25 min and quenched with saturated aqueous Na2SO3 (2.0 mL) for neutralization, followed by pyridine (2.0 mL). The mixture is evaporated to give a residue. The residue is purified by reverse phase column (MeCN and water with 0.1% TEA, 0%-70%) to give [(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5S)-4-(2-azidoethyl)-5-(hydroxylmethyl)-2-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-3-yl]oxy-(2-cyanoethoxy)phosphoryl]oxymethyl]-5-(6-benzamidopurin-9-yl)-4-[tertbutyl(dimethyl)silyl]oxy-tetrahydrofuran-3-yl]oxyphosphinic acid (600 mg, 62% yield, 80% purity) as a white solid. (MS: [M+1] + 1071.5)

[0304] Step 2: Synthesis of N-[9-[(27S,28R,29R,30R,31R,32R,33R,34R)-29-(2-azidoethyl)-32-[tert-butyl(dimethyl)silyl]oxy-67,68-dihydroxy-33-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]-67,68-dioxo-59,60,61,62,63,64 hexaoxa-67,68-diphosphatricyclooctadecan-34-yl]purin-6-yl]benzamide [ka] To a solution of [(2R,3R,4R,5S)-4-(2-azidoethyl)-5-[[[(2R,3R,4R,5R)-5-(6-benzamidopurin-9-yl)-4-[tertbutyl(dimethyl)silyl]oxy-2-(hydroxymethyl)tetrahydrofuran-3-yl]oxy-(2-cyanoethoxy)phosphoryl]oxymethyl]-2-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-3-yl]oxyphosphinic acid (400 mg, 373.48 μmol) in pyridine (9 mL) is added 2-chloro-5,5-dimethyl-1,3,2-dioxaphosphinane 2-oxide (345 mg, 1.87 mmol, 5 equiv.). After 15 min at 25 °C, I2 (379 mg, 1.49 mmol, 4 eq) and H2O (13.5 mg, 747.0 μmol, 13.5 μL, 2 eq) are added and the mixture is stirred at 25 °C for 0.5 h. The reaction is quenched with saturated aqueous NaHCO3 (2.0 mL) and saturated aqueous Na2SO3 (2.0 mL). After evaporation, the residue is dissolved in CH3CN (10 mL) and 2-methylpropan-2-amine (10 mL) is added. The mixture is stirred at 25 °C for 1 h. The reaction mixture is evaporated to give a residue. The residue is purified by reverse phase column (MeCN and water with 0.1% TEA, 0%-70%) to give N-[9-[(27S,28R,29R,30R,31R,32R,33R,34R)-29-(2-azidoethyl)-32-[tert-butyl(dimethyl)silyl]oxy-67,68 dihydroxy-33-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]-67,68-dioxo-59,60,61,62,63,64 hexaoxa-67,68 diphosphatricyclooctadecan-34-yl]purin-6-yl]benzamide (350 mg, 310 μmol, 83% yield, 90% purity) as a white solid. (MS: [M+1] + 1016.4)

[0305] Step 3: Synthesis of 2-amino-9-[(19S,20R,21R,22R,23R,24R,25R,26R)-26-(6-aminopurin-9-yl)-21-(2-azidoethyl)-24-[tert-butyl(dimethyl)silyl]oxy-54,55-dihydroxy-54,55-dioxo-46,47,48,49,50,51-hexaoxa-54,55-diphosphatricyclooctadecan-25-yl]-1H-purin-6-one [ka] N-[9-[(27S,28R,29R,30R,31R,32R,33R,34R)-29-(2-azidoethyl)-32-[tert-butyl(dimethyl)silyl]oxy-67,68-dihydroxy-33-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]-67,68-dioxo-59,60,61,62,63,64-hexaoxa-67,68 diphosphatricyclooctadecan-34-yl]purin-6-yl]benzamide (300 mg, 295 μmol) is dissolved in MeNH2 / EtOH (5 M, 2.95 mL) and the mixture is stirred at 25° C. for 2 h. The mixture is evaporated to give a residue. The residue is purified by reverse phase column (MeCN and water with 0.1% TEA, 0%-35%) to give 2-amino-9-[(19S,20R,21R,22R,23R,24R,25R,26R)-26-(6-aminopurin-9-yl)-21-(2-azidoethyl)-24-[tert-butyl(dimethyl)silyl]oxy-54,55-dihydroxy-54,55-dioxo-46,47,48,49,50,51-hexaoxa-54,55-diphosphatricyclooctadecan-25-yl]-1H-purin-6-one (160 mg, 52% yield, 80% purity) as a white solid. (MS: [M+1] + 842.3)

[0306] Step 4: Synthesis of 2-amino-9-[(19S,20R,21R,22R,23R,24R,25R,26R)-21-(2-aminoethyl)-26-(6-aminopurin-9-yl)-24-[tert-butyl(dimethyl)silyl]oxy-52,53-dihydroxy-52,53-dioxo-44,45,46,47,48,49-hexaoxa-52,53-diphosphatricyclooctadecan-25-yl]-1H-purin-6-one [ka] To a solution of 2-amino-9-[(19S,20R,21R,22R,23R,24R,25R,26R)-26-(6-aminopurin-9-yl)-21-(2-azidoethyl)-24-[tertbutyl(dimethyl)silyl]oxy-54,55-dihydroxy-54,55-dioxo-46,47,48,49,50,51-hexaoxa-54,55-diphosphatricyclooctadecan-25-yl]-1H-purin-6-one (100 mg, 118.8 μmol) in MeOH (8 mL) is added Pd / C (30 mg, 10% purity) in one portion and the mixture is stirred under H2 (10 psi) at 25 °C for 5 h. The mixture is filtered and the filtrate is evaporated to give a residue. The residue is purified by reverse phase column (MeCN and water with 0.1% TEA, 0%-30%) to give 2-amino-9-[(19S,20R,21R,22R,23R,24R,25R,26R)-21-(2-aminoethyl)-26-(6-aminopurin-9-yl)-24-[tert-butyl(dimethyl)silyl]oxy-52,53-dihydroxy-52,53-dioxo-44,45,46,47,48,49-hexaoxa-52,53 diphosphatricyclooctadecan-25-yl]-1H-purin-6-one (70 mg, 77.2 μmol, 65% yield, 90% purity) as a white solid. (MS: [M+1] + 816.5)

[0307] Step 5: Synthesis of 2-amino-9-[(14S,15R,16R,17R,18S,19R,20R,21R)-16-(2-aminoethyl)-20-(6-aminopurin-9-yl)-17,45,46-trihydroxy-45,46-dioxo-39,40,41,42,43,44-hexaoxa-45,46-diphosphatricyclooctadecan-21-yl]-1H-purin-6-one (CDN-A) [ka] To a solution of 2-amino-9-[(19S,20R,21R,22R,23R,24R,25R,26R)-21-(2-aminoethyl)-26-(6-aminopurin-9-yl)-24-[tertbutyl(dimethyl)silyl]oxy-52,53-dihydroxy-52,53-dioxo-44,45,46,47,48,49-hexaoxa-52,53 diphosphatricyclooctadecan-25-yl]-1H-purin-6-one (35 mg, 42.9 μmol) in MeOH (3 mL) is added NHF (127 mg, 3.43 mmol, 80 equiv) in one portion and the mixture is stirred at 70° C. for 0.25 h. After cooling to room temperature, the mixture is evaporated to give a residue. The residue is purified by reverse phase column (MeCN and water with 0.1% HCOOH, 0%-30%) to give 2-amino-9-[(14S,15R,16R,17R,18S,19R,20R,21R)-16-(2-aminoethyl)-20-(6-aminopurin-9-yl)-17,45,46-trihydroxy-45,46-dioxo-39,40,41,42,43,44-hexaoxa-45,46-diphosphatricyclooctadecan-21-yl]-1H-purin-6-one (CDN-A, 8.6 mg, 11.9 μmol, 28% yield, 97% purity) as a white solid. (MS: [M+1] + 702.0) 1H NMR (D2O+buffer, 400MHz): δ(ppm)8.19(s,1H), 8.18(s,1H), 7.76(s,1H), 6.08(s,1H), 5.83-5.81(m,1H), 5.71-5.67(m,1H), 5.03-5.01(m,1H), 4.4 2-4.37(m,2H), 4.30-4.28(m,1H), 4.18-4.16(m,1H), 4.07-4.01(m,2H), 3 .13-3.11(m,2H), 2.68-2.66(m,1H), 2.33-2.30(m,1H), 1.85-1.83(m,1H). 31 P NMR(D2O+buffer):δ(ppm)-1.15,-2.47

[0308] Example 2. Preparation of CDN-B Schemes B1 and B2 below show the synthesis of a CDN disclosed herein ("CDN-B"), the synthesis and characterization of which and the synthetic intermediates used are described below. Synthesis of intermediate 29 from intermediate 14 [ka]

[0309] Step 1: Synthesis of [(2S,3R,4R,5R)-4-acetoxy-3-(2-chloroethyl)-5-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-2-yl]methylbenzoate [ka] To a solution of [(2S,3R,4R,5R)-4-acetoxy-3-(2-hydroxyethyl)-5-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-2-yl]methylbenzoate (19 g, 36.0 mmol) in DMF (100 mL) is added PPh3 (23.6 g, 90.0 mmol, 2.5 equiv.) and CCl4 (17.3 mL, 180.1 mmol, 5 equiv.). After stirring at 25° C. for 16 h, the reaction is quenched with saturated aqueous NaHCO3 (150 mL) and extracted with EtOAc (80 mL×2). The combined organic layers are concentrated and purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10:1 to 1:1) to give [(2S,3R,4R,5R)-4-acetoxy-3-(2-chloroethyl)-5-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-2-yl]methylbenzoate (13 g, 23.8 mmol, 66% yield) as a pale yellow solid. (MS: [M+1] + 546.2)

[0310] Step 2: Synthesis of [(2S,3R,4R,5R)-4-acetoxy-3-(2-acetylsulfanylethyl)-5-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-2-yl]methylbenzoate [ka] To a solution of [(2S,3R,4R,5R)-4-acetoxy-3-(2-chloroethyl)-5-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-2-yl]methylbenzoate (15 g, 27.5 mmol) in DMF (100 mL) is added AcSK (7.84 g, 68.7 mmol, 2.5 equiv). The reaction mixture is stirred at 50° C. for 16 h. After cooling, the reaction mixture is diluted with DCM (200 mL) and washed with aqueous NaHCO3 (sat., 200 mL). The organic layer is concentrated to give [(2S,3R,4R,5R)-4-acetoxy-3-(2-acetylsulfanylethyl)-5-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-2-yl]methylbenzoate (16 g) as a pale yellow oil, which is used in the next step without purification. (MS: [M+1] + 586.3)

[0311] Step 3: Synthesis of N-[9-[(2R,3R,4S,5S)-3-hydroxy-5-(hydroxymethyl)-4-(2-sulfanylethyl)tetrahydrofuran-2-yl]-6-oxo-1H-purin-2-yl]-2-methyl-propanamide [ka] To a solution of [(2S,3R,4R,5R)-4-acetoxy-3-(2-acetylsulfanylethyl)-5-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-2-yl]methylbenzoate (16 g, 27.3 mmol) in EtOH (160 mL) is added NaOH (2 M, 68.3 mL, 5 equiv.) at 0° C. The reaction mixture is stirred at 0° C. for 0.5 h. The pH is adjusted to 7 with HOAc. The mixture is concentrated under reduced pressure to remove most of the solvent. The brown precipitate is collected and treated with DCM / TBME (1 / 100, V / V, 200 mL). After filtration, the filtrate is concentrated to give N-[9-[(2R,3R,4S,5S)-3-hydroxy-5-(hydroxymethyl)-4-(2-sulfanylethyl)tetrahydrofuran-2-yl]-6-oxo-1H-purin-2-yl]-2-methyl-propanamide (11 g, crude, ca. 10% disulfide) as a brown solid, which is used in the next step without further purification. (MS: [M+1] + 398.1)

[0312] Step 4: Synthesis of N-[9-[(2R,3R,4S,5S)-3-hydroxy-5-[[(3-methoxyphenyl)-(4-methoxyphenyl)-phenyl-methoxy]methyl]-4-[2-[(3-methoxyphenyl)-(4-methoxyphenyl)-phenyl-methyl]sulfanylethyl]tetrahydrofuran-2-yl]-6-oxo-1H-purin-2-yl]-2-methyl-propanamide [ka] To a solution of N-[9-[(2R,3R,4S,5S)-3-hydroxy-5-(hydroxymethyl)-4-(2-sulfanylethyl)tetrahydrofuran-2-yl]-6-oxo-1H-purin-2-yl]-2-methyl-propanamide (11 g, 27.7 mmol) in pyridine (110 mL) is added DMTCl (28.1 g, 83.0 mmol, 3 equiv.). After 16 h at 25° C., the reaction is quenched with aqueous NaHCO3 (saturated, 200 mL) and extracted with EtOAc (200 mL×2). The organic phase is dried over Na2SO4, filtered and purified by silica gel chromatography PE:EE (EA:EtOH=3:1)=10:1 to 2:1 to give the compound N-[9-[(2R,3R,4S,5S)-3-hydroxy-5-[[(3-methoxyphenyl)-(4-methoxyphenyl)-phenyl-methoxy]methyl]-4-[2-[(3-methoxyphenyl)-(4-methoxyphenyl)-phenyl-methyl]sulfanylethyl]tetrahydrofuran-2-yl]-6-oxo-1H-purin-2-yl]-2-methyl-propanamide (14 g, 47.0% yield, 93% purity) as a pale yellow solid. (MS: [M+1] + 1002.5)

[0313] Step 5: Synthesis of [(2R,3R,4R,5S)-5-(hydroxymethyl)-4-[2-[(3-methoxyphenyl)-(4-methoxyphenyl)-phenyl-methyl]sulfanylethyl]-2-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-3-yl]oxyphosphinic acid [ka] To a solution of N-[9-[(2R,3R,4S,5S)-3-hydroxy-5-[[(3-methoxyphenyl)-(4-methoxyphenyl)-phenyl-methoxy]methyl]-4-[2-[(3-methoxyphenyl)-(4-methoxyphenyl)-phenyl-methyl]sulfanylethyl]tetrahydrofuran-2-yl]-6-oxo-1H-purin-2-yl]-2-methyl-propanamide (12 g, 8.4 mmol) in pyridine (120 mL) is added phenoxyphosphonoyloxybenzene (7.51 mL, 29.3 mmol, 3.5 equiv.) at 25°C. After 1 h, Et3N / H2O (100 mL, 1:1) is added. After 0.5 h, the mixture is extracted with EtOAc (200 mL x 2). The organic phase is concentrated and then dissolved in aqueous AcOH (80%, 120 mL). The mixture is stirred at 25 °C for 1 h. The reaction mixture is neutralized to pH 7 by addition of saturated aqueous Na2CO3 at 0 °C. The mixture is directly purified by reverse phase column (CH3CN / H2O, 0-60%) to give [(2R,3R,4R,5S)-5-(hydroxymethyl)-4-[2-[(3-methoxyphenyl)-(4-methoxyphenyl)-phenyl-methyl]sulfanylethyl]-2-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-3-yl]oxyphosphinic acid (4.2 g, 5.5 mmol, 65% yield) as a white solid. (MS: [M+1] + 764.4) Synthesis of CDN-B from intermediate 29 [ka]

[0314] Step 1: Synthesis of [(2R,3R,4R,5S)-5-[[[(2R,3R,4R,5R)-5-(6-benzamidopurin-9-yl)-4-[tert-butyl(dimethyl)silyl]oxy-2-(hydroxymethyl)tetrahydrofuran-3-yl]oxy-(2-cyanoethoxy)phosphoryl]oxymethyl]-4-[2-[bis(4-methoxyphenyl)-phenyl-methyl]sulfanylethyl]-2-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-3-yl]oxyphosphinic acid [ka] To a solution of [(2R,5S)-4-[2-[bis(4-methoxyphenyl)-phenyl-methyl]sulfanylethyl]-5-(hydroxymethyl)-2-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-3-yl]oxyphosphinic acid (0.75 g, 0.98 mmol) in 1H-tetrazole (0.45 M in MeCN, 22.50 mL, 10 equiv.) is added N-[9-[(2R,3R,4R,5R)-5-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-[tert-butyl(dimethyl)silyl]oxy-4-[2-cyanoethoxy-(diisopropylamino)phosphanyl]oxy-tetrahydrofuran-2-yl]purin-6-yl]benzamide (1.1 g, 1.1 mmol, 1.1 equiv.). After 1 h, TBHP (0.43 ml, 65% in decane, 3 eq.) is added. The reaction mixture is stirred at 25° C. for 0.5 h. The reaction is quenched with aqueous sodium bisulfite (33%, 4 mL) at 0° C. and extracted with EtOAc (100 mL×2). The organic phase is concentrated and dissolved in aqueous AcOH (80%, 20 mL). After 1 h, the reaction mixture is neutralized with aqueous Na2CO3 (sat.) at 0° C. The mixture is purified by reverse phase column (CH3CN / HO, neutral condition, 0-60%) to give [(2R,3R,4R,5S)-5-[[[(2R,3R,4R,5R)-5-(6-benzamidopurin-9-yl)-4-[tert-butyl(dimethyl)silyl]oxy-2-(hydroxymethyl)tetrahydrofuran-3-yl]oxy-(2-cyanoethoxy)phosphoryl]oxymethyl]-4-[2-[bis(4-methoxyphenyl)-phenyl-methyl]sulfanylethyl]-2-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-3-yl]oxyphosphinic acid (0.79 g, 48% yield, 80% purity) as a white solid. (MS: [M+1] + 1364.0)

[0315] Step 2: Synthesis of N-[9-[(47S,48R,49R,50R,51R,52R,53R,54R)-49-[2-[bis(4-methoxyphenyl)-phenyl-methyl]sulfanylethyl]-52-[tert-butyl(dimethyl)silyl]oxy-87,88-dihydroxy-53-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]-87,88-dioxo-77,78,79,80,81,82-hexaoxa-87,88-diphosphatricyclooctadecan-54-yl]purin-6-yl]benzamide [ka] To a solution of [(2R,3R,4R,5S)-5-[[[(2R,3R,4R,5R)-5-(6-benzamidopurin-9-yl)-4-[tert-butyl(dimethyl)silyl]oxy-2-(hydroxymethyl)tetrahydrofuran-3-yl]oxy-(2-cyanoethoxy)phosphoryl]oxymethyl]-4-[2-[bis(4-methoxyphenyl)-phenyl-methyl]sulfanylethyl]-2-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-3-yl]oxyphosphinic acid (0.79 g, 0.58 mmol) in pyridine (16 mL) is added 2-chloro-5,5-dimethyl-1,3,2-dioxaphosphinane 2-oxide (0.7 g, 3.8 mmol, 6.5 equiv.). After 0.5 h, CCl4 (3.2 g, 20.6 mmol, 1.98 mL, 35.5 equiv), H2O (0.16 mL, 8.79 mmol) and NMM (0.79 mL) are added. The reaction mixture is stirred at 25 °C for 0.5 h and then poured into aqueous NaHSO3 (saturated, 10 mL). After 5 min, aqueous NaHCO3 (saturated, 20 mL) is added slowly. The mixture is extracted with EtOAc (30 mL x 2). The organic phase is concentrated and dissolved in CH3CN (8 mL) and t-BuNH2 (8 mL). After 0.5 h, the mixture is concentrated and purified by reverse phase column (CHCN / HO, neutral condition, 0-40%) to give N-[9-[(47S,48R,49R,50R,51R,52R,53R,54R)-49-[2-[bis(4-methoxyphenyl)-phenyl-methyl]sulfanylethyl]-52-[tert-butyl(dimethyl)silyl]oxy-87,88-dihydroxy-53-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]-87,88-dioxo-77,78,79,80,81,82-hexaoxa-87,88 diphosphatricyclooctadecan-54-yl]purin-6-yl]benzamide (0.5 g, 60% yield, 90.8% purity) as a white solid. (MS:[M+1] + 1309.8)

[0316] Step 3: Synthesis of 2-amino-9-[(39S,40R,41R,42R,43R,44R,45R,46R)-46-(6-aminopurin-9-yl)-41-[2-[bis(4-methoxyphenyl)-phenyl-methyl]sulfanylethyl]-44-[tert-butyl(dimethyl)silyl]oxy-74,75-dihydroxy-74,75-dioxo-64,65,66,67,68,69-hexaoxa-74,75-diphosphatricyclooctadecan-45-yl]-1H-purin-6-one [ka] A mixture of N-[9-[(47S,48R,49R,50R,51R,52R,53R,54R)-49-[2-[bis(4-methoxyphenyl)-phenyl-methyl]sulfanylethyl]-52-[tert-butyl(dimethyl)silyl]oxy-87,88-dihydroxy-53-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]-87,88-dioxo-77,78,79,80,81,82-hexaoxa-87,88-diphosphatricyclooctadecan-54-yl]purin-6-yl]benzamide (500 mg, 0.38 mmol) and methylamine alcohol solution (10 mL, 30%) is stirred for 4 h at 25° C. The reaction mixture is concentrated under reduced pressure. The residue is purified by reverse phase column (CHCN / HO, neutral condition, 0-30%) to give 2-amino-9-[(39S,40R,41R,42R,43R,44R,45R,46R)-46-(6-aminopurin-9-yl)-41-[2-[bis(4-methoxyphenyl)-phenyl-methyl]sulfanylethyl]-44-[tert-butyl(dimethyl)silyl]oxy-74,75-dihydroxy-74,75-dioxo-64,65,66,67,68,69-hexaoxa-74,75-diphosphatricyclooctadecan-45-yl]-1H-purin-6-one (220 mg, 48% yield, 95% purity) as a white solid.

[0317] Step 4: Synthesis of 2-amino-9-[(19S,20R,21R,22R,23R,24R,25R,26R)-26-(6-aminopurin-9-yl)-24-[tert-butyl(dimethyl)silyl]oxy-51,52-dihydroxy-51,52-dioxo-21-(2-sulfanylethyl)-43,44,45,46,47,48-hexaoxa-51,52-diphosphatricyclooctadecan-25-yl]-1H-purin-6-one [ka] To a solution of 2-amino-9-[(39S,40R,41R,42R,43R,44R,45R,46R)-46-(6-aminopurin-9-yl)-41-[2-[bis(4-methoxyphenyl)-phenyl-methyl]sulfanylethyl]-44-[tert-butyl(dimethyl)silyl]oxy-74,75-dihydroxy-74,75-dioxo-64,65,66,67,68,69-hexaoxa-74,75-diphosphatricyclooctadecan-45-yl]-1H-purin-6-one (190 mg, 0.17 mmol) in DCM (4 mL) is added 2,2-dichloroacetic acid (0.8 mL, 9.74 mmol, 58 equiv.). The mixture is stirred at 25° C. for 1 h and neutralized at 0° C. with water / Et3N (1:1, V / V, 3 mL). The mixture is concentrated and purified by reverse phase column (CH3CN / HO, containing 0.05% TEA, 0%-40%) to give 2-amino-9-[(19S,20R,21R,22R,23R,24R,25R,26R)-26-(6-aminopurin-9-yl)-24-[tert-butyl(dimethyl)silyl]oxy-51,52-dihydroxy-51,52-dioxo-21-(2-sulfanylethyl)-43,44,45,46,47,48-hexaoxa-51,52-diphosphatricyclooctadecan-25-yl]-1H-purin-6-one (36 mg, 25% yield, 98% purity, TEA salt) as a white solid. (MS: [M+1] + 833.3)

[0318] Step 5: Synthesis of 2-amino-9-[(14S,15R,16R,17R,18S,19R,20R,21R)-20-(6-aminopurin-9-yl)-17,44,45-trihydroxy-44,45-dioxo-16-(2-sulfanylethyl)-38,39,40,41,42,43-hexaoxa-44,45-diphosphatricyclooctadecan-21-yl]-1H-purin-6-one (CDN-B) [ka] To a solution of 2-amino-9-[(19S,20R,21R,22R,23R,24R,25R,26R)-26-(6-aminopurin-9-yl)-24-[tert-butyl(dimethyl)silyl]oxy-51,52-dihydroxy-51,52-dioxo-21-(2-sulfanylethyl)-43,44,45,46,47,48-hexaoxa-51,52 diphosphatricyclooctadecan-25-yl]-1H-purin-6-one (36 mg, 0.043 mmol) in MeOH (4 mL) is added NHF (0.16 g, 4.32 mmol, 100 equiv.). The mixture is stirred at 70 °C for 1 h, concentrated, and purified by reverse phase column (CHCN / HO, containing 0.05% FA, 0% to 30%) to give 2-amino-9-[(14S,15R,16R,17R,18S,19R,20R,21R)-20-(6-aminopurin-9-yl)-17,44,45-trihydroxy-44,45 dioxo-16-(2-sulfanylethyl)-38,39,40,41,42,43-hexaoxa-44,45 diphosphatricyclooctadecan-21-yl]-1H-purin-6-one (CDN-B, 7 mg, 22.5% yield, 99.8% purity) as a white solid. 1H NMR (400MHz, D2O) δ=8.25(s,1H), 8.19(s,1H), 7.77(s,1H), 6.10(s,1H), 5.80(d,J=8.3Hz, 1H), 5.67(q,J=8.2Hz,1H), 5.05-4.98(m,1H), 4.43(d,J=9.0Hz,1H), 4.36(d,J=12.1Hz,1H ), 4.31(brs, 1H), 4.18(d,J=11.7Hz,1H), 4.08-3.97(m,2H), 3.11(q,J=7.2Hz,1H), 2.79-2 .66(m,2H), 2.62-2.51(m,1H), 2.28-2.13(m,1H), 1.84-1.73(m,1H), 1.19(t,J=7.3Hz,1H). 31 P NMR: -0.951, -2.201. MS: [M+1] + 718.9.

[0319] Example 3. Preparation of target-binding antibodies Anti-PD-L1 antibody Ab-A1 (mu-anti-PDL1): An expression vector encoding the mouse anti-human PD-L1 antibody Ab-A1 (mu-anti-PDL1), having a heavy chain of SEQ ID NO: 3 and a light chain of SEQ ID NO: 5, was prepared by cloning cDNAs encoding the variable heavy (VH) chain of SEQ ID NO: 1 and the variable light (VL) chain of SEQ ID NO: 2 into separate pFUSEss-CHIg-mG2a (mouse IgG2a heavy chain constant region) and pFUSE2ss-CLIg-mk (mouse kappa light chain constant region) expression vectors, respectively. The VH and VL of Ab-A1 are based on Atezolizumab.

[0320] Ab-A2 (mu-anti-PDL1-cys): An expression vector encoding the mouse anti-human PD-L1 antibody Ab-A2 (mu-anti-PDL1-cys), with a heavy chain of SEQ ID NO: 4 and a light chain of SEQ ID NO: 5, was prepared using a technique similar to that for Ab-A1. The VH and VL sequences of Ab-A2 are based on Atezolizumab. The heavy chain constant region of Ab-A2 has two mutations compared to wild-type mouse IgG2a, the first being a leucine to phenylalanine substitution at position 234 of the CH2 domain (i.e., L234F, numbered according to the wild-type mouse IgG2a sequence aligned with the human IgG1 sequence using Eu numbering), and the second being a serine to cysteine ​​substitution at position 239 of the CH2 domain to present an additional cysteine ​​for binding (i.e., S239C, using the same numbering).

[0321] The sequences of the heavy chains of anti-human PD-L1 antibodies Ab-A1 and Ab-A2 are shown below as SEQ ID NOs: 3 and 4, respectively. The heavy chain variable region is underlined in each sequence, is identical in both sequences, and corresponds to SEQ ID NO: 1. The CH2 domain mutations of L234F and S239C in SEQ ID NO: 4 of Ab-A2 are shown in bold. Heavy chain of Ab-A1 (SEQ ID NO:3) EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSA AKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEEDDPDVQISWFVNNV EVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK Heavy chain of Ab-A2 (SEQ ID NO:4) EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSAAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNFLGGPCVFIFPPKIKDVLMISLSPIVTCVVVDVSEEDDPDVQISWFVNNV EVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK

[0322] The sequence of the light chain of anti-human PD-L1 antibodies Ab-A1 and Ab-A2 is shown below as SEQ ID NO: 5. The light chain variable region is underlined in the sequence and corresponds to SEQ ID NO: 2. Light chain of Ab-A1 and Ab-A2 (SEQ ID NO:5) DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIK RADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC

[0323] Ab-A3 (rt-anti-PDL1): Rat anti-mouse PD-L1 antibody Ab-A3 with a rat IgG2b heavy chain constant region was commercially available from BioXcell (BE0101).

[0324] Anti-EGFR antibody Ab-B1 (mu-anti-EGFR): Mouse anti-human EGFR antibody Ab-B1 with mouse IgG2a heavy chain constant region was commercially available from BioXcell (BE0279).

[0325] Ab-B2 (mu-anti-EGFR-cys): An expression vector encoding the mouse anti-human EGFR antibody Ab-B2 with a heavy chain of SEQ ID NO:8 and a light chain of SEQ ID NO:9 was prepared by cloning cDNAs encoding the variable heavy (VH) chain of SEQ ID NO:6 and the variable light (VL) chain of SEQ ID NO:7 into separate pFUSEss-CHIg-mG2a (mouse IgG2a heavy chain constant region) and pFUSE2ss-CLIg-mk (mouse kappa light chain constant region) expression vectors, respectively. The VH and VL sequences of Ab-B2 are based on cetuximab. The CH2 domain of the heavy chain of Ab-B2 is characterized by the mutations L234F and S239C compared to wild-type mouse IgG2a, as previously described for Ab-A2.

[0326] The sequence of the heavy chain of anti-human EGFR antibody Ab-B2 is shown below as SEQ ID NO: 8. The heavy chain variable region is underlined and corresponds to SEQ ID NO: 6. The L234F and S239C mutations in the CH2 domain are shown in bold. Heavy chain of Ab-B2 (SEQ ID NO:8) QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSA AKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNFLGGPCVFIFPPKIKDVLMISLSPIVTCVVVDVSEEDDPDVQISWFVNNV EVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK

[0327] The sequence of the light chain of Ab-B2 is shown below as SEQ ID NO: 9. The variable region is underlined and corresponds to SEQ ID NO: 7. Light chain of Ab-B2 (SEQ ID NO: 9) DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC

[0328] Ab-B3 (hu-anti-EGFR): An expression vector encoding the mouse-human chimeric anti-human EGFR antibody Ab-B3 having a heavy chain of SEQ ID NO: 12 and a light chain of SEQ ID NO: 13 was prepared by cloning cDNAs encoding the variable heavy (VH) chain of SEQ ID NO: 10 plus human IgG1 heavy chain constant region, and the variable light (VL) chain of SEQ ID NO: 11 plus human Ig kappa light chain constant region into separate pcDNA3.4 expression vectors. The full-length heavy and light chain sequences of Ab-B2 are based on cetuximab.

[0329] The sequence of the heavy chain of anti-human EGFR antibody Ab-B3 is shown below as SEQ ID NO: 12. The heavy chain variable region is underlined and corresponds to SEQ ID NO: 10. Heavy chain of Ab-B3 (SEQ ID NO: 12) QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSA ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0330] The sequence of the light chain of Ab-B3 is shown below as SEQ ID NO: 13. The variable region is underlined and corresponds to SEQ ID NO: 11. Light chain of Ab-B3 (SEQ ID NO: 13) DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0331] Ab-B4 (hu-anti-EGFR-A / C, V / C): An expression vector encoding the human anti-human EGFR antibody Ab-B4 having a heavy chain of SEQ ID NO: 16 and a light chain of SEQ ID NO: 17 was prepared by cloning cDNAs encoding the variable heavy (VH) chain of SEQ ID NO: 14 + human IgG1 heavy chain constant region, and the variable light (VL) chain of SEQ ID NO: 15 + modified human Ig kappa light chain constant region into separate pcDNA3.4 expression vectors. The VH and VL of Ab-B4 are based on cetuximab, with the VH having an alanine to cysteine ​​mutation at position 109 adjacent to the CH1 domain (i.e., A109C). The light chain of Ab-B4 is characterized by a valine to cysteine ​​mutation at position 205 (i.e., V205C).

[0332] The sequence of the heavy chain of anti-human EGFR antibody Ab-B4 is shown below as SEQ ID NO: 16. The heavy chain variable region is underlined and corresponds to SEQ ID NO: 14. The A109C mutation is shown in bold. Heavy chain of Ab-B4 (SEQ ID NO: 16) QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSC ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0333] The sequence of the light chain of Ab-B4 is shown below as SEQ ID NO: 17. The variable region is underlined and corresponds to SEQ ID NO: 15. The V205C mutation is shown in bold. Light chain of Ab-B4 (SEQ ID NO: 17) DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSSPCTKSFNRGEC

[0334] Anti-HER2 antibody Ab-C1 (anti-HER2): The humanized anti-human HER2 antibody Ab-C1 was marketed as trastuzumab (Herceptin®).

[0335] The sequence of the heavy chain of anti-human HER2 antibody Ab-C1 is shown below as SEQ ID NO: 20. The heavy chain variable region is underlined and corresponds to SEQ ID NO: 18. Heavy chain of Ab-C1 (SEQ ID NO:20) EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGDGGFYAMDYWGQGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0336] The sequence of the light chain of Ab-C1 is shown below as SEQ ID NO: 21. The variable region is underlined and corresponds to SEQ ID NO: 19. Light chain of Ab-C1 (SEQ ID NO:21) DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0337] Anti-CD47 antibody Ab-D1 (rt-anti-CD47): Rat anti-mouse CD47 antibody Ab-D1 with rat IgG2b heavy chain constant region was commercially available from BioXcell (BE0270).

[0338] Expression and purification Plasmids encoding the heavy and light chains of the target-binding antibodies were transfected into CHO cells for antibody expression using ExpiFectamine™ CHO Transfection Kit (ThermoFisher Scientific, Cat. No. A29129) according to the manufacturer's protocol. The total amount of plasmid used for transfection was 0.5ug / ml CHO cells, with a heavy to light chain plasmid ratio of 2:3. Six days after transfection, CHO cells were spun down, the medium was filtered, and then loaded onto Protein A beads (HiTrap Protein A HP, GE, Cat. No. 17-0403-01) and eluted with 0.1M glycine, pH 3.0. The eluted antibody fractions were pooled, concentrated to 1ml, and buffer exchanged into PBS by size exclusion (ENrich Sec650, Bio-Rad, Cat. No. 780-1650), before being stored at -80°C.

[0339] Example 4. Preparation of CDN-A ADC Synthesis of CDN-A-linker [ka] CDN-A (27 mg, 0.0385 mmol) is coevaporated with pyridine (3 × 3 ml) and dried under high vacuum before use. 4-((S)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl(4-nitrophenyl)carbonate (54 mg, 0.0732 mmol, 2.0 equiv.), HOBt (5.2 mg, 0.0385 mmol, 1.0 equiv.) and DMF (2.5 ml) are added. With stirring, DIPEA (67 μl, 0.385 mmol, 10 equiv.) is added. The mixture is stirred at room temperature under N2 for 42 h. The reaction mixture is diluted with a solvent mixture of ethyl acetate (25 ml), t-butyl methyl ether (75 ml) and acetic acid (30 μL, 0.521 mmol). The solid is collected by centrifugation and washed with t-butyl methyl ether (3×75 ml) to give 44 mg of crude product. 20 mg of crude product is further purified by reverse phase column (CH3CN / H2O, 0.1% FA, 0%-30%) to give the desired product (7 mg, 31% yield, 97% purity). (MS: [M-1] - 1298.2)

[0340] Binding of CDN-A to antibodies Reduction of antibody disulfides: First, the antibody bound to the target was reduced with tris-(2-carboxyethyl)-phosphine hydrochloride (TCEP) (2.3 molar equivalents of TCEP at room temperature for 1.5 hours or 40 molar equivalents of TCEP at 37° C. for 2 hours). Excess TCEP was removed using a desalting column (HiTrap Desalting column, GE, Cat. No.: 29048684).

[0341] Hinge cysteine ​​reoxidation: Hinge cysteines of reduced antibodies were reoxidized with 200 molar equivalents of dehydroascorbic acid (DHA, 0.5M in DMSO) for 4 hours at 37°C. Reoxidation was verified using SDS-PAGE under non-reducing conditions. Excess DHA was removed by a 30Kd MWCO cutoff centrifugal filter (Amicon Ultra-15, Merck Millipore, Cat. No.: UFC903024).

[0342] Conjugation with CDN-A: (Type I for reduced antibodies) The reaction mixture of reduced antibodies was cooled at 4°C for 20 min. Histidine buffer (20 mM, pH 7.4) containing CDN-A-linker (4.8 molar equivalents relative to antibody) was added and incubated at 4°C for 80 min. (Type II for reoxidized antibodies) Reoxidized antibodies were mixed with 10 molar equivalents of CDN-A-linker and incubated at room temperature for 4 h. After conjugation, the reaction was quenched with N-acetylcysteine ​​and excess CDN-A-linker and N-acetylcysteine ​​were removed with a 5 ml desalting column (GE) in PBS under the control of an FPLC system. The resulting ADC was concentrated and stored at 4°C. DAR measurement

[0343] To determine the DAR of ADCs with CDN-A as the CDN, the OD260 / OD280 ratio was measured by UV spectrometer and compared to a standard curve made using a mixture of CDN-A and antibody with known ratios. As shown in the table below, the DAR values ​​of the exemplary ADCs ranged from 1 to 6.3. The DAR values ​​of the ADCs using Ab-A2 antibody with an additional cysteine ​​by substitution (mu-anti-PDL1-cys) showed a larger DAR value than when the wild-type Ab-A1 antibody (mu-anti-PDL1) was used. [Table 1]

[0344] Example 5. Preparation of CDN-B ADC Synthesis of 2,5-dioxopyrrolidin-1-yl 4-(pyridin-2-yldisulfanyl)pentanoate (Linker I) [ka] To a DMA solution containing 4-(pyridin-2-yldisulfanyl)pentanoic acid (24 mg, 0.1 mmol) and NHS (14 mg, 0.12 mmol), EDC (HCl salt, 61 mg, 0.32 mmol) is added. The solution is stirred at room temperature overnight. After filtration, the filtrate is concentrated and purified by column (MeOH / DCM=0%-10%) to give 2,5-dioxopyrrolidin-1-yl 4-(pyridin-2-yldisulfanyl)pentanoate as a white solid (8 mg, 23.5%). (MS: [M+1] + 341.1)

[0345] Binding of CDN-B to antibodies 0.2 ml of 3 mM 2-amino-9-[(14S,15R,16R,17R,18S,19R,20R,21R)-20-(6-aminopurin-9-yl)-17,44,45-trihydroxy-44,45-dioxo-16-(2-sulfanylethyl)-38,39,40,41,42,43-hexaoxa-44,45 diphosphatricyclooctadecan-21-yl]-1H-purin-6-one in phosphate buffer pH 6.0 was mixed with 0.2 ml of DMA containing 2 mM 2,5-dioxopyrrolidin-1-yl 4-(pyridin-2-yldisulfanyl)pentanoate. After overnight incubation at room temperature, 2 ml of PBS containing 3.6 mg of target-bound antibody was added and incubated for another 2 hours at room temperature. The mixture was concentrated and the conjugate was purified on a 5 ml desalting column controlled by an FPLC system equilibrated with PBS. The resulting ADC was concentrated and stored at 4°C.

[0346] DAR measurement To release CDN-B from the ADC, DTT was added to the ADC to a final concentration of 10 mM, incubated at 95 °C for 5 min, and passed through a 30 KD cutoff filter. The filtrate was diluted and added to THP1-Lucia ISG cells permeabilized with 0.5 nM perfringolysin (PFO). After 16 h, luciferase activity was measured and the concentration of active compound released from the ADC and DAR values ​​were calculated by comparison to a standard curve. As shown in the table below, the DAR values ​​of the exemplary ADCs ranged from 0.33 to 1.66. [Table 2]

[0347] Example 6. Cellular activity of CDN-A and CDN-B ADCs IFN stimulating activity Two reporter cell lines, mouse macrophage RAW-Lucia ISG and human monocyte THP1-Lucia ISG, were used to evaluate the activity of the ADCs. Both cell lines have an IFN-stimulated response element (ISRE) fused to the ISG54 minimal promoter. Various concentrations (0.3, 1.0 and / or 3 μM) of the ADCs were added to the reporter cells and incubated for 16 hours. Luciferase activity, which represents induction of interferon expression, was compared to serial dilutions of a standard compound (cGAMP).

[0348] ADC-I through ADC-XI demonstrated effective interferon stimulating activity of various potencies, as summarized in Table 3. The reported "cGAMP equivalent" values ​​are defined as the concentration (in μM) of cGAMP required to induce the same level of response induced by 1 μM of ADC. [Table 3]

[0349] All ADCs showed strong interferon stimulating activity in mouse RAW-Lucia ISG reporter assay (Table 3). ADC-I and ADC-VI were most potent (Figures 1B and 6B, respectively), followed by ADC-VIII, ADC-IX (Figures 8B and 9B, respectively), then ADC-IV, ADC-V and ADC-X (Figures 4B, 5B and 10, respectively), then ADC-III (Figure 3B), ADC-II (Figure IIB) and ADC-XI. As shown in Figures 3B, 4B, 5B and 6B, treatment with the disclosed ADCs shows synergistic interferon stimulating activity when compared to treatment with antibody alone, or CDN alone, or the combined potency of both antibody and agonist.

[0350] The CDN-A antibody conjugates also exhibited interferon stimulatory activity in a reporter assay using human monocytic THP1-Lucia ISG cells (Table 3). Of those tested, ADC-I was the most potent (Figure 1C), followed by ADC-II (Figure 1C) and ADC-III.

[0351] The activity of ADC-VIII and ADC-IX was further tested in the THP1-lucia ISG cell line stably expressing human EGFR. Both ADCs showed strong interferon stimulatory activity in these cells (Table 4). The reported "cGAMP equivalent" value is defined as the concentration (nM) of cGAMP required to induce the same level of response induced by 1 nM of ADC. EC50 is the half-maximal effective concentration. [Table 4]

[0352] Example 7. Antitumor effects of CDN-A and CDN-B ADCs The antitumor efficacy of selected ADCs was tested in mouse syngeneic tumor models B16-F10 metastatic melanoma, B16F10 transfected with human EGFR (B16F10-EGFR) and Lewis lung carcinoma transfected with human HER2 (LLC1-HER2). 6 Log-phase tumor cells in 100 μL of PBS were injected subcutaneously into the right flank of C57BL6 mice. After 4–6 days, tumor volumes increased to 50–100 mm. 3 When tumors reached 100%, mice were regrouped according to their tumor size and treated intraperitoneally with 50 μg to 200 μg of ADC, or unconjugated antibody, unconjugated CDN, or mock PBS as a control (see figure legends for treatment details).

[0353] Tumor volume and survival of mice were monitored. ADC-IV, ADC-VI, ADC-VII, ADC-VIII and ADC-IX showed strong antitumor efficacy in both regression and survival and are promising candidates for treating human tumors. ADC-X was shown to slow tumor progression. ADC-I was also shown to slow tumor progression, but toxicity was observed.

[0354] Tumor volume In B16F10 tumor-bearing mice, treatment with ADC-I (anti-PDL1-CDN-B) delayed tumor progression compared with mock, anti-PDL1 antibody alone, CDN-B alone, and the combination of anti-PDL1 antibody and nonconjugated CDN-B (Figure 1C).

[0355] In mice bearing B16F10-EGFR tumors, treatment with ADC-IV (anti-EGFR-CDN-A) delayed tumor progression and reduced tumor volume compared to mock treatment or treatment with anti-PDL1 antibody (Figure 4C and Figure 4E). Comparative treatment with anti-EGFR antibody + unconjugated CDN failed to halt tumor growth (Figure 4C), suggesting improved efficacy when using ADC for targeted CDN delivery. Complete inhibition of tumor growth was observed when ADC-IV was combined with anti-PDL1 antibody (Figure 4E), suggesting improved efficacy when CDN ADC is combined with checkpoint inhibitors.

[0356] In mice bearing B16F10-EGFR tumors, ADC-VI (anti-PDL1-CDN-A) administered intraperitoneally at a dose of 200 μg (FIG. 6C) or ADC-VI administered intratumorally at doses of 10 μg or 50 μg (FIG. 6D) prevented tumor growth. Within 2 weeks of treatment with ADC-VI, B16F10-EGFR tumors showed complete remission, whereas treatment with anti-PDL1 antibody alone or mock failed to halt tumor growth.

[0357] In mice bearing B16F10-EGFR tumors, ADC-VII (anti-EGFR-CDN-A) resulted in a significant reduction in tumor growth compared to mock treatment or treatment with anti-PDL1 antibody (Figure 7C and Figure 7E). Comparative treatment with anti-EGFR antibody + unconjugated CDN failed to halt tumor growth (Figure 7C), suggesting improved efficacy when ADC is used for targeted CDN delivery. Enhanced tumor suppression was observed when ADC-VII was combined with anti-PDL1 antibody, whereas treatment with anti-PDL1 antibody alone or mock failed to halt tumor growth (Figure 7E), suggesting improved efficacy when CDN ADC is combined with checkpoint inhibitors.

[0358] In mice bearing B16F10-EGFR tumors, ADC-VIII (anti-EGFR-CDN-A) led to a significant reduction in tumor growth (Figure 8C). This effect was enhanced when ADC-VIII was combined with an anti-PDL1 antibody, whereas treatment with anti-PDL1 antibody alone or mock failed to halt tumor growth, suggesting improved efficacy when the CDN ADC was combined with a checkpoint inhibitor.

[0359] In mice bearing B16F10-EGFR tumors, ADC-IX (anti-EGFR-CDN-A) led to a reduction in tumor growth, and a similar effect was observed when ADC-IX was combined with an anti-PD-L1 antibody (Figure 9C). Treatment with anti-PDL1 antibody alone or mock failed to halt tumor growth.

[0360] In mice bearing LLC1-HER2 tumors, ADC-X (anti-HER2-CDN-A) reduced tumor growth in two separate mouse studies (Figures 10C and 10E), whereas treatment with anti-PDL1 antibody alone or mock failed to halt tumor growth. Comparative treatment with anti-HER2 antibody plus unconjugated CDN failed to halt tumor growth, suggesting improved efficacy when ADC was used for targeted CDN delivery. Figure 10E further shows that intratumoral administration of ADC-X at a dose of 30 μg resulted in complete tumor remission.

[0361] survival Survival of mice bearing B16F10-EGFR or LLC1-HER2 tumors was monitored. Treatment with ADC-IV (anti-EGFR-CDN-A) extended survival of B16F10-EGFR tumor-bearing mice (3 / 5 on day 37, FIG. 4D; 0 / 5 on day 39, FIG. 4F) compared to treatment with anti-PDL1 antibody alone (0 / 5 on day 26, FIG. 4D; 0 / 5 on day 29, FIG. 4F) and mock (0 / 5 on day 23, FIG. 4D; 0 / 5 on day 20, FIG. 4F). Survival after ADC-IV treatment exceeded that of comparative treatment using anti-EGFR antibody + non-conjugated CDN (0 / 5 on day 34, FIG. 4D), suggesting improved efficacy when ADC was used for targeted CDN delivery. Combination treatment with ADC-IV and anti-PDL1 antibody improved survival to 80% of mice (4 / 5 at day 42), suggesting improved efficacy when combining a CDN ADC with a checkpoint inhibitor.

[0362] Treatment with intraperitoneally administered ADC-VI (anti-PDL1-CDN-A) resulted in overall survival of B16F10-EGFR tumor-bearing mice (5 / 5 at day 43) compared to treatment with anti-PDL1 antibody alone (0 / 5 at day 29) or mock (0 / 5 at day 27) (Figure 6D). Similarly, treatment with intratumorally administered ADC-VI resulted in overall survival of tumor-bearing mice (Figure 6F).

[0363] Treatment with ADC-VII (anti-EGFR-CDN-A) enhanced survival of B16F10-EGFR tumor-bearing mice at the endpoint (2 / 5 at day 36, Figure 7D and Figure 7F) compared to treatment with anti-PDL1 antibody alone (0 / 5 at day 27, Figure 7F) or mock (0 / 5 at day 23, Figure 7D and Figure 7F). Survival after ADC-VII treatment exceeded that of comparative treatment using anti-EGFR antibody + unconjugated CDN (0 / 5 at day 22, Figure 7D), suggesting improved efficacy when using ADC for targeted CDN delivery. Combined treatment of ADC-VII with anti-PDL1 antibody improved survival by 60% of mice (3 / 5 at day 36, Figure 7F) compared to ADC-VII, suggesting improved efficacy when combining CDN ADC with checkpoint inhibitors.

[0364] Treatment with ADC-VIII (anti-EGFR-CDN-A) increased survival of B16F10-EGFR tumor-bearing mice (1 / 5 at day 35) compared to treatment with anti-PDL1 antibody alone (0 / 5 at day 27) or mock (0 / 5 at day 25) (Figure 8D). Treatment with the combination of ADC-VIII and anti-PD-L1 antibody improved survival to 80% of mice (4 / 5 at day 35), suggesting improved efficacy when combining CDN ADC with checkpoint inhibitors.

[0365] Treatment with ADC-IX (anti-EGFR-CDN-A) increased survival of B16F10-EGFR tumor-bearing mice (3 / 5 at day 30) compared to treatment with anti-PDL1 antibody alone (0 / 5 at day 23) or mock (0 / 5 at day 19) (Figure 9D). Treatment with the combination of ADC-IX and anti-PD-L1 antibody improved survival to 60% of mice (3 / 5 at day 30), suggesting improved efficacy when combining CDN ADC with checkpoint inhibitors.

[0366] Treatment with ADC-X (anti-HER2-CDN-A) extended survival of LLC1-HER2 tumor-bearing mice (0 / 5 at day 41) compared to mock treatment (0 / 5 at day 32) (Figure 10D). Survival following ADC-X treatment exceeded that following comparative treatment with anti-HER2 antibody plus unconjugated CDN (0 / 5 at day 32), suggesting improved efficacy when using ADC for targeted CDN delivery. [Sequence List Free Text]

[0367] SEQ ID NO: 1 to 21 <223> Synthetic Polypeptides

Claims

1. Structure of Formula Ia: (Formula Ia) Ab - [-L-D] n 1. An antibody-drug conjugate (ADC) having the formula: During the ceremony, "D" is the structure of formula IIk: 【Chemistry 1】 A cyclic dinucleotide (CDN) having the formula: or a pharma- ceutically acceptable salt thereof, During the ceremony, W, X, Y and Z are independently CH or N; R 1 is thiol, amino, or C 1-6 C substituted with alkylamino group 2-4 is alkyl, R P each independently represents hydroxyl, thiol, C 1-6 Alkyl, borano (-BH 3 - ), or -NR'R'', where R' and R'' are each independently hydrogen or a halogen, thiol, hydroxyl, carboxyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C 1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 alkyl)C(O)C 1-6 Alkyl, Amino, C 1-6 Alkylamino, di(C 1-6 C optionally substituted with one or more groups selected from amino, oxo, and azido 1-6 alkyl, or R′ and R″ on the same nitrogen are taken together as C 3-5 Forming a heterocyclic ring, "Ab" refers to an antibody or binding fragment thereof that binds to a target antigen; each "L" independently represents a linker linking one or more D's to Ab; "n" represents the number of Ds linked to Ab via the linker (L); wherein the CDN(D) is the R 1 The thiol, amino or C 1-6 covalently attached to a linker (L) via an alkylamino group; Antibody-drug conjugates (ADCs).

2. R 1 is substituted with an amino group 2-4 2. The ADC of claim 1 , wherein the ADC is alkyl.

3. R 1 is substituted with a thiol group 2-4 2. The ADC of claim 1 , wherein the ADC is alkyl.

4. The ADC has the structure of formula IIn: 【Chemistry 2】 or a pharma- ceutically acceptable salt thereof.

5. The ADC has the structure of formula IIo: 【Chemistry 3】 or a pharma- ceutically acceptable salt thereof.

6. The ADC has the structure of Formula III: 【Chemistry 4】 2. The ADC of claim 1, having the following structure:

7. The ADC has the structure of Formula IV: 【Chemistry 5】 2. The ADC of claim 1, having the following structure:

8. The ADC of any one of claims 1 to 7, wherein X and Z are N.

9. The ADC of any one of claims 1 to 7, wherein X and Z are CH.

10. The ADC of any one of claims 1 to 7, wherein X is N and Z is CH.

11. R P The ADC of any one of claims 1 to 10, wherein each is independently a hydroxyl or a thiol.

12. The ADC has the following structure: 【Chemistry 6】 CDN with or a pharma- ceutically acceptable salt thereof 2. The ADC of claim 1, obtained from

13. The ADC has the following structure: 【Chemistry 7】 CDN with or a pharma- ceutically acceptable salt thereof 2. The ADC of claim 1, obtained from

14. The ADC of any one of claims 1 to 13, wherein L comprises one or more cleavable linkers.

15. 15. The ADC of any one of claims 1-14, wherein L is attached to Ab via a maleimide group, an activated disulfide, an active ester, a haloformate, an acid halide, an alkyl halide, or a benzyl halide.

16. 16. The ADC of any one of claims 1 to 15, having a covalent bond formed between L and Ab with a thiol group or a primary amino group on Ab.

17. The ADC has the following structure: 【Chemistry 8】 2. The ADC of claim 1, having the following structure:

18. The ADC has the following structure: 【Chemistry 9】 2. The ADC of claim 1, having the following structure:

19. The ADC of any one of claims 1 to 18, wherein the Ab is an antibody that binds to PD-L1, CD47, an antigen selectively expressed or overexpressed in cancer cells, or an antigen derived from a microorganism that infects human cells.

20. The ADC of any one of claims 1 to 18, wherein the Ab is an antibody that binds to an antigen that is a growth factor receptor (GFR).

21. 21. The ADC of claim 20, wherein the GFR is EGFR.

22. 21. The ADC of claim 20, wherein the GFR is ErbB.

23. 21. The ADC of claim 20, wherein the GFR is ErbB2 (HER2).

24. The ADC described in claim 20, wherein the GFR is a HER family receptor.

25. A pharmaceutical composition comprising the ADC of any one of claims 1 to 24.

26. The pharmaceutical composition of claim 25 for stimulating an immune response.

27. ​​A pharmaceutical composition described in claim 25 or 26 for treating cancer.

28. Formula IIk: 【Chemistry 10】 or a pharma- ceutically acceptable salt thereof, During the ceremony, W, X, Y and Z are independently CH or N; R 1 is an amino group or C 1-6 ethyl substituted with an alkylamino group; R P each independently represents hydroxyl, thiol, C 1-6 Alkyl, borano (-BH 3 - ), or -NR'R'', where R' and R'' are each independently hydrogen or a halogen, thiol, hydroxyl, carboxyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C 1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 alkyl)C(O)C 1-6 Alkyl, Amino, C 1-6 Alkylamino, di(C 1-6 C optionally substituted with one or more groups selected from amino, oxo, and azido 1-6 alkyl, or R′ and R″ on the same nitrogen are taken together as C 3-5 A compound, or a pharma- ceutically acceptable salt thereof, which forms a heterocycle.

29. R P 30. The compound of claim 28, or a pharma- ceutically acceptable salt thereof, wherein each is independently hydroxyl or thiol.

30. 30. The compound of claim 28 or 29, wherein Y and W are both CH and X and Z are both N, or a pharma- ceutically acceptable salt thereof.

31. R 1 The compound according to any one of claims 28 to 30, or a pharma- ceutically acceptable salt thereof, wherein is ethyl substituted with an amino group.

32. R P or a pharma- ceutically acceptable salt thereof. The compound of any one of claims 28 to 31, wherein at least one of is hydroxyl.

33. R P 32. The compound according to any one of claims 28 to 31, or a pharma- ceutically acceptable salt thereof, wherein at least one of is a thiol.

34. Formula: 【Chemistry 11】 or a pharma- ceutically acceptable salt thereof.

29. The compound of claim 28,

35. Cyclic dinucleotides (CDNs), and A composition comprising a linker or a binder, or both a linker and a binder, A composition, wherein the CDN is a compound according to any one of claims 28 to 34 or a pharma- ceutically acceptable salt thereof, and the binding agent promotes binding between the CDN and the linker.

36. The CDN has the following structure: 【Chemistry 12】 36. The composition of claim 35, comprising:

37. A compound of formula L-CDN, During the ceremony, L is a linker comprising a site capable of binding to a complementary site on an antibody or antigen-binding fragment, The CDN has the structure of formula IIk: 【Chemistry 13】 A cyclic dinucleotide having the formula or a pharma- ceutically acceptable salt thereof. During the ceremony, W, X, Y and Z are independently CH or N; R 1 is thiol, amino, or C 1-6 C substituted with alkylamino group 1-6 is alkyl, R P each independently represents hydroxyl, thiol, C 1-6 Alkyl, borano (-BH 3 - ), or -NR'R'', where R' and R'' are each independently hydrogen or a halogen, thiol, hydroxyl, carboxyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkoxy, -OC(O)C 1-6 Alkyl, -N(H)C(O)C 1-6 Alkyl, -N(C 1-3 alkyl)C(O)C 1-6 Alkyl, Amino, C 1-6 Alkylamino, di(C 1-6 C optionally substituted with one or more groups selected from amino, oxo, and azido 1-6 alkyl, or R′ and R″ on the same nitrogen are taken together as C 3-5 Forming a heterocyclic ring, CDN is R 1 The thiol, amino or C 1-6 A compound wherein L is bound to an alkylamino group.

38. 38. The compound of claim 37, wherein CDN is linked to L via a thioether, amide, ester, carbamate, carbonate, urea, disulfide, or ether group.

39. The compound has the structure of formula IXb: 【Chemistry 14】 having In the formula, R L represents the remainder of the linker L.

40. The compound has the structure of formula IXf: 【Chemistry 15】 having In the formula, R L represents the remainder of the linker L.

41. R P The compound of any one of claims 37 to 40, wherein each is independently hydroxyl or thiol.

42. 42. The compound of any one of claims 37 to 41, wherein Y and W are both CH and X and Z are both N.

43. R 1 The compound according to any one of claims 37 to 42, wherein is ethyl substituted with an amino group.

44. R P The compound according to any one of claims 37 to 43, wherein at least one of is hydroxyl.

45. R P The compound according to any one of claims 37 to 43, wherein at least one of is a thiol.

46. The CDN has the following structure: 【Chemistry 16】 38. The compound of claim 37, wherein:

47. The CDN has the following structure: 【Chemistry 17】 38. The compound of claim 37, wherein:

Citation Information

Patent Citations

  • Cyclic dinucleotide compounds as sting agonists

    JP2018522914A

  • Cyclic dinucleotide compounds and methods of use

    JP2019509339A

  • Antibody conjugates comprising sting agonist

    WO2018200812A1

  • Pro-cyclic dinucleotides and pro-cyclic dinucleotide conjugates for cytokine induction

    WO2019129880A1